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Abstract 
Background: Serine/Threonine protein phosphatase 4 (PP4) plays a crucial role in cell 
signalling, proliferation and apoptosis, and its catalytic subunit has been reported as an 
important regulator in many types of cancer, including breast and lung cancers. 
 
Aims: Evaluate the effects of PP4c endogenous modulation in leukaemic cell lines; K562 
for chronic myeloid leukaemia and HL-60 for acute promyelocytic leukaemia, on cell 
viability, apoptosis, and proliferation. 
 
Methods: K562 and HL-60 cells were transfected with pcDNA3.1-PP4c to over-express or 
with specific siRNAs to down-regulate PP4c. Following transfection, cell viability, total 
apoptosis percentage, proliferation rate and cell cycle were assessed. The response of these 
cells to four different therapeutic drugs (imatinib, cisplatin, doxorubicin and rapamycin) 
was assessed post PP4c silencing. 
 
Results: This study demonstrated that PP4c over-expression in K562 cells significantly 
reduce cell viability and cell proliferation, accompanied by a significant increase in 
apoptosis at 24 and 48 hours post re-plating. It also altered the cell cycle profile by 
increasing the number of cells in G0/G1 phase and reducing the cell number in S phase. On 
the other hand, PP4c silencing significantly increased cell viability in K562 cells at 48 
hours. PP4c down-regulation also enhanced and promoted the action of both imatinib and 
rapamycin by increasing apoptosis in K562 cells. PP4c over-expression in HL-60 
decreased the viable cell number at 48 hours, while PP4c down-regulation increased the 
viable cell number at 72 hours and altered the cell cycle profile by reducing the cell 
number in S phase and increasing the cells number in G2/M phase. PP4c silencing in HL-
60 cells had no effect on the action of the chemotherapeutic drugs. 
xiv 
 
Conclusion: The results suggested that PP4c regulates cell proliferation, cell death, and 
cell cycle in K562 cell line in addition to enhancing their response to imatinib and 
rapamycin. Such studies are important to identify molecular regulators of the pathways 
involved in the pathogenesis of leukaemia and will contribute to greater understanding of 
the mechanism(s) by which phosphatases regulate cell survival in cancer and may allow 
design of optimised targeted therapies in the future. 
1 
 
1. General Introduction 
Protein post translational modifications are known to play crucial roles in many cellular 
processes. One of the most biologically important post translational modifications is 
protein phosphorylation (Khoury et al., 2011). Reversible protein phosphorylation controls 
a wide spectrum of cellular processes, including gene transcription and translation, cell-
division cycle, cell proliferation, apoptosis and invasion (Bauman and Scott, 2002).  
Cancer cells are characterised by modifications in specific signalling pathways leading to 
the loss of tumour suppressor gene function, and the gain of unrestrained proto-oncogene 
expression and activity (Griffiths et al., 2000). Increased expression and activity of 
oncoproteins cause an abnormal increase in cell proliferation and survival accompanied 
with inhibition of apoptosis and differentiation, promoting the expansion of tumour cell 
clones (Perrotti and Neviani, 2013). The gain of oncogene function associated with loss of 
tumour suppressors is now widely accepted as a hallmark of cancer initiation and 
progression (Hanahan and Weinberg, 2011).  
 
1.1. Leukaemia 
Haematological malignancies are a group of heterogeneous diseases that are initiated by 
leukaemic stem cells that are able to self-renew and differentiate similarly to the normal 
haematopoietic stem/progenitor cells (HSCs) but in an abnormal way, i.e. characterised by 
the excessive build up or accumulation of either immature or abnormal blood cells (Orkin 
and Zon, 2008). Four large groups of haematological malignancies have been described; 
Acute Lymphocytic Leukaemia (ALL), Chronic Lymphocytic Leukaemia (CLL), Acute 
Myelogenous Leukaemia (AML), and Chronic Myelogenous Leukaemia (CML). They are 
classified depending on the stage of the disease (acute or chronic leukaemia), and 
immunophenotype of the cells (myeloid or lymphoid) (Warr et al., 2011). 
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1.1.1. Chronic Myeloid Leukaemia (CML)  
Chronic myeloid leukaemia (CML) was the first human malignancy shown to be 
associated with a specific chromosomal aberration (Nowell & Hungerford, 1960). It is a 
clonal disorder of the pluripotent haematopoietic stem cells characterised by an increase in 
myeloid, erythroid cells and platelets in peripheral blood and marked myeloid hyperplasia 
of the bone marrow (Rowley, 1973). Clinically, CML is characterised by two distinct 
stages, an extended myeloproliferative disorder named the chronic phase (CML-CP) that 
progresses to a rapidly fatal blast crisis (CML-BC) (Calabretta and Perrotti, 2004).  
The Philadelphia chromosome is the cytogenetic hallmark of CML. It is the product of the 
reciprocal translocation between chromosome 9 and chromosome 22, t(9;22)(q34;q11) 
(Groffen et al., 1984). This translocation results in the fusion of the breakpoint cluster 
region (Bcr) from chromosome 22 to the Ableson leukaemia virus (c-Abl) gene from 
chromosome 9 (Nowell and Hungerford, 1960; Groffen et al., 1984; Rowley, 1973). The 
Bcr-Abl fusion gene encodes for a 210 kDa protein, p210- Bcr-Abl and is another hallmark 
of CML, which displays constitutive tyrosine kinase activity and confers on leukaemic 
cells a growth and proliferation advantage, as well as resistance to apoptosis (Melo, 1996; 
Ren, 2005). Depending on the location of the break point on the Bcr locus, the product of 
the t(9;22) can also be a p190- or a p230- Bcr-Abl, which are normally detected in 
Philadelphia-positive B-acute lymphoblastic leukaemia (Ph1 ALL) and chronic 
neutrophilic leukaemia (CNL) respectively (Ravandi et al. ,1999; Pane et al., 1996; Wilson 
et al., 1997).  
The unrestrained tyrosine-kinase activity of Bcr-Abl leads to the stimulation of different 
signalling pathways that transduce oncogenic signals leading to growth factor-independent 
proliferation, genetic instability, increased survival, altered differentiation of 
haematopoietic progenitors and resistance to apoptosis (Thielen et al., 2011; Druker, 2008; 
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Huang et al., 2011; Mancini et al, 2012). These pathways include RAS/MAPK (Sawyers et 
al., 1995; Thielen et al., 2011), PI3K/Akt (Varticovski et al., 1991; Skorski et al., 1997) 
and nuclear factor-kappa B (NF-κB) (Reuther et al., 1998; Asimakopoulos et al., 1999). In 
fact, the effects of Bcr-Abl transformation is mostly dependent on phosphorylation of key 
signalling molecules involved in RAS/MAPK, PI3K/Akt and NF-κB pathways (Thielen et 
al., 2011; Druker, 2008). Phosphorylation of these proteins control cell growth, survival 
and differentiation of haematopoietic cells by modifying the activity or expression of 
downstream effectors in their signalling pathways (Druker, 2008; Huang et al., 2011; 
Mancini et al, 2012).  
Since the constitutive Bcr-Abl kinase activity is the characteristic cause of CML, drugs 
such as imatinib and other tyrosine kinase inhibitors, which target the kinase catalytic 
domain and inhibit it, are considered the most effective for CML treatment (Druker et al., 
1996; Druker et al., 2001a; 2001b; Kantarjian et al., 2006; Talpaz et al., 2006). However, 
some patients fail to respond, or develop resistance, to this treatment due to intrinsic 
heterogeneity of the disease (Druker et al., 2006; Irvine et al., 2010). Resistance to the 
kinase inhibitors could be the result of Bcr-Abl 1 amplification or over-expression and 
mutations in the ATP-binding domain and catalytic domain activation loop (Hughes et al., 
2003; Druker et al., 2006). Thus, many studies are now dedicated to dissecting the 
signalling pathways involved in the pathogenesis of CML. This could lead to the 
development of novel therapeutic targets needed in order to improve the survival and long-
time cure of CML patients (Irvine et al., 2010). 
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1.1.2. Acute Promyelocytic Leukaemia (APL)  
Acute myeloid leukaemia (AML) is a heterogeneous group of genetically and 
phenotypically aggressive disorders where the differentiation of haematopoietic 
progenitors (HPs) is blocked, increasing their self-renewal ability and disturbing the 
normal regulation of proliferation (Frohling et al., 2005). AML is classified based on 
morphology, immunophenotyping, genetics and clinical manifestations, into four main 
groups: AML with recurrent genetic abnormalities, AML with myelodysplasia (MDS)-
related changes, therapy-related AML and MDS or AML that does not fit into any of these 
groups (Estey and Döhner 2006; Mrózek et al., 2007). In this type of leukaemia, 
constitutive activation of the PI3K/Akt signalling pathway is frequently detected in 
approximately 50–70% of patients (Martelli et al., 2006). Generally, acute myeloid 
leukaemia is characterised by mutations and deregulation of various types of tyrosine 
kinases such as c-KIT (CD117; a transmembrane protein encoded by the oncogene c-KIT), 
platelet derived growth factor receptor (PDGFR) and receptors Fms-like tyrosine kinase 
(Flt-3) (Smith et al., 2011). 
In 1957, Leif Hillestad was the first who described APL as a unique subtype of AML that 
has a distinct morphological appearance, caused by an arrest of leukocyte differentiation at 
the promyelocyte stage, and associated the pattern of an acute leukaemia with 
coagulopathy and some clinical features including fibrinolysis, hypofibrinogenemia and 
catastrophic haemorrhage (Hillestad, 1957). The unique morphology of APL has both 
classical hypergranular and variant microgranular forms and they are characterized by a 
balanced translocation between the long arms of chromosomes 15 and 17, 
[t(15;17)(q22;q21)], giving rise to a unique fusion gene PML-RARa (RARa: retinoic acid 
receptor-a), an abnormal chimeric transcription factor, which disrupts 
normal myeloid differentiation programs (Rowley et al., 1977; Testa et al., 1978). The 
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discovery and elucidation of the molecular pathogenesis for APL has turned it from being 
once considered ‘the most malignant form’ to 'the most curable form' of AML (Lo-Coco et 
al., 2016). 
According to European registries, APL represents 3-13% of AML cases (Grimwade et al., 
2010; Lehmann et al., 2011) and its therapy has improved over 50 years of research from 
traditional chemotherapy started in the mid-1960s, through to the empirical discovery of 
targeted therapies including all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) 
agents that directly target the molecular foundation of the disease, in which a complete 
remission can occur in most APL patients (Lo-Coco et al., 2016). 
 
1.2. Hallmarks of Cancer 
Cellular homeostasis is maintained through signalling pathways that promote survival and 
growth, while preventing unrestrained proliferation by inducing cell senescence and 
apoptosis in response to DNA damage and other factors such oxidative stress and ageing.  
In 2011, Hanahan and Weinberg described the existence of eight hallmarks of cancer, 
which are defined as distinctive and complementary abilities that permit the growth of 
tumours and the development of metastasis (Hanahan and Weinberg, 2011). The eight 
hallmarks of cancer are detailed in the following sections.  
 
1.2.1. Self-sufficiency in growth signals 
In contrast to normal cells that require growth molecules to divide and grow, cancer cells 
do not respond to these signals that regulate cell growth and division and instead maintain 
prolonged proliferation even without any external growth signal (Hanahan and Weinberg, 
2011). This results in overproduction of growth factors, which in turn interact with cell-
surface receptors leading induction of the tyrosine kinase activity of these receptors, 
including transforming growth factor-β (TGF-β) (Cheng et al., 2008a), constitutively 
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activating signalling pathways leading to altered gene expression, such as the NF-κB 
signalling pathway, which is reported in several cancer types (Karin et al., 
2002). Moreover, in cancer cells the alterations in cell cycle due to the activation of these 
signalling pathways, initiate uncontrolled cell division and growth because of the alteration 
of the proteins themselves that control the timing of the events in the process so that each 
individual process is turned on and off at an appropriate time (Cheng et al., 2008a, 
Hanahan and Weinberg, 2011). 
 
1.2.2. Insensitivity to growth-inhibitory (antigrowth) signals 
The second hallmark involves evading growth suppressors. In order to sustain cell 
proliferation, even when the cell has severe abnormalities, cancer cells must avoid the 
actions of tumour suppressors, which are responsible for the negative regulation of cell 
proliferation such as TP53 (also known as p53) and RB proteins (retinoblastoma-
associated protein) and its two relatives, p107 and p130. In cancer, these tumour 
suppressors are mutant or altered so that they lose their signalling abilities as cell division 
controllers so the cancer cells continue to divide and consequently they accumulate even 
more damaged DNA (Hanahan and Weinberg, 2011). On the other hand, normal cells 
show contact inhibition, so that they will stop dividing when they are confluent and start 
touch each other, while cancer cells lose this characteristic and will grow and divide 
continuously despite the overgrowth that surrounds them, causing a large mass of cells to 
form (McClatchey and Yap, 2012). 
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1.2.3. Evasion of programmed cell death (apoptosis) 
Defects in programmed cell death or apoptosis is considered as one of the essential 
changes in cells that cause malignant transformation, and its resistance plays a critical and 
a vital role in carcinogenesis (Kerr et al., 1972; Norbury and Hickson, 2001). Normal cells 
switch on molecular pathways of apoptosis in response to stress-inducing events such as 
DNA damage, while cancer cells develop resistance to cell death machinery regardless of 
their abnormalities, thereby resulting in continuous cell growth (Ghobrial et al., 2005). 
This is carried out by the alteration of apoptosis signalling pathways that detect the damage 
or abnormalities by disrupting the balance of pro-apoptotic and anti-apoptotic proteins, 
reducing caspase function or by death receptor signalling impairment (Elmore, 2007). 
 
1.2.4. Limitless replicative potential 
Another hallmark of cancer is enabling replicative immortality; most normal cells possess 
cellular mechanisms that limit cell division to a finite number, blocking further growth 
(Hanahan and Weinberg, 2011). This is called the Hayflick limit or Hayflick phenomenon, 
and represents a finite number of times that normal human cells will divide before they 
become senescent or die, due to the shortening of telomeres (specific DNA-protein 
structures found at both ends of each chromosome) slightly with each cell division 
(Hayflick, 1965). Normal cells can divide only about fifty times before they die; this is 
related to their ability to replicate DNA only a limited number of times while many lines of 
evidence indicate that in cancer cells, telomerase, an enzyme that maintains telomere 
length, is activated (Blasco, 2005; Shay and Wright, 2000). By extending telomeric DNA, 
telomerase is able to prevent the progressive telomere erosion that would otherwise occur 
in its absence, allowing cell proliferations to continue (Blasco, 2005, Shay and Wright, 
2000; Hanahan and Weinberg, 2011). 
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1.2.5. Sustained angiogenesis or inducing angiogenesis  
Tumour angiogenesis is a very important multistep process that involves signalling input 
from several pro-angiogenic growth factors (Hicklin and Ellis, 2005). The process is 
crucial for continuous cancer growth and metastasis by providing increased oxygen, 
nutrients and growth factors to benefit cancer cell growth (Hicklin and Ellis, 2005). In 
other words, when the tumour grows larger, the cancerous cells produce new vasculature 
by increasing the production of growth factors which induce formation of new capillary 
blood vessels to supply the cells in the middle of the tumour with nutrients and oxygen 
(Hanahan and Weinberg, 2011). 
 
1.2.6. Tissue invasion and metastasis 
Another cancer hallmark that distinguishes malignant tumours from benign tumours is 
metastasis. In contrast to normal cells, cancer cells have the ability to penetrate the blood 
vessel walls and spread from an initial or primary site to a different or secondary site due 
to genetic alterations that develop their ability to proliferate rapidly and indefinitely (van 
Zijl et al., 2011). Activating invasion and metastasis processes encompass molecular 
changes in the way cells attach to other cells and extracellular matrix components 
(Hanahan and Weinberg, 2011). This is usually initiated through local tissue invasion, 
intravasation, transition through blood and lymphatic system and colonisation of foreign 
tissue (Hanahan and Weinberg, 2011).  
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1.2.7. Reprogramming energy metabolism 
In order to maintain unrestrained proliferation, cancer cells alter their energy production by 
reprogramming glucose metabolic rate via aerobic glycolysis, or the Warburg effect, a very 
important process for cancer cell growth, migration and invasion (López-Lázaro, 2008). 
The cancerous cells up-regulate glucose transporters and glycolytic enzymes such as 
hexokinases (HK1 and HK2) by the action of the transcription factor, Hypoxia-inducible 
factor-1α (HIF1α), to accelerate cell proliferation and survival (Hanahan and Weinberg, 
2011). On the other hand, the role of some pro-apoptotic Bcl-2 family proteins, such as 
BAD, in the regulation of reprogrammed metabolism has been reported (Danial et al., 
2003). Up-regulation of the glucose transporters activates many Bcl-2 family proteins, 
increasing their expression and subsequently preventing apoptosis (Danial et al., 2003).  
 
1.2.8. Evading immune destruction 
Immune surveillance is the process responsible for preventing tumour formation in the 
body by eliminating the vast majority of cancer cells before forming a tumour mass 
(Hanahan and Weinberg, 2011). Cancer cells can escape the immune system and 
consequently, become immune to its elimination processes (Teng et al., 2008). Studies 
have suggested that the immune system can block tumour formation and progression in 
non-virus induced cancer (Hanahan and Weinberg, 2011). Others supported the 
antitumoral immune responses in patients with colon and ovarian tumours that are 
infiltrated with CTLs and NK cells, having a better prognosis than those that lack such 
abundant killer lymphocytes (Nelson, 2008). 
Figure 1.1 illustrates the eight hallmarks of cancer. 
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1.3. Programmed cell death (Apoptosis) 
Maintaining self-sufficiency in proliferation and/or growth signals and limitless replicative 
potential require cancer cells to withstand stimuli that promote the initiation of cellular 
apoptosis. The most obvious strategy for cancer therapy is to target the lesions that 
suppress apoptosis in tumour cells, this and mechanisms responsible for drug resistance 
and endogenous mechanisms of apoptosis evasion, continue to be an interesting area for 
research. 
Apoptosis is a tightly regulated process, it was first defined in 1972 by Kerr and colleagues 
as spontaneous cell deletion which occurs either normally i.e. aging, or as a defense 
mechanism in some pathological conditions such as cancer (Kerr et al., 1972). It is 
Hallmarks of 
Cancer
Self-sufficiency 
in growth 
signals
Insensitivity to 
growth-
inhibitory 
signals
Evasion of 
programmed 
cell death 
Limitless 
replicative 
potential
Sustained 
angiogenesis 
or inducing 
angiogenesis
Tissue 
invasion and 
metastasis
Re-
programming 
energy 
metabolism
Evading 
immune 
destruction
Figure 1.1 The hallmarks of cancer. The eight hallmark capabilities of cancer as illustrated by 
Hanahan and Weinberg, 2011. 
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considered the most common type of programmed physiological cell death (PCD) and is 
essential during stages of embryonic development and throughout the lifespan (Green and 
Evans, 2002). Apoptosis plays a crucial role in the maintenance of  tissue homeostasis, 
eliminating unfit cells from the body and balancing cell proliferation (Claveria et al., 2013; 
Czabotar et al., 2014), as well as  playing an important role in the regulation of immune 
system function (Jacobson et al., 1997; Baehrecke, 2002). Therefore, any abnormality in 
this type of programmed cell death will result in various pathological problems, including 
cancer (Okada and Mak, 2004). Apoptosis is a complex and energy-dependent process 
characterised by distinctive morphological changes and biochemical mechanisms. The 
morphological changes include; rounding of the cell, cell shrinkage leading to chromatin 
condensation, nuclear DNA fragmentation and extensive plasma membrane blebbing, and 
the shedding of apoptotic bodies, vacuoles containing cytoplasm and intact organelles 
(Kerr et al., 1972; Hacker, 2000; Green, 2005).  
Apoptosis has two main signalling pathways: the intrinsic (also called mitochondrial 
pathway) and the extrinsic (also called death receptor pathway; acts by binding to cell 
surface death receptors, such as tumor necrosis factor-α (TNF1α), Fas (CD95/APO1) and 
TNF related apoptosis inducing ligand (TRAIL) receptors), whilst the two pathways are 
also linked and can be influenced/activated by each other (Cowling and Downward, 2002; 
Elmore, 2007). Stimulation of both pathways results in the activation of caspases; a family 
of inactive proenzymes (cysteine proteases) that have proteolytic activity and the ability to 
cleave proteins next to aspartate residues (Degterev et al., 2003; Green, 2005). Caspase 
activation leads to the permeabilisation of the mitochondrial membrane, chromatin 
condensation and DNA fragmentation, therefore leading to cell death (Green, 2005). Once 
a caspase is activated, it can lead to the activation of other procaspases by cleavage at 
identical sequences to initiate a protease cascade, therefore, the apoptotic signalling 
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pathway is amplified leading to many of the morphologic changes (Degterev et al., 2003). 
Numerous caspases have been identified and classified according to their roles. Caspases 
that have known roles in apoptosis are divided into two subgroups; the initiator caspases 
(caspase- 8 and -9) and effector or executioner caspases (caspase-3, -6, and -7). Caspases 
that have known roles in inflammation are caspase-1, -4, -5, -11, and -12, whilst the roles 
of caspase-2, -10, 13, and -14 are not well categorised (Elmore, 2007; Mcllwain et al. 
2013). 
Many important proteins including Bcl-2 family proteins that control apoptosis are 
reversibly phosphorylated. The activity of these proteins is determined by their 
phosphorylation status which is the result of the balance between the activities of protein 
kinases and phosphatases (Ruvolo et al., 1998). The Bcl-2 family, which consists of 25 
genes including Bcl-2 itself, BAD, Bid and Bim, have the ability to inhibit or induce 
apoptosis by governing mitochondrial outer membrane permeabilisation (MOMP) (Chipuk 
and Green, 2008). Another essential protein involved in apoptotic signalling pathways is 
cytochrome c (Cyt c) (Huttemann et al., 2011). It is a small haemoprotein located in the 
inner membrane of the mitochondrion and has many important roles besides its 
intermediate role in apoptosis; for example in oxidative phosphorylation or as a radical 
scavenger (Huttemann et al., 2011). By the action of some Bcl-2 family members, 
especially the pro-apoptotic Bax and Bak, Cyt c releases from mitochondria into the 
cytosol where it binds with the apoptotic protease-activating factor 1 (Apaf-1), and 
subsequent formation of the apoptosome, leading to activation of caspase 9 and initiation 
of a caspase cascade, including the activation of the effector caspases  3 and 7, which 
regulate the cell death process (Figure 1.2; Lopaz and Tait, 2015; Cardone et al., 1998; 
Wang, 2001).  
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Figure 1.2 Intrinsic or mitochondrial apoptosis pathway. Death stress signals induce death receptors 
from extrinsic pathway that affects the intrinsic pathway by promoting the accumulation of BH3-only 
proteins leading to oligomerisation of BAX/BAK, mitochondrial outer membrane permeabilisation 
(MOMP) and release of Cytochrome c and Smac/Omi proteins. Cytochrome c leads to caspase activation 
and apoptosis (From Lopez and Tait, 2015). 
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1.4. Reversible protein phosphorylation 
Mammalian cells must have the ability to adapt to external stimuli in order to survive when 
conditions change and a way in which cells manage this is the post-translational 
modification of their proteins. One form of which is reversible protein phosphorylation, 
which is able to cause distinct changes in the structure and activity of proteins and is 
considered as the most important type of post-translational modification used in signal 
transduction (Khoury et al., 2011). It is believed that approximately one third of cellular 
proteins are partly regulated via phosphorylation. Reversible phosphorylation controls 
metabolism, gene transcription and translation, cell-cycle progression, cell proliferation, 
cell differentiation, apoptosis and invasion (Virshup and Shenolikar, 2009).  
 
1.4.1. Kinases and phosphatases: types and roles 
A protein can be phosphorylated by kinases and dephosphorylated by phosphatases, 
therefore this is a reversible reaction and for each phosphorylation of a protein that can 
occur by a kinase, a phosphatase exists with the ability to dephosphorylate that same 
protein. This process of phosphorylation occurs mainly on three hydroxyl-containing 
amino acids, serine, threonine, and tyrosine, with serine being the predominant target 
(Olsen et al., 2006). The mechanism of action of phosphatases is the ability to 
nucleophilically attack phosphate groups that exist on the hydroxyl-containing amino acid 
residues of a phosphorylated protein in the presence of water resulting in the de-
phosphorylation of that residue (Seshacharyulu et al., 2013). It has been established that 
there are more kinases in existence within cells than there are phosphatases, therefore one 
phosphatase will be responsible for reversing the activity of more than one kinase (Ubersax 
and Ferrell, 2007).  
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Five hundred and eighteen putative protein kinase genes were found in the sequence of the 
human genome, these kinases were classified into two families; 90 Tyrosine kinases 
(PTKs) and 428 serine/threonine (Ser/Thr) kinases (PSKs) (Lander et al., 2001; Venter et 
al., 2001; Johnson and Hunter, 2005). On the other hand, only 125 putative Protein 
Tyrosine Phosphatases (PTPs) and 30 Protein Serine/Threonine Phosphatases (PSTPs) 
were identified (Alonso et al., 2004; 2016; Alonso and Pulido, 2016), and within these two 
classes, further sub-classes exist. Protein Serine/Threonine phosphatases can be classified 
based on their amino acid sequence homology, structures and biochemical properties (e.g. 
metal dependence) into three distinct gene families; phosphoprotein phosphatases (PPPs), 
metal ion-dependent (Mg2+ or Mn2+) protein phosphatases (PPMs), and aspartate-based 
phosphatases (Figure 1.3; Zhang et al., 2013; Eichhorn et al., 2009; Shi, 2009a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Protein kinases and protein phosphatases. Protein kinases divided into Tyr kinases (PTK 
90 enzyme) and Ser/Thr kinases (PSK>400 enzyme). Protein phosphatases divided into Tyr 
phosphatases (PTP) and Ser/Thr phosphatases (PSTP). The PTP family subdivided into different groups 
(PTP, DUSP and PTEN), while Ser⁄Thr phosphatases are classified into three families; PPP, PPM, and 
aspartate-based phosphatases (From Brautigan, 2013). 
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1.4.2. Kinases and cancer 
Ser/Thr protein kinases (STK) have been considered as the largest group of kinases that 
encode about 2% of proteins in the genomes of most eukaryotes and play a crucial role in 
every aspect of cellular function, such as cell cycle, proliferation and survival (Krupa et al., 
2004; Cohen, 2002). They act as key mediators of many signalling pathways, including 
cancer pathways and consequently they are found to be one of the best anticancer-drug 
targets (Krupa et al., 2004; Cohen, 2002; Han and McGonigal, 2007; Hardie, 2007). 
Tyrosine kinase activity enhancement is a hallmark of many types of cancers (Blume-
Jensen and Hunter, 2001); likewise, serine/threonine kinases have also been implicated in 
human cancer (Freeman and Whartenby, 2004). For example, the deregulation of the 
mitogen-activated protein kinases (MAPK) family has been associated with tumour 
growth, metastasis, and poor clinical outcome (Freeman and Whartenby, 2004). CML is 
characterized by the activation of the Bcr-Abl fusion gene that leads to the activation of 
many vital pathways including PI3K/Akt, RAS/MAPK, STAT5 and NF-κB pathways 
(Figure 1.4; Zaharieva et al., 2013; Druker, 2008; Thielen et al., 2011; Jacquel et al., 2003). 
These signal transduction pathways become constitutively activated leading to increased 
cell movement, uncontrolled cell proliferation and consequently cell death inhibition 
(Jacquel et al., 2003; Thielen et al., 2011). When Bcr-Abl oncogene interacts with the 
growth factor receptor-binding protein (Grb-2)/Gab2 complex, this results in the activation 
of Sos (Son of Sevenless), a guanosine diphosphate/guanosine triphosphate (GDP/GTP) 
exchange factor of Ras; that leads to the continuous Ras activation (Zaharieva et al., 2013; 
Thielen et al., 2011). In addition, the constitutive activation of the signal transducer and 
activator of transcription 5 (STAT5) has been reported in leukaemia (Jacquel et al., 2003). 
Bcr-Abl activates PI3K/Akt pathway through various proteins such as Gab2, Grb2 and Cbl, 
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resulting in BAD phosphorylation and inactivation of the anti-apoptotic protein Bcl-2 
(Zaharieva et al., 2013; Thielen et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to the expanded studies on how to inhibit their activity with small molecules, kinases 
are considered as extremely attractive anti-cancer therapeutic targets. Therefore, selective 
inhibitors that can block or modulate diseases with abnormalities in specific signalling 
pathways for many protein kinases such as Bcr-Abl and protein kinase C (PKC), have been 
developed and applied in cancer therapy (Scapin, 2002).  
Imatinib mesylate (also called Gleevec®) is an example of such a kinase inhibitor, being 
the first of these used in clinical trials against Philadelphia chromosome positive CML 
(Druker, 2008). It is a highly potent cancer drug because of its activity as an inhibitor of 
the critical CML pathogenetic event; the Bcr-Abl tyrosine kinase; and thus it is active in 
Figure 1.4 Bcr-Abl activates some downstream pathways. Bcr-Abl oncogene activates several 
important pathways such as PI3K/AKT, RAS, MAPK, and STAT5 leading to cell proliferation, survival 
and inhibit cell death (From Zaharieva et al., 2013). 
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about 90% of patients with CML (Druker, 2008). Inhibition of Bcr-Abl tyrosine kinase 
activity results in inhibition of proliferation and induction of apoptosis in only Bcr-Abl -
positive cells, while normal cells will not be affected (Peng et al, 2005). Furthermore, 
imatinib has also been successfully used in the treatment of gastrointestinal stromal 
tumours (GIST), where mutations in KIT produce ligand-independent constitutive 
activation of KIT (Also called CD117 or stem cell factor receptor; a tyrosine kinase 
receptor used as a tumour marker) (Din and Woll, 2008). It has been found that imatinib 
interrupts KIT-mediated signal transduction and PDGF-receptor tyrosine kinases in a 
manner analogous to its inhibition of Bcr-Abl (Peng et al, 2005; Savage and Antman, 
2002). 
 
1.4.3. Phosphatases and cancer 
As they work oppositely to kinases, phosphatases are integral to various signalling 
pathways including kinase signalling pathways and protein-protein interaction (Chen et al., 
2017). Protein phosphatases, including phosphatase and tensin homologue deleted on 
chromosome 10 (PTEN), Src homology 2 (SH2)-containing inositol 5′-phosphatase (SHIP) 
(Di Cristofano and Pandolfi, 2000), and the serine/threonine phosphoprotein phosphatase 
(PPP) family member PP2A (Shi, 2009b), have been reported in cancer. 
An intracellular signalling pathway that exists in all types of cells, involving 
PI3K/Akt/mTOR contains three major junctions; i) Phosphatidylinositol 3-kinase (PI3K), 
ii) a serine/threonine kinase known as either Akt or PKB and iii) mammalian target of 
rapamycin (mTOR), a key regulatory pathway of many physiological processes such as 
cell growth, proliferation, and survival (Franke et al., 1997; Hennessy et al., 2005). In this 
pathway, the activation of PI3K results in phosphorylation and activation of Akt, and 
consequently leads to activation of the mTOR pathway (Franke et al., 1997; Hennessy et 
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al., 2005). Activation of the PI3K pathway has been identified as a critical event in tumour 
survival and development (Hennessy et al., 2005).  
The phospholipid phosphatase PTEN, also called mutated in multiple advanced cancers 
(MMAC), dephosphorylates protein substrates on serine, threonine and tyrosine residues 
(Myers et al., 1997). It was identified as one of the most powerful and distinct tumour 
suppressors that is mutated in many types of cancers at high frequency (hence the name). 
Normally, it inhibits the PI3K/Akt signalling pathway by dephosphorylating 
phosphoinositide substrates such as phosphatidylinositol (3,4,5) tri-phosphate (PIP3), thus 
suppressing tumour formation (Stambolic et al., 1998; Sun et al., 1999). In other words, 
PTEN can suppresses the cancer formation process by different mechanisms including the 
inhibition of cell-division cycle progression, leading to arrest cell proliferation and increase 
programmed cell death (apoptosis) by blocking PI3K/Akt activation that activates Bad and 
Caspase-9 (Song et al., 2012). Therefore, many studies revealed that any PTEN mutation 
or loss of function leads to increased concentrations of PIP3, resulting in constitutive 
activation of downstream components of the PI3K signalling pathway, including the 
kinases Akt and mTOR leading to increased cell proliferation and reduced cell death that 
develops in different types of cancers such as breast, lung and prostate cancers (Song et al., 
2012; Yin and Shen, 2008; Sansal and Sellers, 2004). 
Another negative regulator of the PI3K/Akt signalling pathway is SHIP1. Similarly to 
PTEN, many studies suggested a tumour suppressor function of SHIP1 (Luo et al., 2003; 
Horn et al., 2004). The role of SHIP1 has been implicated in many types of leukaemias and 
lymphomas and a reduction in SHIP1 activity as a result of a mutation in a patient with 
AML has been reported (Luo et al., 2003; Gilby et al., 2007). Another study suggested that 
restoration of SHIP1 activity in Jurkat cells, a SHIP1 deficient leukaemic cell line, resulted 
in an increased transit time through the G1 phase of the cell cycle and consequently 
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reduced cell proliferation (Horn et al., 2004). Moreover, the low expression or absence of 
SHIP due to Bcr-Abl oncogene activity contributes to the pathogenesis of CML (Sattler et 
al., 1999).  
The following sections will focus on the serine/threonine phosphoprotein phosphatases 
(PPPs) family, particularly serine/threonine phosphoprotein phosphatase 4, and their role in 
apoptosis and cancer. 
 
1.5. Phosphoprotein phosphatases Family (PPP) 
The phosphoprotein phosphatases family (PPP) is a group of enzymes responsible for 
dephosphorylating almost all the phospho-Ser/Thr residues in cells. A key defining feature 
of all the PPP members is that they are multimeric holoenzyme complexes and the 
complexity in their function lies well beyond the number of genes encoding their catalytic 
subunits (Zhang et al., 2013). While only 13 human genes encode PPP catalytic subunits, 
these are associated with several regulatory subunits (Cohen, 2009). Each catalytic subunit 
is able to combine with several regulatory subunits to maintain specificity and enormous 
diversity of PPPs functions. These phosphatase regulatory subunits do not share extensive 
sequence conservation and are identified by their physical association and function (Cohen, 
2009). They determine the subcellular localisation, substrate specificity, and fine-tuning of 
catalytic subunit activity, conferring significant complexity and specificity to the PPP 
family (Virshup and Shenolikar, 2009).  
In addition to the regulatory subunits, an increasing number of scaffolding and inhibitory 
proteins have been characterised and reported to control the activity of the PPP catalytic 
subunits (Virshup and Shenolikar, 2009). The PPP family consists of protein phosphatase 1 
(PP1), protein phosphatase 2A (PP2A), protein phosphatase 2B (PP2B), protein 
phosphatase 4 (PP4), protein phosphatase 5 (PP5), protein phosphatase 6 (PP6), and 
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protein phosphatase 7 (PP7). These phosphatases exhibit high amino acid sequence 
homology within their catalytic domains and are reported to share similar catalytic 
mechanisms (Table 1.1; Honkanen and Golden, 2002). It has been reported that PP1, 
PP2A, and PP2B share a common catalytic domain of 280 residues but they are contrasting 
and antithetical within their noncatalytic N- and C-terminal domains and consequently they 
are distinguished by their regulatory subunits to form a diverse variety of holoenzymes 
(Bradford et al., 1998). Other studies supported the above findings and revealed that PP1, 
PP2A, PP4 and PP6 are highly homologous phosphatases, but they differ in their N- and C-
terminal domains (Figure 1.5; reviewed in Honkanen and Golden, 2002; Shi, 2009a). 
While the other three phosphoprotein phosphatases; PP2B, PP5 and PP7, have distinct 
structures. PP2B and PP7 contain an insert in the catalytic core, PP2B has a Ca2+-
calmodulin (CaM) binding site, PP5 has an extended N-terminal region with three 
tetratricopeptide (TPR) domains and PP7 has five EF- and EF-like hand domains in the C-
terminal calcium binding domain (reviewed by Honkanen and Golden, 2002). Moreover, 
figure 1.5 shows the similarity in the characteristic motifs; GDxHG, GDxVDRG, GNHE, 
HGG, RH and H (G, glycine; D, aspartic acid; x, any amino acid; H, histidine; V, valine; 
R, arginine; N, asparagine; E, glutamic acid) of the all phosphoprotein phosphatases family 
members (Shi, 2009a). 
The differences in the subunits' architecture gave each catalytic subunit of PPP family 
members' unique physiological roles in which influencing the catalytic activity, targeting it 
to a particular region of the cell and modulating substrate specificity (Honkanen and 
Golden, 2002). Table (1.2) summarises some of the characteristics of phosphoprotein 
phosphatases (PPP) family members. 
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Table (1.1) The catalytic domain sequence homology of PPP family members 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Amino acids sequence homology percentage Reference  
PP1 40% with PP2A Eichhorn et al., 2009 
PP2A 
40% with PP1 
65-66% with PP4 
57% with PP6 
Eichhorn et al., 2009 
Chen et al., 2008 
Chen et al., 1998 
PP4 65-66% with PP2A Chen et al., 2008 
PP5 35-45% with other PPP members Swingle et al., 2004 
PP6 57% with PP2A Chen et al., 1998 
PP7 35% with other PPP members Huang and Honkanen, 1998 
Figure 1.5 The Phosphoprotein Phosphatases (PPP) family's strucures. This figure shows that 
Ser/Thr Protein Phoshatases contain a common catalytic core domain, but they differ primarily in their 
N- and C-terminal domains. Moreover, PP2B has a Ca2+-calmodulin (CaM) binding site, PP5 contains 
an extended N-terminal region with three tetratricopeptide (TPR) domains while PP7 contains gaps 
inside the catalytic core domain. This figure is adapted from Shi, 2009a. 
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Table (1.2) The structural subunits of PPP family members (Adapted from Lee and 
Chowdhury, 2011; Moorhead et al., 2007). 
 
The role of reversible protein phosphorylation in different diseases, including cancer, has 
received a huge amount of interest in the last decades. While much of the attention has 
focused on modulating the activity of the kinases responsible for phosphorylation, the role 
that protein phosphatases play has received relatively little attention. Whilst the focus of 
this thesis is on the role of PP4, the role of the other PPP family members in apoptosis and 
cancer is outlined in the following section. 
 
1.5.1. Role of phosphoprotein phosphatases in apoptosis and cancer 
Most of protein phosphatase inhibitors such as okadaic acid, calyculin, cyclosporine A, 
FK506, and viral proteins (E4orf4) have been shown to induce apoptotic cell death via 
protein phosphatase inhibition (McCluskey et al., 2002). On the other hand, studies on the 
role of protein kinases and phosphatases in cellular signal transduction revealed that 16% 
of protein phosphatases are linked to human cancer (Forbes et al., 2015).  
PP2A, one of the most abundant and best studied members of the PPP family, has a well-
established role as a regulator of cell cycle progression and apoptosis (Sangodkar et al., 
 
Genes encoding catalytic 
subunit isoforms  
Catalyst 
subunit 
Regulatory subunit 
Subunit 
composition 
PP1 3 
Cα, Cβ, Cγ1, 
Cγ2 
PP1-interacting proteins 
(PIPs, more than 90) 
Heterodimer and 
higher order 
PP2A 2 Cα, Cβ 
Scaffolding A subunit (α, β),  
Regulatory B subunit (PR55, 
PR61, PR72) 
Heterodimer and 
higher order 
PP2B 3 
PP3Cα, PP3Cβ, 
PP3Cγ 
Calcineurin B or CNB 
Heterodimer and 
higher order 
PP4 1 C 
PP4R1, PP4R2, PP4R3α, 
PP4R3β, PP4R4 
Monomer and 
higher order 
PP5 1 C None 
Monomer and 
higher order 
PP6 1 C PP6R1, PP6R2, PP6R3 
Monomer and 
higher order 
PP7 2 C Unknown Monomer 
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2016). It has an essential role in controlling apoptosis by regulating both intrinsic and 
extrinsic apoptotic pathways (Sun and Wang, 2012), including  by its interaction with 
caspase-3 (Allan et al., 2003) and by regulating the activity of other key players of 
apoptosis namely members of the Bcl2-family such as BAD and Bcl-2 (Marcellus et al., 
2000; Shtrichman et al., 1999; 2000). Phosphorylation of BAD suppresses, and its 
dephosphorylation by PP2A promotes its pro-apoptotic activity (Chiang et al., 2001), while 
phosphorylation of Bcl-2 activates, and its dephosphorylation by PP2A suppresses its anti-
apoptotic activity (Lin et al., 2006). Xu et al. (2013) have reported that the tyrosine kinase 
Src, which is able to prevent apoptosis by the inactivation of caspase-8, is also regulated by 
PP2A. PP2A inhibits the action of Src through its de-phosphorylation leading to the 
activation of caspase-8 resulting in increased apoptosis (Xu et al., 2013). Inhibition of its 
activity or loss of some of its functional subunits is a characteristic of neoplastic 
transformation; therefore PP2A is now widely designated as a tumour suppressor (Sun and 
Wang, 2012). The first evidence that PP2A was a tumour suppressor was based on studies 
where mice treated with okadaic acid, a specific inhibitor of PP2A, developed tumours 
(Fujiki et al., 1991). 
PP2A has been found to regulate a number of pathways that are deregulated in cancer. It 
regulates the RAS-RAF-mitogen activated protein kinase (MAPK) signalling pathway by 
targeting multiple kinases in the pathway (Eichhorn et al., 2009). Studies using both PP2A 
and okadaic acid have also implicated PP2A in the inhibition of the Wnt signalling 
pathway (Perrotti and Neviani, 2013). Deregulation of the Wnt signalling pathway is 
involved in the control of cell growth and cell survival, and is believed to increase cell 
proliferation, often resulting in tumour formation (Perrotti and Neviani, 2013). The tumour 
formation is due to a member of the Wnt signalling pathway called β-catenin, which upon 
stabilisation, migrates and accumulates in the nucleus of cells, causing tumour growth 
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(Perrotti and Neviani, 2013). An increase in PP2A levels was found to correlate with an 
increase in β-catenin degradation and an increase in the PP2A inhibitor okadaic acid 
caused a decrease in β-catenin degradation (Perrotti and Neviani, 2013).  
It is now well established that deregulation of Akt activity is associated with various 
human malignancies and that PP2A can regulate the activity of Akt by de-phosphorylating 
its Thr308 and Ser473 residues (Li et al., 2005; Sangodkar et al., 2016). Co-expression of 
both Akt and the catalytic subunit of PP2A resulted in a significant decrease in the activity 
of Akt (Li et al., 2005). In addition, the inhibition of PP2A by okadaic acid was found to 
increase Akt activity (Li et al., 2005). PP2A activity is lost in colorectal cancer as a result 
of its catalytic subunit PP2Ac hyperphosphorylation and the anti-tumoural effects of 
forskolin-mediated PP2A activation suggests that PP2A could be a promising therapeutic 
target in colorectal cancer (Cristóbal et al., 2014). 
In addition to PP2A, other PPP family members are reported to be involved in controlling 
apoptosis and many other studies have linked them to cancer development (Klumpp and 
Krieglstein, 2002). Studies have also shown that PP1 inhibition by over-expression of PP1 
inhibitor-1 resulted in the prevention of cardiomyocyte apoptosis (Nicolaou et al., 2009), 
whilst protein phosphatase 1 inhibitor 5 (IPP5) was characterised to be a potential growth 
inhibitor for cervical carcinoma cells (Zeng et al., 2012). Using systematic affinity 
proteomics analysis, it has been found that okadaic acid disrupts the specific interactions of 
PP1 and PP2A, inhibiting their activity, supporting the potential of therapeutics targeting 
them (Yadav et al., 2017). Moreover, Yadav et al., (2017) also describe the structural 
heterogeneity and the functional interaction that link phosphatases to the regulation of 
signalling pathways and to several diseases including distinct cancers; including brain 
tumours, and leukaemia. Down-regulation in PP2B activity was reported in squamous cell 
carcinoma of cervix with high risk HPV infection, indicating that perturbations in PP2B 
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signalling pathways may be involved in development of cervical neoplasia (Padma et al., 
2005).  
PP5 is involved in regulating the activity of the stress and DNA-damage-regulated protein 
kinases (Hinds and Sanchez, 2008). In response to either prolonged hypoxia or acute 
oxidative stress, PP5 binds to ASK1 (apoptosis signal regulating kinase 1) (Morita et al., 
2001; Zhou et al., 2004); this interaction prevents the sustained activation of JNK (c-Jun-
N-terminal kinase) and apoptosis by suppressing ASK1 dependent activation of MKK4 
(Map-Kinase-Kinase-4) (Morita et al., 2001; Huang et al., 2004; Zhou et al., 2004). 
Additionally, PP5 overexpression blocks ASK1 activation and promotes tumour growth in 
a MCF-7 mouse xenograph model (Golden et al., 2004) and it is also reported that 
overexpression of PP5 prevented ASK1 activation and blocked apoptosis in p53 mutant 
rhabdomyosarcoma (Rh30) cell line by inhibiting the activity of the protein kinase mTOR 
using rapamycin, and thus inducing a stress response that includes activation of ASK1 
(Huang et al., 2004). PP7 was also reported to act as a potent negative regulator of ASK1 
(Kutuzov et al., 2010). Elevated levels of PP5 were detected in mantle-cell lymphoma and 
human breast cancer (Ghobrial et al., 2005; Atiye et al., 2005; Golden et al., 2008a; Golden 
et al., 2008b). Recently, it has been found that PP5 knockdown suppresses the proliferation 
and migration of hepatocellular carcinoma cells (Feng et al., 2015), human glioma cells 
(Zhi et al., 2015) and acute myeloid leukaemic cells (Li et al., 2016a).  
PP6c silencing in HeLa cells, cervical carcinoma cells, showed more than a two fold 
increase in the level of apoptosis (MacKeigan et al., 2005). PP6c is overexpressed in high 
grade human ductal carcinoma in situ of the breast (Adeyinka et al., 2002), paediatric acute 
lymphoblastic leukaemia (Ross et al., 2003), pancreatic tumours (Sato et al., 2004), and is 
induced with androgen treatment of LNCaP prostate cancer cells (Nantermet et al., 2004). 
The regulatory subunit of PP6, PP6R1, is one of the top 20 genes overexpressed in 
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hepatocellular carcinoma and metastatic liver tumours (Tackels-Horne et al., 2001). In 
patients with glioblastoma multiforme (GBM), PP6 knockdown inhibits the glioblastoma 
growth and potentiates the sensitivity of GBM cells to radiation (Shen et al., 2011).  
 
1.5.2. PP2A role in leukaemia 
Numerous studies have highlighted the importance of protein phosphatases in leukaemia 
and their potential as targets for novel therapies (McConnell and Wadzinski, 2009; Neviani 
et al., 2005; 2007). In particular, PP2A has emerged as an important tumour suppressor in 
myeloid leukaemia and strategies aimed at reactivating this phosphatase, in addition to the 
inhibition of the tyrosine kinase activity, have shown great promise for a new generation of 
leukaemia therapies (McConnell and Wadzinski, 2009; Neviani et al., 2005; 2007). 
Another study on B55α, a subunit of PP2A regulatory subunit which is identified as a 
specific regulator of the levels of Akt phosphorylation at Thr308, showed that this subunit 
was inhibited and loss of complete haematological remission in AML patients (Ruvolo et 
al., 2011). In CML, it has been reported that PP2A over-expression suppresses the activity 
of Bcr-Abl kinase, promotes apoptosis and enhances imatinib activity (Neviani et al., 2005; 
2007). PP2A inhibition by Bcr-Abl is essential for the development of positive 
Philadelphia chromosome (Ph+) leukaemias including CML, and this occurs as a result of 
the over-expression of SET, a PP2A endogenous inhibitor (also called I2PP2A, TAF-1β or 
PHAP1) that was isolated from a patient with acute undifferentiated leukaemia (Neviani et 
al. 2005; 2007; Adachi et al., 1994). On the other hand, imatinib treatment inhibits Bcr-Abl 
that lead to reduced SET protein expression, which results in the reactivation of PP2A 
leading to dephosphorylation of several substrates such as ERK1/2, Akt, and BAD, which 
are shared by both Bcr-Abl and PP2A (Neviani et al. 2005; Calabretta and Perrotti 2004; 
Janssens and Goris 2001). Restoration of PP2A activity results in PP2Ac association with 
Bcr-Abl via the SHP1 tyrosine phosphatase, Bcr-Abl dephosphorylation, and proteasomal 
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degradation (Neviani et al. 2005). These findings suggested that SET-dependent inhibition 
of PP2A is required for the transduction of aberrant mitogenic, survival and anti-
differentiation signals that contribute to the development of CML from the chronic phase 
into blast crisis (Neviani et al. 2005). 
 
1.6. Protein phosphatase 4 (PP4) 
In the last decades, few studies have highlighted the role of PP4 in apoptosis and diseases 
such as cancer, therefore, this research will focus on the structure, functions and roles of 
PP4, specifically in leukaemia.  
 
1.6.1. PP4 structure 
Protein phosphatase 4 (PP4), also known as PPP4, PPX, and PPH3, is a ubiquitous and 
highly conserved serine/threonine phosphatase. The PP4 holoenzyme consists of a catalytic 
subunit, PP4c, which interacts with different structural and regulatory subunits (Chen et al., 
2008). PP4c was first cloned from a human teratocarcinoma library and named PPX by 
Brewis and Cohen (1992). The human PP4c is mainly localized to the centrosomes with a 
molecular mass of 35 kDa and consists of 307 amino acids (Hastie et al., 2000). Human 
PP4c is 100% identical to the mouse protein, differs from that of the rabbit by only two 
amino acids and shares 91% amino acid identity with the Drosophila PP4c (Hastie et al., 
2000), suggesting a highly conserved protein of functional importance. The Human PP4c 
gene is located on chromosome 16 p11.2, which is linked to the translocational mutation 
associated with acute leukaemia (Bastians et al., 1997).  
PP4c shares about 65-66% identity in the amino acid sequences with the PP2A α and PP2A 
β catalytic subunits, yet its regulatory subunits are very distinct from those of PP2A and 
this elucidates the difference between PP4 and PP2A and their roles in the regulation of the 
cellular functions (Chen et al., 2008; Mourtada-Maarabouni, and Williams, 2008; 2009). 
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Several PP4c-interacting proteins have been identified, including PP4 regulatory subunit 1 
(PP4R1), PP4 regulatory subunit 2 (PP4R2), PP4 regulatory subunit 3 alpha (PP4R3α), 
PP4 regulatory subunit 3 beta (PP4R3β), PP4 regulatory subunit 4 (PP4R4), and alpha 4/ 
immunoglobulin (CD79A) binding protein 1 (α4/ IGBP1) (Hastie et al., 2000; Carnegie et 
al., 2003; Gingras et al., 2005; Chen et al., 2008). PP4R1 was one of the first regulatory 
subunits identified to interact with the catalytically active subunit PP4c (Kloeker and 
Wadzinski, 1999; Wada et al., 2001). Stable complex formation between PP4R1 and PP4c 
was further confirmed by independent proteomic screening approaches (Chen et al., 2008; 
Gingras et al., 2005). PP4R2 is predominantly located in the centrosomes in human cells 
suggesting that it could be involved in targeting PP4c to this location (Hastie et al., 2000). 
Other studies have suggested that PP4R1 and PP4R2 may form PP4c-R1 and PP4c-R2 
complexes that become attached to a third variable subunit to form different PP4 
complexes with different functions (Carnegie et al., 2003; Janssens and Goris, 2001). 
PP4R3 (also known as suppressor of Mitogen-activated Protein/extracellular signal-
regulated Kinase (Smek) is also a regulatory subunit of PP4c (Gingras et al., 2005; 
Chowdhury et al., 2008). In Dictyostelium cells, overexpression of Smek and PP4c 
increased the nuclear accumulation of PP4c; leading to the suggestion that Smek regulates 
PP4c by controlling its localisation to the nucleus (Mendoza et al., 2005). In addition, 
Smek dephosphorylates the phosphorylated histone H2A variant X (γ-H2AX) in 
mammalian cells (Chowdhury et al., 2008) and enhances hepatic gluconeogenesis in vivo 
(Yoon et al., 2010). The fourth regulatory subunit characterised was PP4R4 which displays 
some sequence homology with PP2A scaffolding subunit A (Chen et al., 2008). Despite 
this homology, PP4R4 interacts only with PP4c and this interaction occurs in a direct 
manner and independently of other subunits (Chen et al., 2008). Finally, α4/IGBP1 is the 
only regulatory subunit of PP4c that is reported to bind to both PP4c and PP2Ac (Hastie et 
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al., 2000; Kloeker et al., 2003). McConnell et al. (2010) reported that α4/IGBP1 plays a 
role in the regulation of PP2Ac ubiquitination and protects it from proteasomal-mediated 
degradation, by acting as an adaptor protein that provides a platform for both PP2Ac and 
the E3 ubiquitin ligase Mid1 (Kong et al., 2009; McConnell et al., 2010). Depletion of 
α4/IGBP1 caused a rapid decrease in PP2Ac, PP4c and PP6c levels leading to the 
inhibition of the dephosphorylation of their substrates (Kong et al., 2009). 
 
1.6.2. PP4 functions 
The interaction between the different targeting regulatory subunits of PP4 appears to be 
central to PP4c function. PP4 plays an essential role in human centrosome maturation, cell 
migration (Martin-Granados et al., 2008), DNA damage checkpoint signalling (Nakada et 
al., 2008), and DNA repair (Lee et al., 2010). It is also involved in tumour necrosis factor 
(TNF)-alpha signalling, NF-κB regulation, activation of c-Jun N-terminal kinase (Zhou et 
al., 2002), nutrient sensing pathway (Bertram et al., 2000; Wu et al., 2004), apoptosis 
(Mourtada-Maarabouni et al., 2003; Mourtada-Maarabouni and Williams, 2008) and 
regulation of histone acetylation (Zhang et al., 2005). A study suggested that both 
excessive and insufficient activity of PP4c could be fatal to Human Embryo Kidney 293T 
cells (Mourtada-Maarabouni and Williams, 2008).  
PP4c expression was reported to be altered in different tissues in the murine embryo, 
indicating a potential role in embryonic development (Hu et al., 2001). Knockout mice 
studies have confirmed a vital and non-redundant role for PP4c in ontogenesis and tissue 
development (Shui et al., 2007). In addition, PP4c gene deletion in the T-cell lineage 
resulted in abnormal thymocyte development and maturation, indicating that PP4c is 
essential for thymocyte development and pre-T cell antigen receptor (pre-TCR) signalling 
(Shui et al., 2007). Knockout mice studies have also identified an essential role for PP4c in 
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B cell development, since PP4c knockout mice showed a disruption in pro-B cell 
differentiation leading to a complete absence of mature B cells (Su et al., 2013).  
Studies have also shown that PP4c plays an important role in the spliceosomal assembly 
via interaction with the survival motor neurons (SMNs) complex (Carnegie et al., 2003). 
PP4c is also reported to regulate the activity of Histone deacetylase 3 (HDAC3), a member 
of the human class I HDACs that regulates gene expression by deacetylation of histones 
and non-histone proteins (Zhang et al., 2005). In HeLa cells, the down-regulation and over-
expression of PP4c showed that the activity of HDAC3 is inversely proportional to the 
cellular abundances of PP4c (Zhang et al., 2005).  
PP4c is reported to act as a positive regulator of NF-κB activity in human cervical 
carcinoma SiHa (Yeh et al., 2004), whilst in T Lymphocytes, PP4c negatively regulates the 
activity of NF-κB (Brechmann et al., 2012). Such counteracting effects of PP4c functions 
have been related to the existence of different PP4c complexes that have different 
compositions as a result of interaction with its different regulatory subunits (Cohen et al., 
2005); for example, the negative regulation of the activity of NF-κB in T lymphocytes has 
been linked to PP4c-PP4R1 complex, therefore, substrate specificities, subcellular 
localisations, activities and functions of PP4c depend largely on the composition of its 
different complexes (Brechmann et al., 2012). T cell receptor or tumour necrosis factor 
receptor 1 (TNFR1) stimulation leads to the phosphorylation of IκB kinase (IKK) complex 
followed by the proteasomal degradation of subsequent inhibitory κB proteins (IkBs) 
resulting in the translocation of NF-κB proteins to the nucleus, where they bind to DNA 
and activate the transcription of NF-κB-regulated genes (Hayden and Ghosh, 2008). 
Brechmann et al. (2012) have showed that PP4R1 potentiates the activity of PP4c and 
allows its association with IKK complex leading to its dephosphorylation and inactivation 
and consequently the inhibition of the aberrant NF-κB signalling activity. These findings 
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suggested that PP4R1 deficiency leads to inactivation of PP4c that causes PP4c disability 
to dephosphorylate the IKK complex, resulting in uncontrolled IKK phosphorylation and 
abnormal NF-κB activity (Brechmann et al., 2012). 
 
1.6.3. PP4 role in apoptosis, DNA damage repair and cancer 
Many studies have supported the hypothesis that PP4c may function as a tumour 
suppressor gene and implicated its role in the regulation of apoptosis (Mourtada-
Maarabouni et al., 2003; Mourtada-Maarabouni and Williams, 2008; 2009). The first 
experiment that suggested that PP4 plays an important role in apoptosis was carried using 
mouse lymphoma W7.2c cells, where over-expression of PP4c resulted in an increase in 
cell death and a decrease in cell proliferation (Mourtada-Maarabouni et al., 2003). 
Subsequent studies on HEK 293T human embryonic cells and both leukaemic human T 
cells and primary human peripheral blood T-cells also showed that over-expression of 
PP4c enhanced apoptosis, while PP4c down-regulation suppressed apoptosis (Mourtada-
Maarabouni and Williams, 2008; 2009). These studies also showed that modulation of PP4 
expression affects the phosphorylation status of proteins that are involved in apoptosis and 
cell proliferation such as extracellular signal-regulated kinase 1 (ERK1), extracellular 
signal-regulated kinase 2 (ERK2) (Mourtada-Maarabouni and Williams, 2008) and 
Phosphoprotein Enriched in Astrocytes (PEA15), a member of the death effector domain 
(DED) protein family involved in regulating both ERK1 and ERK2 (Krueger et al., 2005, 
and Mourtada-Maarabouni and Williams, 2008). PEA-15 inhibits apoptosis through its 
death effector domain (DED) which interacts with the DED of other proteins such as 
apoptotic adaptor protein (FADD) and inhibits apoptosis via inhibiting assembly of 
apoptotic signalling complexes (Greig and Nixon, 2014). PEA-15 function is tightly 
regulated by phosphorylation; the anti-apoptotic effect of PEA-15 is stabilised by 
Akt/PKB, which promotes its phosphorylation (Toker and Newton, 2000). Previous studies 
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suggested that the level of PP4 influenced the gene mutation rate, which is crucial to 
oncogenesis (Mourtada-Maarabouni and Williams, 2008; 2009). PP4c over-expression 
reduced the mutation in the indicator gene, hypoxanthine phosphoribosyl transferase (hprt), 
whilst the PP4 down regulation increased the mutation frequency of this gene (Mourtada-
Maarabouni and Williams, 2008; 2009). The PEA-15 gene has been found to be over-
expressed in human breast cancer and other human cancers (reviewed in Krueger et al., 
2005) and such over-expression was associated with a resistance to a broad range of anti-
cancer drugs (Stassi et al., 2005). Akt, which phosphorylates and stabilises the anti-
apoptotic action of PEA-15, is also up-regulated in breast cancer and the hyper activation 
of PI3K/Akt/mTOR pathway is implicated in the tumorigenesis of ER+ breast cancer and 
resistance to endocrine therapy, suggesting that Akt and PEA-15 might function 
cooperatively in breast tumorigenesis (Ciruelos Gil, 2014). A recent study suggested that 
modulating the levels and activities of PP4c and/or PEA-15 may have a novel role in the 
treatment of breast cancer (Mohammed et al, 2016). Mourtada-Maarabouni and Williams 
(2009) have also reported that the pro-apoptotic effects of PP4c in leukaemic cells was 
partly mediated by the dephosphorylation of PEA-15, providing evidence that the 
interaction between PEA-15 and PP4c may be critical in leukaemogenesis and/or 
leukaemia progression (Mourtada-Maarabouni and Williams, 2009).  
On the other hand, other studies have supported the hypothesis of the role of PP4c in the 
progression of several cancers suggesting that PP4c might function as oncogene and this 
action could be a result of the deregulation in the expression or activity of PP4 regulatory 
subunits (Martin-Granados et al., 2008; Wang et al., 2008; Weng et al., 2012; Li et al., 
2016b). It has been reported that depletion of PP4c in HEK293 cells resulted in severely 
decreased cell migration and suggested that PP4c complexes may coordinate centrosome 
maturation and cell migration via regulation of Rho GTPases (Martin-Granados et al., 
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2008). The high expression of PP4c has been also reported in breast and lung tumours 
(Wang et al., 2008). In their study, Wang and colleagues (2008) also suggested that the 
inhibition of PP4c expression may increase the sensitivity of breast and lung cancer cells to 
cisplatin treatment (Wang et al., 2008). In addition, an immunohistochemical study on 
stage II pancreatic ductal adenocarcinoma (PDAC) samples revealed that PP4c over-
expression is associated with poor prognosis and this over-expression was associated with 
a distant metastasis (Weng et al., 2012). This study also suggested that PP4c could act as a 
marker for the diagnosis of invasive PDAC and a new approach for the treatment of this 
disease via targeting its signalling pathways (Weng et al., 2012). Recently, a study 
suggested that PP4c also plays an oncogenic role in glioma's development and progression 
(Li et al., 2016b).  
Studies have also implicated PP4 in DNA repair mechanisms. The loss of DNA repair 
systems that prevent the fixation of pre-mutagenic lesions in the genome is another major 
cause of oncogenesis in humans and the accumulation of these lesions is essential for 
carcinogenesis (Shimada and Nakanishi, 2013). The PP4c-PPP4R2 complex regulates the 
phosphorylation status of the replication protein A2 (RPA2) which is essential in the DNA 
double strand break (DSB) repair pathway (Davis and Chen, 2012). Dephosphorylation of 
RPA2 is essential for the continuation of post damage DNA synthesis and this in turn 
allows the cell to restart the cell cycle (Lee et al., 2010). In response to DNA double-strand 
breaks, the histone H2A variant H2AX is rapidly phosphorylated by ATR to produce γ-
H2AX. γ-H2AX functions to stabilise cell-cycle checkpoint proteins and DNA repair 
factors at the break site (Chowdhury et al., 2008). A complex containing PP4c, PP4R2, and 
PP4R3β is reported to dephosphorylate γ-H2AX generated during DNA replication, a 
process required for DNA damage repair (Chowdhury et al., 2008). Another finding 
suggests PP4c is involved in controlling the proliferation and differentiation of neural 
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progenitor cells in the mouse neocortex by regulating the phosphorylation status of nuclear 
distribution protein nudE-like1 (Ndel1) (Xie et al., 2013).  
The role of PP4c regulatory subunits in cancer is also studied. In vitro, PP4R1 knockdown 
inhibits cell proliferation and colony formation in breast cancer cells (Qi et al., 2015), 
hepatocellular carcinoma cells (Wu et al., 2015) and lung cancer cells (Zhu et al., 2016). A 
recent study suggested that insufficient PP4R2 may contribute to the pathogenesis of AML 
by increased DNA damage (Herzig et al., 2017). PP4R2 suppression results in de-
phosphorylation impairment of phosphorylated DNA damage response proteins such as 
γH2AX and p53 and thus developed AML (Herzig et al., 2017). 
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1.7. The aims of the study 
Many studies support the hypothesis that protein phosphatase 4 catalytic subunit (PP4c) 
may function as a tumour suppressor gene. PP4c has also been implicated in the regulation 
of the growth and survival of leukaemic T-cells and untransformed human peripheral blood 
T-cells (Mourtada-Maarabouni and Williams, 2008; 2009). While others suggest that PP4c 
might function as oncogene, since high expression of PP4c levels have been reported in 
breast and lung tumours (Wang et al., 2008) and pancreatic ductal adenocarcinoma 
(PDAC) (Weng et al., 2012). 
Therefore, the overall aims of this study are: 
 The evaluation of the role of PP4c in leukaemia, using two types of model system 
cell lines; K562 for chronic myeloid leukaemia and HL-60 for acute myeloid 
leukaemia. 
 
The objectives are: 
 To over-express and down-regulate PP4c in two types of leukaemic cell lines, 
K562 and HL-60 cells, and evaluate the effect on cell viability, apoptosis, and 
proliferation. 
 To investigate the response of K562 and HL-60 cells to the first line therapeutic 
drugs post PP4c silencing. The functional effects of PP4c down-regulation on the 
cellular response to cisplatin, doxorubicin, imatinib (only with K562) and 
rapamycin was investigated by measuring changes in apoptosis and cell viability. 
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2. Materials and Methods 
2.1. Materials 
Roswell Park Memorial Institute (RPMI)-1640 medium (R0883), gentamicin (G1272), L-
glutamine (200 mM solution), trypan blue (0.4%), dimethyl sulphoxide (DMSO), β-actin 
antibody (#A5441), horseradish peroxidase-conjugated (HRP-conjugated) anti-goat IgG 
secondary antibody (#A5420), doxorubicin hydrochloride (#25316-40-9) and Cis-
Diammineplatinum (II) dichloride (cisplatin) (#15663-27-1) were purchased from Sigma-
Aldrich. Imatinib mesylate (#A03-901B) was purchased from SignalChem and rapamycin 
(#1292) from TOCRIS bioscience. Nucleofection solution V (MIR 50115) was purchased 
from Mirus Bio LLC, USA, HiPerFect transfection reagent (#301704) was purchased from 
Qiagen. Scrambled or negative control siRNA (-siRNA) (#4605), PP4c siRNA1 (#105835) 
and PP4c siRNA2 (#105834), were purchased from Ambion, while PP4c siRNA8 
(S102658698) and PP4c siRNA9 (S102658705) were purchased from Qiagen. All these 
siRNAs were annealed and ready to use. The primary anti-PP4c (PPX/PP4 (C-18), a goat 
polyclonal IgG, #sc-6118 & (C-6), a mouse monoclonal IgG, #sc-374106) were purchased 
from Santa Cruz Biotechnology. HRP-conjugated anti-mouse IgG secondary antibody 
(#P0447) was purchased from Dako. CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (MTS) was purchased from Promega. 
The Muse Count and Viability Kit (#MCH 100102), Muse Annexin V and Dead Cell Kit 
(#MCH 100105), Muse Cell Cycle Kit (#MCH 100106), and Muse Ki67 Proliferation Kit 
(#MCH 100114) were purchased from Merck Millipore, Germany. The 6, 24, and 96 well 
plates and tissue culture flasks were purchased from Greiner. 
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2.2. Cell lines and routine cell culture 
Human chronic myelogenous leukaemia (CML) cell line K562 and acute promyelocytic 
(APL) cell line HL-60 were used in this study. The K562 cell line was established from the 
pleural effusion of a 53-year-old female with CML in terminal blast crises and is 
characterised by a positive Philadelphia chromosome (Lozzio and Lozzio, 1975), while 
HL-60 (a non-adherent human leukocyte cell line) was derived from a 36-year-old 
Caucasian female with APL (Collins et al., 1978).  
Both cell lines were originally purchased from the ATCC (K562; CRL-343™ and HL-60; 
CCL-240™), cell lines were provided with a specification document containing STR 
profiles and expressed isoenzymes. Secondary stocks were generated and frozen down 
within two weeks receipt from the ATCC. Cultured cells were replaced from these 
secondary stocks after a maximum culture period of 2 months, with cellular morphology 
and growth characteristics monitored routinely throughout culture periods.   
K562 and HL-60 cell lines were cultured in RPMI-1640 medium supplemented with 10% 
heat-inactivated foetal bovine serum (FBS), 2 mmol/L L-glutamine and 10 mg/mL 
gentamicin at 37°C in a humidified atmosphere of 5% CO2:95% air. K562 and HL-60 cells 
are suspension cells and they were sub-cultured three times per week at 2×105 cells/mL for 
K562 cells and 3×105 cells/mL for HL-60 cells. 
 
39 
 
2.3. Freezing and thawing of the cell lines  
For long term storage of the cells, 1×106 cells were harvested and re-suspended in 1.0 mL 
of cryoprotectant medium comprising 40% FBS-supplemented RPMI-1640 medium with 
10% dimethyl sulphoxide (DMSO). The cell suspension was transferred into a cryo-tube 
and immediately stored at -80 °C or at -140°C in liquid nitrogen for long term storage.  
For thawing cryopreserved cells, cells were rapidly thawed at 37°C and immediately re-
suspended in 10 mL of complete RPMI-1640 medium to dilute the DMSO, then 
centrifuged at 1200×g for 5 minutes and the cell pellet re-suspended in an appropriate 
volume of fresh culture medium (section 2.2).  
 
2.4. Plasmid preparation and purification 
Prior to the current study, the PP4c EST (accession #BG913014), containing the full length 
cDNA encoding the catalytic subunit of PP4, was directionally cloned into pcDNA3.1 
using the EcoRI and XhoI restriction sites of the vector. Recombinant (pcDNA3.1-PP4c) 
and native (pcDNA3.1) vectors were transformed into E.coli by electroporation and 
positive (ampicillin resistant) colonies isolated; insert incorporation into the recombinant 
vector was confirmed by sequencing (MWG) using vector-specific primers, and glycerol 
bacterial stocks prepared for long-term storage at -80C (Mourtada-Maarabouni et al., 
2003).  
The preparation and purification of the plasmids pcDNA3.1 and pcDNA3.1-PP4c were 
carried out using the Qiagen® Plasmid Maxi Kit. Briefly, around 10 μL of frozen bacterial 
glycerol suspension was added to a starter culture of 2-5 mL Lennox broth (LB) medium 
containing 50 μg/mL of ampicillin and then incubated at 37°C for eight hours with 
vigorous shaking (at 300 rpm). The starter medium was then diluted in a ratio of 1/500-
1/1000 in LB media containing 50 µg/mL ampicillin and incubated at 37°C for up to 16 
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hours with vigorous shaking (at 3000 rpm). The purification protocol was based on an 
alkaline lysis procedure; 100 mL of the LB culture bacterial cell were pelleted by 
centrifuging at 6000×g for 15 minutes at 4°C, then 10 mL of re-suspension buffer 
composed of 50 mM Tris-Cl, pH 8.0; 10 mM EDTA; 100 μg/mL RNase A was added to 
homogenize the bacterial pellet. A further  10 mL of a lysis buffer composed of 200 mM 
NaOH and 1% SDS (w/v) was added and the samples mixed by vigorously inverting the 
tube 4-6 times, followed by incubation at room temperature (15-25°C) for 5 minutes. 
Plasmid DNA was then isolated by initially binding to a QIAGEN resin under low-salt and 
pH conditions by adding 10 mL from a chilled neutralization buffer composed of 3.0 M 
potassium acetate, pH 5.5, then the bacterial lysate was transferred to a barrel of the 
QIAfilter Cartridge and incubated at room temperature (15-25°C) for 10 minutes and then 
the lysate was filtered into a 50 mL tube. By a medium-salt wash (1.0M NaCl; 50 mM 
MOPS [free acid], pH 7.0; 15% isopropanol (v/v)), the column was washed twice (30 mL 
each wash) so that all impurities including RNA, proteins, and low-molecular–weight 
particles were removed. Plasmid DNA was then  eluted with 15 mL of a high-salt buffer 
(1.6 M NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol (v/v)) and then concentrated and 
desalted by 10.5 mL isopropanol precipitation followed by centrifugation ≥ 15000×g at 
4°C for 30 minutes. The extracted plasmid DNA concentration and purity was determined 
using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific), any samples with 
A260/A280 value that was less than 1.8 were discarded. The identity of the plasmid DNA 
was verified by a diagnostic digest and sequence analysis (MWG Biotech); sequencing 
results were checked against the ncbi entry for human PP4c (accession #BG913014). 
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2.5. Plasmid DNA transfection  
The effects of PP4c over-expression on cell viability, proliferation and apoptosis in CML 
and APL were investigated by introducing the pcDNA3.1-PP4c expression construct or the 
empty pcDNA3.1 vector (negative control) into the K562 and HL-60 cell lines using 
nucleofection as a transfection method. (2×106 cells) were re-suspended in 0.1 mL 
nucleofection solution V containing 2 μg of plasmid DNA then transfected by 
Nucleofector TM II 2b using programme T-016 for K562 cells and T-019 for HL-60 cells 
(see chapter 3 section 3.4.1). Cells were then seeded in 3.0 mL of pre-incubated growth 
medium in 6-well plates and incubated for 24 hours to allow recovery and PP4c 
expression, cells were then re-plated at 2×105 cells/mL for further functional assays (see 
section 2.7). 
  
2.6. RNA interference  
Small interfering RNA (siRNA), also called short interfering RNA or silencing RNA, are 
double-stranded RNA molecules, usually 20-25 pairs in length with phosphorylated 5' ends 
and hydroxylated 3' ends, which can be introduced into cells by various transfection 
methods to silence any gene. When the siRNA molecules enter the cell they incorporated 
into a siRNA-protein complex called siRNA induced silencing complex (RISC), which 
contains helicase activity that unwinds the two strands of the siRNA molecule (Zamore et 
al., 2000). The siRNA/RISC complex is responsible for the degradation of the target RNAs 
that contain homologous sequences to the siRNA (Figure 2.1; Tuschl, 2001).  
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Figure 2.1 How do siRNA Gene Silencers work. From Santa Cruz Biotechnology Inc. 
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2.6.1. K562 cell line 
In this study, the effects of PP4 down-regulation on the K562 cell viability, proliferation 
and apoptosis were also conducted using nucleofection as a transfection method. K562 
cells were incubated in the log phase for 24 hours before 1-2×106 cells per transfection 
were harvested. Cells were re-suspended in 100 µL nucleofection V solution and then 
nucleofected using 50 nM of either the non-silencing negative control siRNA, PP4c 
siRNA1 (targeting exon 4 and 5), PP4c siRNA2 (targeting exon 7), PP4c siRNA8 
(targeting exon 7, distinct sequence from PP4c siRNA2) or PP4c siRNA9 (targeting exon 
6), using the Nucleofector TM II 2b. The transfected cells were then transferred to 7.0 mL 
of pre-incubated complete growth medium in 25cm2 flasks and incubated for 72 hours 
before being re-plated at 2×105 cells/mL for further functional assays (see section 2.7).  
 
2.6.2. HL-60 cell line  
HiPerFect transfection reagent (Qiagen) was used to introduce the siRNAs into HL-60 
cells. Cells were seeded in 6 well plates at a density of 8×105 cells per well in 0.4 mL 
complete culture medium. A mixture of 0.4 mL of Opti-MEM™ medium, 12 µL HiPerFect 
transfection medium and 3.2 µL siRNAs (200 ng) were allowed to form transfection 
complexes for 5-10 minutes at room temperature and added dropwise to the cells. Plates 
were incubated for 6 hours before 1.6 mL of complete culture medium was added to each 
well and the plates incubated for 72 hours at 37°C in a 5% CO2 humidified incubator (see 
chapter 3 section 3.4.2.2). The cells were re-plated in 6-well plates at 2×105 at 72 hours 
post transfection for further functional assays. 
Previous studies investigating PP4c knockdown in HEK 293T, CEM-C7 and Jurkat cell 
lines, cells were analysed for PP4c expression by qRT-PCR and Western blotting 48 hours 
post-transfection, yielding a 80-90% decrease (Mourtada-Maarabouni and Williams, 2008; 
2009). Further investigations prior to the current study also determined a comparable 
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reduction in expression levels at 48-72 hours post transfection and therefore cells were 
harvested at 72 hours post transfection in this study to ensure efficient knock-down of 
PP4c at the mRNA and protein level. 
Whilst there is a 60-65% sequence homology between PP4 and PP2A, as well as homology 
with other PPP family members (see Chapter 1, Table 1), selectivity of the siRNAs 
towards only PP4c (hence precluding any off-target effects on down-regulation of other 
PPPs) is validated by the manufacturers, with no ‘off-target’ effects reported, even with 
high homology transcripts. Both Western blot and qRT-PCR techniques could be used in 
the current study to confirm the specificity of the PP4c siRNAs manually, however in-
house validation (prior to the current study) similarly observed no effect of PP4c siRNAs 
on the expression levels of PP2A in Jurkat, CEM7 and MCF-7 cells, similarly there was no 
effect of PP2A siRNAs on the expression of PP4c (Mourtada-Maarabouni et al., 2003; 
Mourtada-Maarabouni and Williams 2008; 2009).   
    
2.7. Determination of cell viability 
2.7.1. Trypan blue dye exclusion 
Viable cell number was determined by Trypan blue exclusion analysis in 6-well plates 
following plasmid DNA and siRNA transfection and re-plating after 24 or 72 hours, 
respectively, or in 24-well plates for drug treatment (see section 2.12), at 2×105 cells/mL. 
Using a haemocytometer, 10 μL of the cell suspension from each well of the plates were 
mixed with an equal volume of 0.4% Trypan blue dye and 10 µL loaded to the counting 
chamber with coverslip. The cells in the four corner 4x4 grids were counted as viable if 
they excluded the dye and dead if they stained blue. Trypan blue is taken up by all cells but 
is actively excluded by viable cells, which retain membrane integrity. The results were 
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represented either as the number of viable cells/mL (×105) or viability expressed as a 
percentage of the total cell number (% viability). 
 
2.7.2. MTS assay 
The CellTiter 96® AQueous One Solution Cell Proliferation Assay is another cell viability 
method used in this research. It is a colorimetric method to determine the viability of cells 
in proliferation or drug dose response assays (The CellTiter 96® AQueous One Solution 
Cell Proliferation Assay user guide). The reagent contains MTS (3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), which acts as inner 
salt and PES (phenazine ethosulfate), which acts as an electron coupling reagent and 
enhances the chemical stability by forming a stable solution when combined with MTS. 
MTS tetrazolium is converted to a soluble formazen, this conversion is carried out by 
NADPH-dependent dehydrogenases (NADPH or NADH) and the quantity of this product 
is directly proportional to the number of living cells in culture. The assay was performed 
by adding 20 µL of the CellTiter 96® AQueous One Solution Reagent directly to cultures 
in 96 well plates and incubating the plates for 3 hours at 37°C in a 5% CO2 humidified 
incubator. Absorbance was then measured at 490 nm on a 96-well plate reader and results 
expressed as cell viability as a percentage of untreated control cells after taking the blank 
wells values out of the values of all wells containing cell cultures (% viability).  
 
2.8. Determination of programmed cell death (Apoptosis) 
Programmed cell death or apoptosis was assessed by the Muse™ Annexin V and Dead 
Cell Assay kit. This method depends on the externalization of phosphatidylserine (PS), as 
an early hallmark of apoptosis, translocated to the outer surface of the cell membrane 
which binds Annexin V, a 35-36 kDa calcium-dependent phospholipid-binding protein, 
which has a high affinity for phosphatidylserine. (Tait et al., 1989; van Engeland et al., 
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1998; Arur et al., 2003). The dead cell marker (7-amino actinomycin D; 7-AAD) is used as 
an indicator of cell membrane structural integrity and it is excluded from live and early 
apoptotic cells. The percentage of live (non-apoptotic), early apoptotic, late stage 
apoptotic, dead cells, and debris were therefore determined in this method. This technique 
was used to determine the percentage of cells undergoing apoptosis 24 and 48 hours after 
re-plating the cells. 24 hours post-transfection with plasmids and 72 hours post-transfection 
with siRNAs, cells were re-plated in fresh medium at 2×105 cells/mL in 6 well plates. 24 
hours post re-plating; 100 µL of cell suspension was isolated from culture plates and mixed 
with 100 µL of Annexin V reagent. Samples were incubated for 20 minutes in the dark 
before reading the result using the Muse cell analyser. The results were expressed as total 
apoptotic percentage (% Total apoptotic).   
 
2.9. Clonogenic assay 
Clonogenic or long term survival assay was performed to determine the cell’s ability to 
proliferate and form colonies. An equal cell number proportion of parental, transfected or 
treated cells was diluted in 3.0 mL Iscove’s medium (Sigma) containing 20% heat-
inactivated foetal bovine serum (FBS), 10% cell-specific conditioned medium and 10% 
noble agar solution (0.5% w/v, Difco) and plated in 6-well plates. Each well was overlaid 
with 1.5 mL Iscove’s complete medium containing 10% cell conditioned medium. The 
number of colonies formed was counted following 2-3 weeks incubation at 37ºC in a 5% 
CO2 humidified incubator. 
 
47 
 
2.10. Cell cycle analysis 
The cell-division cycle represents the series of significant processes that take place in 
eukaryotic cells resulting in their replication. The Muse™ Cell Cycle premixed reagent, a 
mixture of propidium iodide (PI) (a nuclear DNA intercalating stain) and 
pancreatic ribonuclease (RNAse A) that cleaves single-stranded RNA, discriminates and 
measures the percentage of cells in G0/G1, S, and G2/M phases of the cell cycle 
(Darzynkiewicz et al., 2001). In G0/G1 phase, metabolic changes prepare the cell for 
division and moves into the S phase where DNA synthesis replicates the genetic material 
so each chromosome now consists of two sister chromatids. In G2/M phase, the metabolic 
changes assemble the cytoplasmic materials necessary for mitosis and cytokinesis/a 
nuclear division (mitosis) followed by a cell division (cytokinesis) and ends with  the 
formation of two daughter cells. After 24 hours of re-plating cells following transfection, at 
least 2×105 cells were collected and washed once with phosphate buffered saline (PBS), 
centrifuged at 300×g for 5 minutes, the supernatant discarded and the cells fixed in 1.0 mL 
ice cold 70% ethanol/30% PBS and incubated at -20°C for at least 3 hours. After the 
incubation, cells were centrifuged at 300×g for 5 minutes, the supernatant was discarded, 
and the cells were re-suspended in 200 μL of Muse™ Cell Cycle reagent. They were then 
incubated for 30 minutes in the dark before reading the result by Muse cell analyser. The 
results were expressed as percentage of cells in each phase of the cell cycle (% Cells). 
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2.11. Ki67 proliferation analysis 
The nuclear antigen Ki67 is one of several markers that have been used to assess cell 
growth and proliferation (Iatropoulos and Williams, 1996). Ki67 is considered as a cell-
division cycle related nuclear protein because it is expressed in all active phases of the cell-
division cycle (G1, S, G2 and M phases) and is absent in the resting phase (G0), making 
Ki67 a good marker of cell proliferation (Scholzen & Gerdes, 2000). A fluorescent based 
analysis distinguishes between the proliferating Ki67 (+) cells and non-proliferating Ki67 
(-) cells. After 24 hours post-transfection with plasmids and 72 hours post-transfection 
with siRNAs, cells were harvested and plated in fresh growth medium at 2×105 cells/mL in 
6 well plates. Following 24 hours incubation, up to 1×105 cells for each sample were 
harvested and washed once with 200 μL PBS. 50 μL of a 1×Fixation Solution were added 
to each sample and mixed thoroughly, followed by incubation at room temperature for 15 
minutes and then samples washed once in 1×Assay Buffer. A volume of 150 μL of the 
1×Assay Buffer was added to each sample and centrifuged for 5 minutes at 300×g. The 
supernatant was discarded and 100 μL of Permeabilisation Buffer added to each sample. 
These were mixed thoroughly and incubated for 15 minutes at room temperature, before a 
further wash in 1×Assay Buffer. Another 100 μL of the 1×Assay Buffer was added to each 
sample and centrifuged for 5 minutes at 300×g then the supernatant was discarded and 50 
μL of 1×Assay Buffer was added. Samples were mixed thoroughly and incubated at room 
temperature for 15 minutes, before 10 μL of either the Muse® Hu IgG1-PE or Muse® Hu 
Ki67-PE reagent was added to each sample, mixing thoroughly. The samples were 
incubated for 30 minutes at room temperature in the dark. After incubation, 150 μL of 
1×Assay Buffer was added to each sample and the sample were run on the Muse cell 
analyser, with the results expressed as proliferation percentage (% Proliferation).  
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2.12. Drug treatment  
In some experiments, the effect of PP4c down-regulation on the cytotoxic response of the 
cells to four different drugs was investigated. K562 and HL-60 parental cells were initially 
treated with five different, increasing concentrations of imatinib (0.0-1.5 µM) (K562 cells 
only), cisplatin (0.0-15.0 µM), doxorubicin (0.0-0.6 µM) and rapamycin (0.0-100.0 nM) 
using 96-well plates. K562 cells were plated at a density of 75,000 cells/mL, while HL-60 
cells were plated at 100,000 cells/mL and incubated for 24 and 48 hours before assessment 
of cell viability, to determine the optimum concentration to use in subsequent 
investigations. To determine effect of PP4c siRNAs on viability response to drug 
treatment, after 72 hours of PP4c down-regulation, the transfected cells were re-plated in 
24-well plates at 2×105 cells/mL and treated with 0.2 µM imatinib (K562 cells only), 
cisplatin (2.0 µM for HL-60 cells and 10.0 µM for K562 cells), doxorubicin (0.1 µM for 
HL-60 cells and 0.2 µM for K562 cells) and 20 nM rapamycin (both cell lines). The 
transfected cell's viability/apoptosis was measured as described in sections 2.7, 2.8 and 2.9. 
 
2.13. Analysis of the level of PP4c expression by Western blotting 
Samples for protein analysis were collected from all transfected cells from every 
experiment in order to examine the level of PP4c expression to ensure that the effects 
observed in the results can be attributed to the changes in PP4c expression levels. A total 
of 1×106 cells were collected by centrifuging at 1200×g and washed twice in 500 µL PBS. 
Cells were then suspended in 20 µL of RIPA (Radioimmunoprecipitation Assay) buffer 
containing protease inhibitor (at a 1:100 dilution), followed by 20 µL of Laemmli sample 
buffer (Sigma). Samples were then heated at 95C for 10 minutes to denature and solubilise 
proteins. Samples were then loaded (40 µL/lane) on SDS-PAGE gels using a 12% 
resolving gel and separated at 150V for 60 minutes in a 1× SDS-PAGE running buffer 
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(0.025M Tris, 0.192M glycine, 0.1% SDS, pH 8.5). Proteins were then electro-transferred 
onto a polyvinylidenedifluoride (PVDF) membrane (BIO-RAD), which had been pre-
wetted in 100% methanol, using either a semi-dry transfer unit (at 0.8mA/cm2) for 1 hour, 
or a wet transfer system at 30V, 90mA overnight at 4°C with stirring. The blot was 
incubated in 5% non-fat milk in TBST (Tris Buffered Saline Tween 20; 25 mM Tris, 
0.13M NaCl, and 0.1% Tween) for 1 hour to block free binding sites. The membrane was 
washed three times with TBST and probed with primary anti-PP4c (PPX/PP4c) using 
either a goat-polyclonal IgG (C-18, 1:1000 dilution) or a mouse-monoclonal IgG (C-6, 
1:200 dilution) at 4°C for 12 hours (or overnight). The membrane was then washed three 
times with TBST for 10 minutes each to remove residual primary antibody and then 
incubated with a 1:2500 dilution of HRP-conjugated anti-goat IgG secondary antibody (C-
18) for 1 hour or 1:800 dilution of HRP-conjugated anti-mouse IgG secondary antibody 
(C-6) overnight followed by washing five times with TBST for 10 minutes each. Protein 
bands were visualised by enhanced chemiluminescence (ECL) according to the 
manufacturer's instructions (BIO-RAD, # 170-5060) and imaged and quantified using the 
C-DiGit blot scanner (LI-COR Biosciences). After analysis, blots were stripped by 
incubating in stripping buffer (Thermo, # 46430) for 30 minutes and re-probed with a 
mouse-anti-β-actin antibody (1:5000 dilution), followed by a HRP-conjugated anti-mouse 
IgG secondary antibody (1:800 dilution) with bands visualised as before.  
 
2.14. Statistical analysis  
Data are presented as the mean and standard error of the mean (SEM) (mean ± SEM). Data 
were analysed using Graghpad prism 7.0 statistical programme. One-way ANOVA and 
two-way ANOVA followed by Bonferroni post-hoc test were used to compare the test and 
control values. P-value of <0.05 was considered as statistically significant.  
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3. Optimisation  
3.1. Introduction  
There is a need to choose optimal conditions that maximise the accurate output of each 
experiment, minimises the errors and troubleshoots the difficulties. For example, optimal 
siRNA interference or DNA delivery into mammalian cell lines depends on the cell 
specificity besides other factors. The conditions that published by the manufacturing 
companies or previous studies can be used as a guide, but for best results it is 
recommended to optimise the transfection conditions for the cell of interest by evaluate the 
transfection efficiency, low cytotoxicity and reproducibility in each lab. 
Hence, this chapter will focus on the cell lines that have been selected in this research and 
why they have been considered as models to use in vitro, the structures of the 
chemotherapeutic drugs and their mode of action, the growth inhibition or dose response 
optimisation and lastly the optimisation of the transfection methods that have been used in 
this research. This is necessary to i) establish appropriate culture and transfection 
procedures with the selected cell lines for further investigation into functional effect of 
manipulating PP4c levels and ii) to establish dose-response profiles and optimisation of 
treatment conditions with a range of chemotherapeutic drugs for further work into the 
effects of PP4 silencing on drug toxicity. 
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3.1.1. Cell lines 
Two leukaemic cell lines have been used in this study, K562 cells for chronic myelogenous 
leukaemia (CML) and HL-60 cells for acute promyelocytic leukaemia (APL).  
 
3.1.1.1. K562 cell line 
The human myelogenous leukaemic cell line, K562, was the first myeloid cell line that was 
derived from a 53-year-old female chronic myelogenous leukaemia patient at the terminal 
stage of blast crisis (Lozzio and Lozzio, 1975). It is an erythro-megakaryoblastic 
leukaemia cell line that is characterised by positive Philadelphia (Ph) chromosome t(9;22); 
a specific genetic abnormality that results in the Bcr-Abl fusion gene and consequently 
activates tyrosine kinases, and also by a second reciprocal translocation between the long 
arm of chromosome 15 with chromosome 17 (Lozzio and Lozzio, 1975; 1979). These cells 
are a non-adherent, suspension cell line with rounded morphology and can spontaneously 
develop characteristics similar to early-stage erythrocytes, granulocytes and monocytes 
(Lozzio and Lozzio, 1979; Lozzio et al., 1981). It has been reported that K562 cells can 
express many phosphatases, including PTEN and SHIP2, but they fail to express others 
such as SHIP1 (Sattler et al., 1999; Bruecher-Encke et al., 2001). Owing to the lack of 
Major Histocompatibility Complex (MHC) class I antigens on their membrane that are 
required for inhibiting natural killer (NK) cells activity, K562 cells are very sensitive to 
NK cell activity (Lozzio and Lozzio, 1979).  
Several pathways have been reported to be deregulated by Bcr-Abl fusion gene in myeloid 
leukaemia (Jacquel et al., 2003). Activation of NF-κB by the IKK pathway may play an 
important role in the pathogenesis of myeloid leukaemia induced by Bcr-Abl, resulting in 
targeting NF-κB and IKKs as therapeutic agents of Philadelphia-positive leukaemias 
(Hsieh and Van Etten, 2014). The mammalian target of rapamycin (mTOR) pathway is one 
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of the multiple signalling pathways (canonical PI3K/Akt/mTOR) activated by Bcr-Abl (Ly 
et al., 2003). mTOR is a serine/threonine kinase that forms two different complexes; 
mTORC1 and mTORC2, mTORC1 positively regulates the biosynthesis of proteins 
necessary for cell growth, and proliferation, and is also known to inhibit the autophagy 
process, while mTORC2 is a critical regulator of Akt (Gentzler et al., 2012).  
The K562 cell line is considered as the most appropriate CML cell line model to detect 
differentiation in vitro for different reasons. They are highly undifferentiated cells with an 
active proliferative capacity, which were simultaneously accompanied by apoptosis and 
autophagy (Lozzio and Lozzio, 1979). Moreover, K562 cells are less clumping than other 
suspension cell lines due to the Bcr-Abl activity that results in down-regulation of surface 
adhesion molecules (Lozzio and Lozzio, 1979).  
 
3.1.1.2. HL-60 cell line 
The human promyelocytic leukaemia cell line, HL-60, was derived from a 36-year-old 
woman with acute promyelocytic leukaemia (APL) (Collins et al., 1977). Unlike other 
acute promyelocytic leukaemia cell lines that are characterised by a specific chromosome 
translocation t(15;17), which results in the promyelocytic leukaemia (PML) fusion gene 
and retinoic acid receptor α gene (RARα), HL-60 cell line lack this chromosomal 
translocation (Lee et al., 2002). It has been reported that HL-60 cells have amplified c-myc 
oncogene expression from 16 to 32 fold (Dalla Favera et al., 1982), altered N-ras and c-
neu gene expression (Murray et al., 1983) and lack p53 expression due to a deletion of a 
large proportion of the gene that encodes it (Wolf and Rotter, 1985).  
Using cDNA microarray assay, granulocytic differentiation  induced by all-trans retinoic 
acid (ATRA) was observed in two acute promyelocytic leukaemia cell lines; HL-60 and 
NB4 (Lee et al., 2002). Lee and colleagues observed that ATRA-treated HL-60 up-
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regulated 35 genes and down-regulated 36 genes as compared to untreated HL-60 cells, 
while ATRA-treated NB4 cells up-regulated 119 genes and down-regulated only 17 genes 
as compared to untreated NB4 cells, however, there were no common gene expression 
profiles regulated by the ATRA, suggesting that the molecular mechanisms and genes 
involved in ATRA-induced differentiation of APL cells may be different and cell type 
specific (Lee et al., 2002). 
HL-60 cells are rounded, highly proliferative suspension cells with doubling time in 
culture of approximately 36-48 hours (Collins, 1987). Moreover, HL-60 cells express both 
transferrin and insulin receptors on their cell surface, which are believed to be required for 
cell proliferation, growth and differentiation (Collins, 1987). HL-60 cells are 
predominantly a neutrophilic promyelocyte (precursor) and they can differentiate to 
eosinophils and eosinophilic precursors when cultured in mildly alkaline medium 
(Breitman et al., 1980; Birnie, 1988). One of the major properties that have made the HL-
60 cell line an attractive model for studies of human myeloid cell differentiation is the 
expressing of an amplified c-myc proto-oncogene (Birnie, 1988). In contrast to the c-myc 
gene of the normal cells which is localized to chromosome 8q24, it has been found that the 
c-myc mRNA levels in HL-60 cells are 30-fold amplification of the c-myc gene located in 
an abnormal banded region on chromosome 8q24 (Birnie, 1988). 
 
From the previous studies highlighting the characteristics and features of K562 and HL-60 
cells, these two cell lines were selected for use in this study as well-defined models of 
CML and AML respectively (Lozzio and Lozzio, 1979; Birnie, 1988). 
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3.1.2. Drugs used in cancer treatment and their targets 
Chemotherapy is a term that refers to one or a group of toxic medications (chemicals) that 
are used to treat cancer by killing the cancer cells and preventing them from dividing and 
growing. The best anticancer agents would attack the cancer cells only without harming 
normal tissues but unfortunately, such agents are not available (Moschovi et al., 2015).  
In the last century, when the era of chemotherapy had begun, Mustard Gas was used as 
chemotherapy for the first time during World War II, with nitrogen mustard being found to 
be active against Lymphoma (DeVita and Chu, 2008; Galmarini et al., 2012). This 
compound was used as a model for alkylating agents, a group of similar but more effective 
agents to nitrogen mustard, which killed cancer cells by activation of DNA damage 
pathways (DeVita and Chu, 2008; Galmarini et al., 2012). After the discovery of nitrogen 
mustard, another compound related to folic acid called aminopterin, has been used in 
childhood acute leukaemia to produced remissions by blocking DNA replication (DeVita 
and Chu, 2008; Galmarini et al., 2012). Aminopterin is considered as the predecessor of 
methotrexate, a cancer treatment drug commonly used nowadays (DeVita and Chu, 2008; 
Galmarini et al., 2012). Over the years, continued research has led to the development of 
further drugs that block crucial functions such as cell cycle checkpoints that affect cell 
growth and replication. These chemotherapeutic drugs have been successfully applied in 
long-term remissions and even cure of many people with cancer (DeVita and Chu, 2008; 
Galmarini et al., 2012).  
Over the past decades, many studies have reported the discovery and validation of novel 
cancer therapeutics called targeted therapies. These drugs can be used individually or in 
combination with other conventional therapies including surgery, radiation or traditional 
chemotherapy (Meiler and Schuler, 2006). For example, rapamycin can be used in 
combination with imatinib to induce apoptosis by inhibition the mTORC1 (Ly et al., 2003; 
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Sillaber et al., 2008) and to prevent outgrowth of resistant subclones and consequently 
improve the overall outcome in CML patients (Sillaber et al., 2008). These anti-cancer 
drugs act to prime the apoptotic machinery, as promising apoptosis-inducing agents, such 
as by targeting the cell cycle either by slowing it down or by blocking it at checkpoints 
(Makin, 2002). The DNA damage caused by the anti-cancer drugs leads  to cell cycle arrest 
at the S phase or G2/M phase, resulting in cell death, bearing high hopes for the 
management of cancers resistant to conventional treatments (Makin, 2002). Traditional 
chemotherapy drugs are cytotoxic agents that act on all rapidly dividing cells, while 
targeted therapies interact with their specific molecular targets that are associated with 
cancer and block tumour cell proliferation (Charlton and Spicer, 2016). 
There are two major types of targeted therapies; small molecule drugs such as tyrosine 
kinase inhibitors, and monoclonal antibodies including blinatumomab, inotuzumab and 
rituximab that are used in the treatment of different types of lymphomas and leukaemias 
(Jabbour et al., 2015; Charlton and Spicer, 2016). The first very potent and advances in 
cancer targeted therapy were made with haematological malignancies (Druker et al., 
2001a; 2001b). Imatinib, which is used in this study, is an example of a small molecule 
targeted therapy, which inhibits the signalling of the Bcr-Abl tyrosine kinase, the genetic 
abnormality causing CML (Druker et al., 2001a; 2001b).  
 
This section will highlight the structure and mode of action for four anti-cancer drugs used 
in this study. 
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3.1.2.1. Cisplatin 
Cisplatin, cis-diamminedichloroplatinum (II), is a neutral, square-planar, coordination 
complex of divalent platinum that has been used for many years to treat different kinds of 
cancers, inducing cytotoxicity via cell cycle inhibition as a result of the formation of DNA 
adducts and subsequent induction of apoptosis (Dasari and Tchounwou, 2014; Johnstone et 
al., 2016). It is classified as an ‘alkylating-like agent not alkylating agent’ since it has 
no alkyl group and therefore cannot carry out alkylating reactions.  
Cisplatin’s mode of action has been linked to its ability to crosslink with purine bases in 
DNA in a process known as aquation, in which one of the two chloride ligands is slowly 
displaced by water forming cis-[PtCl(NH3)2(H2O)]
+ (Basu and Krishnamurthy, 2010; 
Johnstone et al., 2015). The aquo complex itself is easily displaced by the N-heterocyclic 
bases on DNA; interfering with DNA repair mechanisms and displaying cytotoxicity 
towards the fastest proliferating cells leading to cell cycle arrest and subsequently cell 
death (Figure 3.1; Basu and Krishnamurthy, 2010; Johnstone et al., 2015). 
Cisplatin affects many signalling pathways and induces apoptosis via p53 or its family of 
transcription factors. p53 can regulate cisplatin-induced apoptosis by several mechanisms 
including direct binding and counteracting the anti-apoptotic function of B-cell lymphoma-
extra-large (Bcl-xL) or phosphatase and tensin homolog (PTEN) up-regulation (Basu and 
Krishnamurthy, 2010). Moreover, p38 MAP kinase pathway activation may mediate and 
regulate cell death in response to cisplatin. p38 mediates stress-induced EGFR (epidermal 
growth factor receptor) phosphorylation that triggers cisplatin-induced receptor 
incorporation (Winograd-Katz and Levitzki, 2006). Cisplatin induces cell death also by 
JNK pathway activation via p73. This can occur directly by p73 phosphorylation or 
indirectly through c-Jun, and forms a complex at several serine and threonine residues 
leading to cell death (Jones et al., 2007). Moreover, cisplatin activates extracellular signal-
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regulated kinase (ERK) in many types of cancer cells via p53 phosphorylation, causing p21 
up-regulation and Gadd45 (45kd-growth arrest and DNA damage) leading to activation of 
cell cycle checkpoints, resulting in either DNA repair or, if the damage cannot be repaired, 
the cells are permanently eliminated by inducing cell death (Dasari and Tchounwou; 
2014). Cisplatin also induces DNA damage by BAD phosphorylation at Ser-136 via PI-
3K-PKB/Akt or at Ser-112 via an ERK cascade (Hayakawa et al., 2000; Dasari and 
Tchounwou; 2014); inhibition of either of these cascades sensitizes both Caov-3 and 
A2780 ovarian cancer cells to cisplatin (Hayakawa et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cellular 
processes 
leading to 
Apoptosis 
Figure 3.1 Cisplatin mechanism of action. This mechanism of action can be divided into four distinct 
sequential steps: (1) cellular uptake, (2) aquation/activation, (3) DNA platination, and (4) cellular 
processing leading to apoptosis. This figure is adapted from Johnstone et al., 2015. 
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3.1.2.2. Doxorubicin 
Doxorubicin (14-hydroxydaunomycin), also known as Adriamycin, is an anthracycline 
anti-tumour antibiotic produced by Streptomyces peucetius var. caesius  after introducing a 
genetic mutation using N-nitroso-N-methyl urethane (Arcamone et al., 1969). Since the 
1970's, doxorubicin has been used as a potent and safe treatment of a wide variety of 
cancers including solid tumours, lymphomas, and leukaemias (Cortes-Funes and 
Coronado, 2007). 
The action of doxorubicin in cancer cells can be summarised by two major mechanisms 
(Figure 3.2). The first one by a process called intercalation in which doxorubicin interacts 
with DNA and inhibits the progression of topoisomerase-II, an enzyme that controls 
supercoils in DNA by cutting and resealing both DNA strands (Nitiss, 2009). In other 
words, inhibition of topoisomerase-II results in unwinding of the DNA and double-strand 
breakage, preventing the DNA double helix from being resealed and thereby stopping the 
process of replication (Nitiss, 2009). Pang and colleagues (2013) found that doxorubicin 
intercalation could also induce histone eviction from transcriptionally active chromatin 
leading to a DNA damage response. The second mechanism by which  doxorubicin affects 
cancerous cells is by increasing the production of reactive oxygen species (ROS), 
particularly the quinone type, and subsequently leading to lipid peroxidation, damage to 
cellular membranes, DNA and proteins, hence contributing to doxorubicin cytotoxicity 
(Gewirtz, 1999). 
It has been reported that doxorubicin-induced apoptosis occurs through several signal 
transduction mechanisms (Wang et al., 2004a). Numerous studies have revealed that 
doxorubicin treatment activates the tumor suppressor protein, p53, leading to apoptosis 
(Nobori et al., 2002; Lorenzo et al., 2002), while others reported that the transcription 
factor NF-κB, is also involved in doxorubicin-induced apoptosis (Wang et al., 2004a). 
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Some studies have reported NF-κB as up-regulator of p53 gene expression (Pei et al., 
1999), while others reported that both p53 and NF-κB work as inhibitors for each other 
(Wang et al., 2004b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Doxorubicin mechanism of action. Two mechanisms used by doxorubicin to cause DNA 
damage and consequently cell death. In the first mechanism, which is called intercalation, doxorubicin 
interacts with DNA and inhibits the progression of topoisomerase-II and results in break the DNA 
double-strand and thereby stopping the process of replication and cause cell death. While in the second 
mechanism doxorubicin treatment increase the production of reactive oxygen species (ROS) in the 
cytoplasm then ROS inter the nucleus, the high exposure of the DNA to ROS causes DNA damage and 
consequently cell death (From Yang et al., 2014). 
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3.1.2.3. Imatinib mesylate 
Imatinib mesylate (Novartis compound STI-571) is a tyrosine kinase inhibitor with activity 
against Abl, Bcr-Abl, PDGFR, and c-KIT. Imatinib has been used as a first-line treatment 
for Philadelphia chromosome-positive CML since the late 1990s (Li et al., 2015a). In Bcr-
Abl-positive cells, the activities of STAT5, Akt/PKB and NF-κB are inhibited by imatinib 
treatment (Deininger et al., 2000). It is also a potent inhibitor of receptor tyrosine kinases 
encoded by c-KIT, PDGFR and stem cell factor (SCF) oncogenes, and inhibits PDGF- and 
SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces 
apoptosis in those cells overexpressing c-KIT such as gastrointestinal stromal tumour 
(GIST) cells (Li et al., 2015a).  
Generally, imatinib works by occupying the tyrosine kinase active site, leading to tyrosine 
de-phosphorylation and subsequently enhances cell death (Bende et al., 2010; Yada et al., 
2012; Li et al., 2015a). In leukaemias, imatinib inhibits Bcr-Abl tyrosine kinase activity 
and restores interleukin-3 (IL-3) dependent growth resulting in decreased cell proliferation 
and enhanced apoptosis in CML and ALL by binding close to the ATP binding site of Bcr-
Abl tyrosine kinase, locking it in a closed or self-inhibited conformation and leading to the 
inhibition of the protein semi-competitively and thereby inhibition of the downstream 
signalling pathways that promote leukaemogenesis (Figure 3.3; Lee et al., 2011; Bende et 
al., 2010; Yada et al., 2012; Li et al., 2015a). It has been reported that imatinib inhibits the 
colony-forming growth of CML myeloid cells (about 92%-98%), yet it has minimal effect 
on colony formation from normal cells (Deininger et al., 1997; Druker et al., 1996).  
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Figure 3.3 Imatinib mechanism of action. Imatinib binds to the amino acids of the Bcr-Abl ATP 
binding site leading to preventing tyrosine autophosphorylation and subsequently the phosphorylation of 
its substrates resulting in inhibiting the downstream signalling pathways that promote leukaemogenesis 
(From Lee et al., 2011). 
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3.1.2.4. Rapamycin 
A natural macrocyclic lactone (also known as sirolimus), produced by the bacterium 
Streptomyces hygroscopicus, with both immunosuppressant (Vezina et al., 1975; Sehgal et 
al., 1975) and anti-tumor properties (Douros and Suffness, 1981).  
Rapamycin is a potent cell growth inhibitor and its mechanism of action can be 
summarized as the following: sirolimus binds to the cytosolic protein FK-binding protein 
12 (FKBP12) (a 12 kDa FK506-binding protein; also known as FKBP1A), leading to the 
formation of the active sirolimus-FKBP12 complex (Sabers et al., 1995). This then binds to 
and inhibits the activation of the key regulatory kinase pathway, mammalian Target 
Of Rapamycin (mTOR), directly by binding to mTOR Complex 1 (mTORC1) (Figure 3.4; 
Belinda, 2012; Huang and Houghton, 2003; Sawyers, 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Rapamycin mechanism of action. Rapamycin binds directly to mTORC1 leading to 
inhibition of cell cycle progression, cell proliferation and antibody production (From Belinda, 2012). 
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This immunosuppressive complex has no effect on PP2B activity but it is believed to 
suppress cytokine-driven T-cell proliferation, inhibiting cell cycle progression from the G1 
to S phase (Figure 3.4; Brown et al., 1994; Hashemolhosseini et al., 1998).  
Studies showed that inhibiting mTOR with rapamycin decreased the phosphorylation of 
some proteins involved in mTOR signaling pathway, induced cell cycle arrest at 
G0/G1 phase and distinctly rescued the differentiation of normal haematopoietic stem cells 
(HSCs) and depleted leukaemic stem cells (Cheng et al., 2008b).  
 
3.1.3. Transfection methods 
Transfection techniques are analytical tools that facilitate the study of various cellular 
functions such as genetic functions, protein synthesis, cell growth and development. 
Transfection can be defined as a process of introducing genetic materials such as DNA or 
RNA into eukaryotic cells, carried out via physical, chemical or biological techniques to 
deliberately modify the genome or the protein production of the targeted cell (Prathees et al 
2011). The transfection could be temporary for short period without integration of the 
DNA with the cellular chromosomes (transient transfection) or long period (stable 
transfection) to integrate plasmid DNA into the cellular genome so it will be passed on to 
the daughter cells. This process is routinely used in in vitro studies of molecular biology 
including gene expression and gene function.  
The preferred transfection method is characterised by high transfection efficiency 
accompanied with minimum toxicity. Four most commonly used techniques are: 
1. Electroporation; an easy, non-chemical technique in which the cell membrane is 
exposed to high-intensity electric pulses that cause a transient aqueous channels in 
the membrane for DNA to enter the cytoplasm, resulting in high transformation 
efficiency and no alteration in the cell morphology or functions (Chang et al., 
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1992). It is a simple and rapid method, however; the transfected cells have high 
cytotoxicity after shocking due to the electric pulses.   
2. Liposome-mediated transfection (lipofection); one of the most efficient procedures 
of transfection that involve the use of liposome to form cationic and neutral lipids 
polymers in which the DNA is complexed within lipid droplets. These droplets 
interact directly with the cell membrane and fuse and then the DNA is liberated into 
the cytoplasm, resulting in highly efficient gene knockdown even when using low 
siRNA concentrations (1 to 5 nM) without concomitant activation of the cells 
(Felgner et.al, 1987).  
3. Calcium phosphate precipitation; the oldest method of transfection with main 
advantage is that it is cheap and easy to perform but it is less efficient than other 
methods and the precipitates often cause cytotoxicity. 
4. Viral delivery; using either adenovirus or retrovirus vector as a carrier to introduce 
DNA into the cells.  
In this research, two of the mentioned methods were used; the electroporation-based 
transfection (nucleofection V reagent) and the lipofection-based transfection (HiPerFect 
reagent). 
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The aims of this chapter are: 
 To determine the optimum concentrations of the anti-cancer drugs that have been 
used in this study (cisplatin, doxorubicin, imatinib and rapamycin) to use the most 
effective dose of these anticancer drugs post PP4c silencing in K562 and HL-60 
cell lines. This will initially be carried out by a dose response; screened using the 
MTS assay, with the confirmation of cytotoxicity of selected drug doses from the 
MTS based on Trypan blue vital dye exclusion assay, flow cytometry (MUSE 
Annexin V) and long-term survival methods. 
 To evaluate the efficiency of the transfection reagents, nucleofection V and 
HiPerFect, based on their transfection efficiency percentage, cytotoxicity and 
reproducibility in order to select the most appropriate transfection method for PP4c 
silencing or up-regulation in K562 and HL-60 cells. 
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3.2. Materials and Methods 
Before starting the drug dose response analysis, optimisation of cell density for use in the 
MTS assay was undertaken using a range of different densities (0.5-2.0×105 cells/well) of 
K562 and HL-60 parental cells seeded in 96-well plates and incubated for 24, 48 and 72 
hours at 37ºC in a 5% CO2 humidified incubator. Cell viability was then assessed using the 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS; Promega), from 
which the optimum density to use in subsequent investigations was determined (see 
chapter 2 section 7.2).  
K562 and HL-60 parental cells were treated with five different, increasing concentrations 
of imatinib (0.0-1.5 µM) (K562 cells only), cisplatin (0.0-15.0 µM), doxorubicin (0.0-0.6 
µM) and rapamycin (0.0-100.0 nM) for 24 or 48 hours at 37°C in a humidified 5% CO2 
incubator, with cell viability measured using the MTS assay with  absorbance measured at 
490 nm on a 96-well plate reader and results expressed as cell viability as a percentage of 
untreated control cells after taking the blank wells values out of the values of all wells 
containing cell culture (% viability).  
Trypan blue exclusion method was used for viable cell count and re-plating (see chapter 2 
section 7.1). Confirmation of drug-induced cytotoxicity was assessed by the Muse™ 
Annexin V and Dead Cell Assay kit, with results  expressed as total apoptotic percentage 
(% Total apoptotic) (see chapter 2 section 8). The ability of K562 and HL-60 cells to form 
colonies (long-term survival) after treatment with certain drugs was also determined (see 
chapter 2 section 9). The number of colonies formed was counted following 2-3 weeks 
incubation at 37ºC in a 5% CO2 humidified incubator. 
In this research, different transfection methods have been used to study the modulation of 
PP4c gene expression in leukaemic cell lines. Here, transfection methods for plasmid DNA 
transfection in K562 and HL-60 cells were optimised using nucleofection (V solution), 
68 
 
Lipofectamine 2000 Reagent and Lipofectamine 3000 Reagent, while nucleofection (V 
solution) and HiPerFect reagent were used for the optimisation of siRNA delivery  in HL-
60 cells. 
For plasmid DNA transfection, transfection efficiency was determined using pmaxGFP in 
both K562 and HL-60 cells. Cells after 48 hours post pmaxGFP transfection were 
harvested and centrifuged at 1200×g then washed once in PBS, around 10 µL from the 
cells added to a microscope slide with coverslip and counted (100 cells) with fluorescence 
and light microscopy to calculate the transfection efficiency.   
For optimisation of siRNA transfection, a scrambled negative siRNA labelled with 
Cyanine dye 3 (Cy3) (labelled using the Silencer siRNA labelling kit from Ambion 
(#1632)) was transfected in parallel transfections to determine transfection efficiency in 
K562 and HL-60 cells using nucleofection V reagent and HiPerFect reagent respectively. 
Cells 72 hours post Cy3 transfection were harvested and centrifuged at 1200×g, washed 
once in PBS, then 10 µL from the cells added to a microscope slide with coverslip and 
counted (100 cells) with fluorescence and light microscopy to calculate the transfection 
efficiency percentage. 
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3.3. Results 
3.3.1. Optimisation of cell density 
To optimise cell density for use in the MTS assay, K562 parental cells were seeded in 96-
well plates (0.5-2.0×105 cell/well) and cultured for 24-72 hours before assessment of 
viability. The results showed that the absorbance at 24 hours increased for all cultures, in 
other words, the cell number in every culture has increased or approximately doubled. On 
the contrary, the absorbance readings for some cultures, especially higher densities, 
decreased at 72 hours suggesting density arrest at these higher cell numbers. Therefore, the 
optimum density for K562 cells in which they continued their proliferation from day 1 to 
day 3 was (0.75×105 cell/well) (Figure 3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Seeding density of parental K562 cells affected over the period of time. Parental K562 
cells where plated 24h, 48h and 72 hours. This figure shows the growth of K562 cells according the 
density of seeding (n=3).  
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Similarly to K562 cells, HL-60 parental cells (0.5-2.0×105 cell/well) were seeded in 96-
well plates prior to drug dose response assay. The results showed that all absorbance 
readings increased for all cultures from 24-72 hours, suggesting an increase in their cell 
number and in some of them doubled. (1.25×105 cell/well) density has been selected for 
HL-60 cells in which they continued their proliferation without confluence from day 1 to 
day 3 (Figure 3.6). 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 3.6 Seeding density of parental HL-60 cells affected over the period of time. Parental HL-60 
cells where plated 24h, 48h and 72 hours. This figure shows the growth of HL-60 cells according the 
density of seeding (n=3). 
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3.3.2. Drug dose response  
Following the optimisation of cell density, (0.75×105 cell/well) of parental K562 cells were 
treated with cisplatin (0.0-15.0 µM), doxorubicin (0.0-0.6 µM), imatinib (0.0-1.5 µM), and 
rapamycin (0.0-100.0 nM) for 24 or 48 hours. Cell survival was measured by MTS assay 
and the results indicated that cell viability decreased with increased drug doses and 
incubation periods (Figures 3.7, 3.8, 3.9, and 3.10).  
In figure 3.7, the cell viability percentage significantly decreased (**p<0.01) when K562 
cells were exposed to high-doses of cisplatin (15.0 µM) at 24hours and 48 hours, as 
compared to untreated cells. On the other hand, treating the cells with medium- to high-
doses (0.2-0.6 µM) doxorubicin significantly decreased cell viability at 24 hours (around 
40% reduction; *p<0.05, **p<0.01; figure 3.8 A), accompanied with further reduction 
(45%-60%) in cell viability  starting from low-doses (0.1 µM) at 48 hours (Figure 3.8 B). 
K562 cells treatment with imatinib showed a noticeable reduction, as expected, with all-
doses starting from low-doses to high-doses at 24 hours (Figure 3.9 A). After 48 hours of 
treatment, about 40% reduction (*p<0.05) in K562 cell viability treated with 0.1-0.2 µM 
imatinib and about 80-90% (**p<0.01, ***p<0.001) reduction when treated with medium- 
to high doses (0.5-1.5 µM) (Figure 3.9 B) was observed.  
Moreover, K562 cells treatment with all-doses of rapamycin resulted in 20-50% reduction 
in cell viability at 24 hours (Figure 3.10 A), with a sustained reduction (about 60%) 
observed after 48 hours (Figure 3.10 B). 
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Figure 3.7 Cytotoxic effect of cisplatin on K562 cells. Cells were treated with or without 1, 2, 5, 10 
and 15 µM of cisplatin for 24h (A) and 48h (B). Cell viability was tested by cell proliferation assay 
(MTS) with absorbance measured at 490 nm and results expressed as viability percentage (viability %) 
(**p<0.01; One-way ANOVA test followed by Bonferroni test; n=3). 
 
 
Figure 3.8 Cytotoxic effect of doxorubicin on K562 cells. Cells were treated with or without 0.05, 0.1, 
0.2, 0.4, and 0.6 µM of doxorubicin for 24h (A) and 48h (B). Cell viability was tested by cell 
proliferation assay (MTS) with absorbance measured at 490 nm and results expressed as viability 
percentage (viability %) (*p<0.05, **p<0.01; One-way ANOVA test followed by Bonferroni test; n=3). 
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Figure 3.9 Cytotoxic effect of imatinib on K562 cells. Cells were treated with or without 0.1, 0.2, 0.5, 
1.0 and 1.5 µM of imatinib for 24h and 48h. Cell viability was tested by cell proliferation assay (MTS) 
with absorbance measured at 490 nm and results expressed as viability percentage (viability %) 
(*p<0.05, **p<0.01, ***p<0.001; One-way ANOVA test followed by Bonferroni test; n=3). 
 
Figure 3.10 Cytotoxic effect of rapamycin on K562 cells. Cells were treated with or without 10.0, 
20.0, 40.0, 80.0, and 100.0 nM of rapamycin for 24h and 48h. Cell viability was tested by cell 
proliferation assay (MTS) with absorbance measured at 490 nm and results expressed as viability 
percentage (viability %) (*p<0.05, **p<0.01; One-way ANOVA test followed by Bonferroni test; n=3). 
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(1.25×105 cell/well) of parental HL-60 cells were treated with cisplatin (0.0-15.0 µM), 
doxorubicin (0.0-0.6 µM), and rapamycin (0.0-100.0 nM) for 24 or 48 hours. Cell survival 
was measured by MTS assay and the results expressed as viability percentage. Figures 
3.11-3.13 showed that the cell viability was decreased with increased drug doses and 
incubation periods.  
Around 30-40% reduction in cell viability was seen in HL-60 cells when treated with high-
doses (10-15 µM) of cisplatin at 24 hours (Figure 3.11A) and this reduction continued at 
48 hours post-treatment to reach 95% with high-doses as well as a further reduction seen 
with low- and medium doses (Figure 3.11B). Similarly to cisplatin, treating HL-60 cells 
with medium- to high-doses (0.2-0.6 µM) doxorubicin significantly decreased cell viability 
after 24 hours (20-40% reduction; figure 3.12 A), further reducing (up to 96%) after 48 
hours (Figure 3.12 B). Similarly to K562 cells, treatment with 10-100 nM rapamycin 
resulted in up to 20% reduction in HL-60 cell viability after 24 hours (Figure 3.13 A), 
sustained  to up to 60% after 48 hours post-treatment (Figure 3.13 B). 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 3.11 Cytotoxic effect of cisplatin on HL-60 cells. Cells were treated with or without 1, 2, 5, 10 
and 15 µM of cisplatin for 24h (A) and 48h (B). Cell viability was tested by cell proliferation assay 
(MTS) with absorbance measured at 490 nm and results expressed as viability percentage (viability %) 
(**p<0.01, ****p<0.0001; One-way ANOVA test followed by Bonferroni test; n=3). 
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Figure 3.12 Cytotoxic effect of doxorubicin on HL-60 cells. Cells were treated with or without 0.05, 
0.1, 0.2, 0.4 and 0.6 µM of doxorubicin for 24h (A) and 48h (B). Cell viability was tested by cell 
proliferation assay (MTS) with absorbance measured at 490 nm and results expressed as viability 
percentage (viability %) (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; One-way ANOVA test 
followed by Bonferroni test; n=3). 
 
 
 
Figure 3.13 Cytotoxic effect of rapamycin on HL-60 cells. Cells were treated with or without 10, 20, 
40, 80 and 100 nM of rapamycin for 24h (A) and 48h (B). Cell viability was tested by cell proliferation 
assay (MTS) with absorbance measured at 490 nm and results expressed as viability percentage 
(viability %) (**p<0.01, ***p<0.001, ****p<0.0001; One-way ANOVA test followed by Bonferroni 
test; n=3). 
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3.3.3. Confirmation with Trypan blue dye, Annexin V and long-term survival 
According to the results of MTS assay, the following drug concentrations were selected for 
use in further studies on K562 cells; 0.2 µM for doxorubicin and imatinib, 10 µM for 
cisplatin and 20 nM for rapamycin. Confirmation of drug toxicity at these selected doses 
was then assessed by viable cell counting using the Trypan blue exclusion method and 
MUSE Annexin V and dead cell assay at 24 and 48 hours post treatment in 24-well plates. 
The results showed the viable cell number (viability %) of K562 cells decreased from 
3.54×105 cells/mL (100%) without treatment to 2.31×105 cells/mL (65.22%) with imatinib, 
2.16×105 cells/mL (61.06%) with cisplatin, 1.69×105 cells/mL (47.56%) with doxorubicin 
and 2.88×105 cells/mL (81.44%) with rapamycin at 24 hours (Figure 3.14 A). The results at 
48 hours showed further decrease in viable cell count (viability %) from 6.35×105 cells/mL 
(100%) without treatment to 2.53×105 cells/mL (39.97%) with imatinib, 1.76×105 cells/mL 
(27.39%) with cisplatin, 1.57×105 cells/mL (24.65%) with doxorubicin and 4.66×105 
cells/mL (71.34%) with rapamycin (Figure 3.14 B). 
Moreover, the findings of total apoptosis percentage showed similar effects on parental 
K562 cells after treatment; total apoptosis increased from 4.61% without treatment to 
9.20% with imatinib and 7.93% with cisplatin at 24 hours, and from 5.75% without 
treatment to 32.55% with imatinib and 15.18% with cisplatin at 48 hours (Figure 3.15). In 
addition, rapamycin treatment showed no difference in total apoptosis percentage at 24 and 
48 hours, suggesting that rapamycin only reduced cell growth, rather than inducing death 
by apoptosis (Figure 3.15). Due to a low number of cells, the apoptotic percentage for cells 
treated with doxorubicin could not be established.  
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Figure 3.14 Effects of selected drug doses on the cell viability of K562 parental cells. Parental K562 
cells were treated with 0.2µM imatinib, 10µM cisplatin, 0.2µM doxorubicin or 20nM rapamycin and 
viable cell number assessed by Trypan blue vital dye exclusion at 24 and 48 hours, expressed as both 
absolute cell numbers/mL (A) or as a percentage viability (B) (**p<0.01, ***p<0.001, ****p<0.0001; 
One-way ANOVA test followed by Bonferroni test; n=3). 
(**p<0.01, ***p<0.001, ****p<0.0001; One-way ANOVA test followed by Bonferroni test; n=3). 
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For long-term survival assays, investigations initially focused on those concentrations 
established from the drug dose-response assay using MTS method, with confirmation of 
data from cell counts and apoptosis assays however, the number of colonies for cells 
treated with cisplatin and doxorubicin was zero, suggesting that whilst cell viability in the 
short-term may be measureable, that long-term survival is more greatly affected under 
these conditions. Therefore the investigation was repeated with a lower dose range of 0.0-
5.0 µM cisplatin, 0.0-0.1 µM doxorubicin, 0.0-0.1 µM imatinib and 0.0-20.0 nM for 
rapamycin. The results showed that treating K562 cells with 1.0, 2.0 and 5.0 µM cisplatin, 
0.02 µM doxorubicin, 0.2 µM imatinib and 20.0 nM rapamycin significantly reduce their 
ability of colony formation (Figure 3.16). 
Figure 3.15 Effects of selected drug doses on the total apoptosis percentage of K562 parental cells. 
Parental K562 cells were treated with 0.2µM imatinib, 10µM cisplatin or 20nM rapamycin and apoptosis 
rate assessed by the Muse™ Annexin V and Dead Cell Assay kit at 24 and 48 hours expressed as 
apoptosis percentage (**p<0.01, ***p<0.001, ****p<0.0001; One-way ANOVA test followed by 
Bonferroni test; n=3). 
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Based on these optimisation results, concentrations that will be used as the optimised doses 
in subsequent chapters following PP4c silencing in K562 cells with Trypan blue exclusion 
and apoptosis assays are 10 µM cisplatin and 0.2 µM doxorubicin, while concentrations of 
imatinib and rapamycin will be used at 0.2 µM and 20 nM respectively for all assays. 
Figure 3.16 Effects of selected drug doses on the colony formation in K562 parental cells. Parental 
K562 cells were treated with (0.1-5.0) µM cisplatin (A), (0.005-0.1) µM doxorubicin(B), (0.01-0.2) µM 
imatinib (C) or (1.0-20.0) nM rapamycin (D) and colonies number assessed by long-term survival assay 
(**p<0.01, ***p<0.001, ****p<0.0001; One-way ANOVA test followed by Bonferroni test; n=3). 
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Similarly, the following drug concentrations were selected for use in further studies on HL-
60 cells; 0.1 µM for doxorubicin, 2.0 µM for cisplatin and 20 nM for rapamycin. Because 
of the high sensitivity of HL-60 cell as seen in MTS assay, the confirmation of drug 
toxicity at these selected doses as assessed by Trypan blue exclusion and MUSE Annexin 
V and dead cell assay was conducted only at 24 hours post treatment.  
The results showed the viable cell number (viability %) of HL-60 cells decreased from 
2.6×105 cells/mL (100%) without treatment to 1.71×105 cells/mL (66.24%) with cisplatin, 
0.93×105 cells/mL (35.91%) with doxorubicin and 2.56×105 cells/mL (87.74%) with 
rapamycin (Figure 3.17). Moreover, the findings of total apoptosis percentage showed 
similar effects on parental HL-60 cells after treatment; total apoptosis increased from 
5.56% without treatment to 10.61% with cisplatin, 75.36% with doxorubicin and 8.66% 
with rapamycin after 24 hours (Figure 3.18).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Effects of selected drug doses on the cell viability of HL-60 parental cells. Parental HL-
60 cells were treated with 2µM cisplatin, 0.1µM doxorubicin or 20nM rapamycin and viable cell number 
assessed by Trypan blue vital dye exclusion at 24 expressed as both absolute cell numbers/mL (A) or as 
a percentage viability (B) (*p<0.05, **p<0.01, ****p<0.0001; One-way ANOVA test followed by 
Bonferroni test; n=3). 
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Similarly to K562 cells, the long-term survival assay was initially carried out using the 
same drug doses used in the MTS method, with colony number for cells treated with 
cisplatin and doxorubicin zero. This was then repeated with a lower dose range from 0.0 to 
5.0 µM with cisplatin, 0.0-0.1 µM with doxorubicin and 0.0-20.0 nM with rapamycin 
(Figure 3.19). The long-term survival assay results showed that 0.5 µM and 1.0 µM 
cisplatin and 0.005 µM and 0.01 µM doxorubicin concentrations significantly inhibited the 
cells’ ability to form colonies, while 20 nM rapamycin did not inhibit HL-60 cells’ colony 
forming ability. Therefore, 0.5 µM cisplatin and 0.01 µM doxorubicin concentrations will 
be used as the optimised doses following PP4c silencing in HL-60 cells with Trypan blue 
exclusion and apoptosis assays instead of the previous concentrations 2.0 µM cisplatin and 
0.1 µM doxorubicin. 
Figure 3.18 Effects of selected drug doses on the total apoptosis percentage of HL-60 parental cells. 
Parental HL-60 cells were treated with 2µM cisplatin, 0.1µM doxorubicin or 20nM rapamycin and their 
apoptosis rate assessed by the Muse™ Annexin V and Dead Cell Assay kit at 24 hours expressed as 
apoptosis percentage (**p<0.01, ****p<0.0001; One-way ANOVA test followed by Bonferroni test; 
n=3). 
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Figure 3.19 Effects of selected drug doses on the colony formation in HL-60 parental cells. Parental 
HL-60 cells were treated with (0.1-5.0) µM cisplatin (A), (0.005-0.1) µM doxorubicin (B) or (1.0-20.0) 
nM rapamycin (C) and colonies number assessed by the long-term survival assay (**p<0.01, 
***p<0.001, ****p<0.0001; One-way ANOVA test followed by Bonferroni test; n=3). 
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3.3.4. Transfection methods optimisation  
As mentioned previously (see section 3.1.3), a preferred transfection method needs to yield 
high transfection efficiency, minimum toxicity and subsequently, gives high quality and 
reproducible results, therefore, this section will focus on the results of inroducing DNA or 
RNA into K562 and HL-60 cells. 
 
3.3.4.1 Plasmid DNA transfection  
3.3.4.1.1. K562 cell line 
The transfection efficiency at 48 hours post GFP transfection in K562 cells using 
nucleofection method was more than 80% at (Figure 3.20).  
 
 
 
 
 
 
 
 
 
 
A B 
Figure 3.20 Transfection efficiency of K562 leukaemic cell line using nucleofection. Representative 
images showing transfected K562 cells with enhanced pmaxGFP by nucleofection using programme T-
016. The transfection efficiency was more than 80% at 48 hours post transfection using [A] fluorescence 
microscopy and [B] light microscopy. 
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3.3.4.1.2. HL-60 cell line 
In this research and after using different transfection reagents that have been used for 
plasmid DNA transfection, HL-60 cells were found to be difficult to transfect and very 
sensitive to these reagents. Similarly to K562 cells, HL-60 cells were initially transfected 
with a GFP-expressing plasmid using nucleofection solution V, however; this resulted in 
low transfection efficiency (<35%, table 3.1). This is contrast to the use of nucleofection 
with K562 cells where transfection efficiency was greater than 80% (see 3.3.4.2.1). 
Alternative methods for plasmid delivery into HL-60 cell using Lipofectamine 2000 
Reagent and Lipofectamine 3000 Reagent were also explored, however; this resulted in no 
visual GFP expression and a negligible transfection rate.  
 
Table 3.1 pmax-GFP transfection optimisation for HL-60 cell line. Three experiments 
using nucleofection V reagent showed very low level of transfection efficiency percentage.  
 
 
 
 
 
 
 
Following the same steps used with K562 cells, figure 3.21 showed the results of the 
transfection efficiency in HL-60 cells at 48 hours post GFP transfection.  
  Transfection efficiency % 
Replicate 1 26% 
Replicate 2 34% 
Replicate 3 33% 
Total  31.0 ± 2.5 % 
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3.3.4.2. Small interfering RNA (siRNA) 
3.3.4.2.1. K562 cell line 
The results of current study revealed that the transfection efficiency of Cy3 labelled siRNA 
in K562 cells was 95% at 72 hours post-transfection using nucleofection method (Figure 
3.22).  
 
 
 
 
 
 
 
 
 
B A 
A B 
Figure 3.21 Transfection efficiency of HL-60 leukaemic cell line using nucleofection. Representative 
images showing transfected HL-60 cells with enhanced pmaxGFP by nucleofection V solution using 
programme T-019. The transfection efficiency was less than 40% at 48 hours post transfection using [A] 
fluorescence microscopy and [B] light microscopy. 
Figure 3.22 Transfection efficiency of K562 leukaemic cell line using nucleofection as a 
transfection method. Representative images showing transfected K562 cells with Cy3-labelled (-) 
siRNA. The transfection efficiency was 95% at 72 hours post transfection using [A] fluorescence 
microscopy and [B] light microscopy. 
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3.3.4.2.2. HL-60 cell line  
Owing to low transfection efficiencies and/or poor recovery of cells post-transfection, a 
variety of transfection methods for the introduction of siRNAs into HL-60 cells were 
explored. HiPerFect transfection reagent (a lipid-based transfection method from Qiagen) 
was used to introduce the siRNAs into HL-60 cells. Optimal transfection efficiency was 
achieved by culturing HL-60 cells for 24 hours prior to transfection to ensure that the cells 
were in logarithmic growth phase. After which, 2×105 cells per well were seeded in 24 
well plates in 100 µL complete culture medium. Transfection effeciency was determined 
using three different volumes of HiPerFect according to the manufactorer's protocol; 750 
ng scrambled negative siRNA labelled with Cy3 was diluted in 100 µL Opti-MEM™ 
culture medium (Gibco) and either 3, 6 or 9 µL HiPerFect transfection reagent was added 
to the diluted siRNA. Samples were mixed by vortexing then incubated at room 
tempeartaure for 5-10 minutes to allow the formation of transfection complexes. The 
complexes were added drop-wise onto the seeded cells in 24-well plates and the plates 
gently swirled to ensure uniform distribution of the transfection complexes. Plates were 
then incubated for 6 hours to allow siRNA delivery and then 400 µL complete RPMI 
culture medium was added to all wells. Cell viability on HL-60 cells transfection with 
HiPerFect at different volumes and Cy3-siRNA amounts resulted in consistent high viable 
cell numbers and cell viability in the region of 95% (Table 3.2). 
Transfections were later repeated using a reduced amount of scrambled negative siRNA 
labelled with Cy3 (200 ng) and, following the same steps above, comparable results for 
transfection efficiency were obtained (Figure 3.23).  
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Table 3.2 HL-60 HiPerFect reagent 48 hours in 24-wells plate (n=3) 
Cy3 HiPerFect 
reagent 
Total cell number×105 
(mean±SEM)  
% Death Transfection 
efficiency % 
200 ng 3 µL 7.90 ± 0.78 4.94 ± 0.97 100 % 
375 ng 3 µL 8.61 ± 2.04 5.48 ± 0.96 100 % 
750 ng 3 µL 8.51 ± 3.05 6.40 ± 3.06 100 % 
750 ng 6 µL 10.87 ± 2.6 5.24 ± 0.45 100 % 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 3.23 Transfection efficiency of HL-60 cell line using HiPerFect as a transfection method. 
Representative images showing transfected HL-60 cells with 200 ng Cy3-labelled (-) siRNA. The 
transfection efficiency was 100% at 72 hours post transfection using [A] fluorescence microscopy and 
[B] light microscopy. 
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3.4. Discussion 
This study aimed to confirm the cytotoxicity of a range of chemotherapeutic drugs against 
K562 and HL-60 cells in order to establish preliminary dose response relationships and 
determine suitable concentrations for use in further studies. Both K562 and HL-60 cells 
were treated with increasing concentrations of cisplatin, doxorubicin, rapamycin, and only 
K562 cells were treated imatinib for 24 and 48 hours, with cell viability assessed using the 
MTS assay. The data obtained from the MTS assay indicated that the cell viability was 
significantly decreased with increased drugs doses and incubation period. This could be 
explained as the drug treatment decreased the number of viable cells either by inducing cell 
death directly or by decreasing their proliferation rate in a concentration- and time-
dependent manner.  
In consistence with the results of this study, previous studies showed that cisplatin and 
doxorubicin inhibit cell proliferation rate in other types of cancers such as breast cancer, 
ovarian cancer and sarcoma (Tsimberidou et al., 2009). The present data showed that the 
cytotoxicity or the inhibition of cell proliferation in HL-60 cells post cisplatin and 
doxorubicin treatment was much higher (up to 95% at 48 hours) than the inhibition level in 
K562 cells (up to 40% with cisplatin and 60% with doxorubicin at 48 hours), and 
consequently, the viability of HL-60 cells post cisplatin or doxorubicin treatment was 
much lower than the viability of K562 cells at 48 hours post-treatment. This may be related 
to the kinases linked with AML and CML that may be interacting with some of the 
downstream targets as well as the phosphatases that these two cells express or lacked. In a 
previous study, a comparison between the response of HL-60 and K562 cells to the same 
stimuli over long time period (up to 14 days) indicated that the execution phase of 
programmed cell death in K562 cells is delayed compared with HL-60 cells (Martins et al., 
1997). Moreover, Martins and colleagues reported that the levels of activation of the 
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effector caspases can vary in these two cell lines undergoing apoptosis after treatment with 
the same apoptosis-inducing stimulus (Martins et al., 1997). Compared to HL-60 cells, the 
caspase activation was delayed in K562 cells, suggesting that the Bcr-Abl kinase acts 
upstream of events that result in cytochrome c release and caspase activation (Martins et 
al., 1997). In addition, by two-dimensional gel electrophoresis assay, three caspase species 
and three active forms of caspase-3 were detected in K562 cytoplasm and nuclei, while 
HL-60 cells contained one active form of caspase-3 and another caspase species (Martins 
et al., 1997). Another study revealed that in contrast to HL-60 cell line, K562 cells 
represent a cell line with an earlier arrest in myeloid differentiation, therefore when the 
K562 cells treated with dimethyl sulfoxide (DMSO) did not induce morphological or 
histochemical changes as it did in HL-60 cells, suggesting that K562 cells did not exhibit 
morphological or histochemical myeloid differentiation (Collins et al., 1978).  
Many studies have suggested that the activation of p53 might increase the cell’s sensitivity 
to cisplatin (Bressac et al., 1990; Qin and Ng, 2002). As K562 cells do not express the p53 
gene and HL-60 cells also lack this oncoprotein (Wolf and Rotter, 1985; Prokocimer et al., 
1986; Durland-Busbice and Reisman, 2002), they thus show reduced sensitivity to cisplatin 
compared to other cells, which express p53 protein (Bressac et al., 1990; Dasari et al., 
2015). Nevertheless, cisplatin does induce apoptosis and causes changes in cell cycle 
progression in cells, whether they express p53 or not, through both p53 dependent and 
independent pathways (Qin and Ng, 2002; Dasari et al., 2015). In a study on p53-deficient 
renal cells, Jiang et al. (2009) revealed that apoptosis can be induced by cisplatin via the 
intrinsic or mitochondrial pathway. Cisplatin induces apoptosis by interdependent 
activation of Bcl-2 members, Bax and Bak, resulting in c cytochrome release and 
subsequently activation of caspases (Jiang et al., 2009).  
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Dasari and colleagues reported that cisplatin induced lipid peroxidation and DNA damage, 
irreversibly inhibiting cell proliferation in HL-60 cells by arresting them in G1 phase of 
cell cycle (Dasari et al., 2015). Cisplatin causes DNA cleavage in APL cells by modulating 
c-jun expression and the protein kinase C-dependent signalling pathway (Rubin et al., 
1992). Inhibition of cell proliferation or cytotoxicity induced by cisplatin in HL-60 cells 
could be the result of collective mechanisms including c-jun expression, protein kinase C-
dependent signalling pathways, Bcl-2 down regulation and inhibition of cell cycle 
progression (Saad et al., 2004; Kumar and Tchounwou, 2015).  
As the mammalian Target Of Rapamycin (mTOR) deregulation has been implicated in 
cancer (Li et al., 2014), rapamycin, a potent inhibitor of mTOR with its ability to inhibit 
cell growth and trigger a nutrient deprivation-like response, was used in this study. The 
results showed a significant decrease in the viability of K562 cells at 24 and 48 hours and a 
decrease in their ability to form colonies when they treated with 20 nM rapamycin, while a 
significant decrease at 48 hours was seen in HL-60 cell when treated with rapamycin, 
associated with significant increase in apoptosis rate. 
This study used a range of complementary methods for the assessment of cell viability, 
apoptosis, or long-term survival following drug treatment. Of the many methods that have 
been developed to measure cell health, these can be divided in to three categories: those 
that exploit loss of membrane integrity, those that directly measure metabolic markers, and 
those that assess metabolic activity. In this research, the Trypan blue dye exclusion assay 
(cell membrane integrity) and the MTS assay (a measure of metabolic status) were used as 
complementary methods for assessing cell viability. In the Trypan blue dye exclusion 
assay, viable cell numbers are counted directly by the ability of viable cells (which retain 
membrane integrity) to actively exclude the dye. While MTS (3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) indirectly reflects cell 
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viability by measuring the mitochondrial metabolic rate (Berridge and Tan, 1993). 
Differences in mode of action in terms of assessment of cell viability, can explain slight 
variation of the data obtained from these two methods and emphasises the importance of 
using a number of complementary methods in these approaches. The effect of a 
concentration of a drug on cell survival measured with long term survival, an important 
method for the assessment of survival by measuring the ability of a single cell to form 
colonies. K562 and HL-60 cells were highly sensitive to both doxorubicin and cisplatin so 
that long-term survival method was carried out first with the same concentration of these 
drugs that been used with Trypan blue exclusion and Muse™ Annexin V and Dead Cell 
Assay kit (10 µM cisplatin and 0.2 µM doxorubicin with K562 cells and 2 µM cisplatin 
and 0.1 µM doxorubicin with HL-60 cells), but the results showed that the cells were 
incapable of forming colonies. The experiment was then repeated with new set of lower 
concentrations to select another concentration in which the cells can form colonies.   
Each cell line has its own characteristics that determine a special requirement for the 
transfection method. A comparative study on many transfection methods demonstrated that 
nucleofection is more effective at delivering DNA for different cell types than chemical 
transfection reagents such as Lipofectamine 2000 and Lipofectamine Plus, resulting in high 
levels of transfection efficiency associated with low toxicity (Maurisse et al., 2010). These 
findings are in agreement with the results of this study in term of K562 cells and support 
the present results in HL-60 cells despite the low transfection efficiency (less than 35%; 
due to the high toxicity results from electric pulses) when they transfected by nucleofection 
solution V, while they showed a negative response to Lipofectamine 2000 and 
Lipofectamine 3000 reagents. On the other hand, in this research HiPerFect reagent has 
been used instead of nucleofection V reagent to down-regulate PP4c in HL-60 cells when 
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the first experiments showed high toxicity, as HiPerFect reagent is recommended for 
rapidly growing cells.    
Collectively, these two different models of leukaemic cell lines showed different response 
to the transfection methods that been used to deliver plasmid DNA or small interfering 
RNA as well as their response to the selective drugs applied in this research. In depth 
studies, different types of cell viability assays, proliferation and apoptosis are crucial to 
assess cell health, monitor the growth rate and to examine how the cells conducted 
programed cell death by gene modulation or by exposing to pharmacological compounds. 
The next chapter will focus on the effects of protein phosphatase 4 catalytic subunit's 
modulation on cell viability, proliferation and apoptosis in both K562 and HL-60 cell lines 
using some of the methods optimised in this chapter. 
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4. The effects of modulating the endogenous level of PP4c on the viability, 
apoptosis and proliferation of leukaemic K562 and HL-60 cell lines 
4.1. Introduction 
As several cancers are characterized by the unrestrained activation of oncogenic kinases, it 
is not surprising that many protein phosphatases can counteract the activity of these 
kinases and function as tumour suppressors (Lee and Muller, 2010; Perrotti and Neviani, 
2013). The study of protein phosphatases and their regulation has therefore become an 
expanding field of research aimed at determining the importance of these proteins in 
cancer (Tonks, 2006; Perrotti and Neviani, 2006; 2013).  
One of the best known example of oncoproteins with unrestrained tyrosine kinase activity 
is the product of the Philadelphia chromosome t(9;22) translocation, Bcr-Abl. The Bcr-Abl 
fusion protein is a constitutively active tyrosine kinase that acts as a driving force in the 
induction of chronic myeloid leukaemia (CML) and the survival of CML cells (Nowell and 
Hungerford, 1960; Rowley, 1973). Mutations and dysregulation of a number of tyrosine 
kinase including receptors Fms-like tyrosine kinase (Flt-3), c-KIT and platelet derived 
growth factor receptor (PDGFR) are also characteristics of the heterogeneous disease 
Acute myeloid leukaemia (AML) (Neviani et al., 2005). While much of the focus for 
targeted therapies in myeloid leukaemias has concentrated on the tyrosine kinases 
responsible for phosphorylation events, research over the past decade has now started to 
highlight the importance of protein phosphatases in myeloid leukaemias and their potential 
as targets for novel therapies (Neviani et al., 2005; 2007).  
PP2A is the most studied member of the PPP family due to discoveries indicating its 
important role as a tumour suppressor in many cancers, including myeloid leukaemia 
(McConnell and Wadzinski, 2009). Many studies have implicated PP2A in a wide range of 
cellular signalling pathways, such as Wnt, mTOR and MAPK pathways, many of which 
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are involved in cellular proliferation, apoptosis, cell-cycle division and differentiation 
(McConnell and Wadzinski, 2009). The inactivation of PP2A by mutant c-KIT receptors 
that consequently altered expression of the endogenous PP2A inhibitory protein SET, was 
found to be a common theme in acute myeloid leukaemia, therefore, re-activation of PP2A 
results in dephosphorylation, and deactivation, of the kinase and subsequent inhibition of 
leukaemogenesis (Roberts et al., 2010). Therefore, re-activation of PP2A is considered as 
an attractive strategy for leukaemia therapy (Neviani et al., 2005; 2007; Kalla et al., 2007; 
Cristóbal et al., 2012; Smith et al., 2016). The expression of PP1 and PP2B was also 
evaluated in various acute myelogenous leukaemic (AML), acute lymphocytic leukaemic 
(ALL) and chronic lymphocytic leukaemic (CLL) cells compared to normal peripheral 
leukocytes (Yamamoto et. al., 1999). The results showed that the levels of these protein 
phosphatases were lower in leukaemic cells compared to normal peripheral leukocytes, 
suggesting that they play a role in regulating important signalling pathways that contribute 
to leukaemogenesis (Yamamtoto et.al., 1999).  
 
4.1.1. Protein phosphatase 4  
Due to its location on chromosome 16 p11.2, the human PP4c gene is linked to the 
translocational mutation associated with acute leukaemia (Bastians et al., 1997). PP4c 
interacts with four regulatory subunits which regulate and control its activity (Martin-
Granados et al., 2008) and is believed to be involved in many signalling pathways such as 
tumour necrosis factor (TNF)-alpha signalling and regulation of histone acetylation (Zhang 
et al., 2005). It has been reported that the silencing of PP4R1, a constitutive interacting 
partner of PP4c, causes cell cycle arrest at G2/M phase leading to decreased cell 
proliferation and colony formation in hepatocellular carcinoma cell lines (Wu et al., 2015). 
PP4R1 silencing also inhibits cell growth and proliferation in breast cancer cells (Qi et al., 
2015) and lung cancer cells (Zhu et al., 2016). 
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Brechmann and colleagues (2012) have reported that a specific PP4c-PP4R1 interaction 
occurs in human malignant T lymphocytes as a negative regulator of inhibitor of NF-κB 
kinase (IKK) activity (Brechmann et al., 2012). T cell receptor or tumour necrosis factor 
(TNF) receptor 1 (TNFR1) stimulation leads to the phosphorylation of NF-κB kinase 
(IKK) complex followed by the proteasomal degradation of subsequent inhibitory kB 
proteins (IkBs) resulting in the translocation of NF-κB proteins to the nucleus, where they 
bind to DNA and activate the transcription of NF-κB-regulated genes (Hayden and Ghosh, 
2008). PP4R1 enhances PP4c activity and allows its association with IKK complex leading 
to its dephosphorylation and inactivation and consequently the inhibition of NF-κB 
activity. So, PP4c is unable to dephosphorylate the IKK complex in the absence of PP4R1 
resulting in unrestrained IKK phosphorylation and abnormal NF-kB activity (Brechmann 
et al., 2012). 
PP4 plays a crucial role in different cellular functions such as human centrosome 
maturation, cell migration (Martin-Granados et al., 2008), DNA damage checkpoint 
signalling (Nakada et al., 2008), and DNA repair (Lee et al., 2010). In numerous types of 
cancers including breast and lung tumours (Wang et al., 2008), pancreatic ductal 
adenocarcinoma (PDAC) (Weng et al., 2012), and in glioma development and progression 
(Li et al, 2016), PP4 catalytic subunit is over-expressed and these findings suggested that 
PP4c might function as an oncogene. It is also reported that depletion of PP4 catalytic 
subunit in HEK293 cells resulted in a decrease in cell migration and PP4c complexes may 
coordinate centrosome maturation and cell migration via regulation of Rho 
GTPases (Martin-Granados et al., 2008).  
An experiment carried out on W7.2c mouse lymphoma cells implicated that over-
expression of PP4c results in an increase in cell death and a decrease in cell proliferation 
suggesting that PP4 has an important role in apoptosis regulation and may function as a 
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tumour suppressor gene (Mourtada-Maarabouni et al., 2003). Moreover, other studies on 
HEK 293T human embryonic cells and on both human leukaemic T cells and primary 
human peripheral blood T-cells, as well as  various breast cancer cells, have also shown 
that over-expression of PP4c enhances apoptosis, while PP4c down-regulation suppresses 
apoptosis (Mourtada-Maarabouni and Williams, 2008; 2009; Mohammed et al., 2016).  
Changes in PP4c expression levels affect the phosphorylation status of many proteins 
involved in apoptosis and cell proliferation, extracellular signal-regulated kinase 1 (ERK1) 
and extracellular signal-regulated kinase 2 (ERK2), and their regulator; PEA-15 
(Phosphoprotein Enriched in Astrocytes), which is also identified to be significantly over-
phosphorylated when PP4c expression was suppressed (Krueger et al., 2005; Mourtada-
Maarabouni and Williams, 2009; Mohammed et al, 2016). Increasing evidence also 
supports a role for PP4c in MAPK-mediated apoptosis. MAPK cascades consist of three 
major branches: p38, JNK (JUN-N-terminal protein kinase), and ERK pathways which are 
involved in the regulation of apoptosis and cell proliferation (Rose et al., 2010; Cohen et 
al., 2005).  
 
Therefore, the aim of this chapter is: 
 To evaluate the effects of the modulation of the PP4c endogenous level on the 
viability, apoptosis, proliferation rate and cell long-term survival of K562 and HL-
60 cell lines using the most appropriate transfection method for each cell line to 
ultimately determine if this phosphatase plays a role in the cell fate of CML and/or 
AML cell models. 
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4.2. Methodology 
K562 and HL-60 cell lines were maintained in RPMI-1640 medium supplemented with 
10% heat-inactivated FBS, 2 mM L-glutamine and 10 mg/mL gentamicin at 37°C in a 
humidified atmosphere of 5% CO2 (see chapter  2 section 2).  
To over-express PP4c in these cells, (1-2×106) K562 or HL-60 cells per transfection were 
harvested and re-suspended in 100 µL nucleofection V solution containing 2 μg of plasmid 
DNA (either pcDNA3.1-PP4c or pcDNA3.1) and the transfection was achieved by 
Nucleofector TM II 2b, Lonza using programme T-016 for K562 cells and T-019 for HL-
60 cells. Following transfection, cells were seeded in 3.0 mL of RPMI medium in 6-well 
plates and incubated for 24 hours to allow PP4c expression, before being re-plated 
according to the type of the following functional assay (see chapter 2 sections 5.1 and 5.2).  
PP4c down-regulation was carried out in these cell lines using different methods depending 
on their sensitivity to the transfection reagent (see chapter 3 section 3). (1-2×106) K562 
cells per transfection were harvested and re-suspended in 100 µL nucleofection V solution 
containing 50 nM of either -siRNA, PP4c siRNA1, PP4c siRNA2, PP4c siRNA8 or PP4c 
siRNA9, using Nucleofector TM II 2b. The cells were then transferred to 7.0 mL of pre-
incubated growth medium in 25cm2 flasks and incubated for 72 hours before being re-
plated at 2×105 cells/mL for further functional assays (see chapter 2 section 6.1). HiPerFect 
transfection reagent was used to introduce the above siRNAs into HL-60 cells in 6-well 
plates using 250 ng/well, following the method described in chapter 2 section 6.2. 
Western blotting was performed to determine the level of PP4c expression and confirm 
that Plasmid DNA transfection or RNA interference were accomplished correctly (section 
2.13). 
Cell viability and apoptosis were assessed using a variety of complementary methods 
following re-plating of cells after plasmid or siRNA transfection as described in sections 
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2.7.1 and 2.8. Briefly, count and cell viability were performed by manual Trypan blue 
exclusion method. Programmed cell death (Apoptosis) was determined by Muse™ 
Annexin V and Dead Cell Assay kit using Muse™ Cell Analyser and cell cycle analysis 
was carried out using Muse™ Cell Cycle kit (section 2.10). 
Methods for assessment of cell proliferation were also used in this study. Determination of 
the cell’s ability to form colonies was performed by long term survival assay over a period 
of 2-3 weeks (see section 2.9) and the Muse® Ki67 Proliferation Kit (section 2.11) was 
used to determine the percentage of cells positive for the proliferation marker Ki67.   
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4.3. Results 
4.3.1. K562 cell line 
4.3.1.1. PP4c over-expression (up-regulation) 
The effects of PP4c over-expression on the K562 cell line were investigated and compared 
to negative control (vector only). K562 cells were transfected with pcDNA3.1-PP4c 
(accession #BG913014) or pcDNA3.1 empty vector. The cells were counted and plated 
after 24 hours post-transfection and the effects of PP4c over-expression on the cell count, 
viability, apoptosis, Ki-67 proliferation and cell-division cycle were examined 24 and 48 
hours post-plating.  
The degree of over-expression of PP4c was determined by Western blotting, with a 1.5 
fold increases in the level of PP4c protein observed in K562 cells transfected with 
pcDNA3.1-PP4c as compared to mock transfected cells and cells transfected with 
pcDNA3.1 only (Figure 4.1, p<0.05 vs vector only transfection).  
Overexpression of PP4c in K562 cells showed a significant decrease in viable cell number 
from 2.25×105 cells/mL with pcDNA3.1 empty vector to 1.5×105 cells/mL (p<0.05), as 
assessed by Trypan blue vital dye exclusion assay (Figure 4.2). When the effects of PP4c 
overexpression on the basal apoptosis rate were studied, a significant increase in the 
percentage of cells scored as apoptotic was observed in PP4c overexpressing cells at 48 
hour post plating (p<0.01) (Figure 4.3). 
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Figure 4.1 Effects of pcDNA3.1-PP4c transfection on endogenous PP4c levels in K562 cells. 
Western blotting and subsequent quantification shows a significant elevation in the expression of PP4c 
in transfected cells as compared to control (*p<0.05; one-way ANOVA test followed by Bonferroni 
test). A) Representative immunoblot of PP4c protein expression in K562-pcDNA3.1-PP4c-transfected 
cells, K562-pcDNA3.1-transfected cells and K562 parental cells. Cells lysates of 1x106 cells/lane were 
separated by SDS-PAGE on 12% resolving gels followed by transfer to PVDF and detection of PP4c. 
Blots were stripped and re-probed for -actin. B) A bar graph represents three independent experiments 
expressed as mean ± SEM. Relative expression is the ratio of PP4c level versus β-actin as determined 
using Licor image analysis software. (n=3). 
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Figure 4.2 PP4c over-expression in K562 cell line decreases the viable cell count. K562 cells were 
transfected with empty vector pcDNA3.1 and pcDNA3.1-PP4c. The number of viable cells was 
determined by Trypan blue vital dye stain 24 hours post-plating. Cells transfected with pcDNA3.1-PP4c 
were significantly less viable than cells transfected with pcDNA3.1 only (*p<0.05; one-way ANOVA 
test followed by Bonferroni test; n=3).   
 
Figure 4.3 PP4c over-expression in K562 cell line increases the percentage of total apoptosis. K562 
cells were transfected with empty vector pcDNA3.1 and pcDNA3.1-PP4c and apoptosis levels were 
measured by Muse annexin V & dead cell assay at different time points. After 24 and 48 hours of the 
plating, the percentage of total apoptosis is higher in the cells transfected with pcDNA3.1-PP4c than that 
in the pcDNA3.1 transfected cells (**p<0.01; one-way ANOVA test followed by Bonferroni test) A) 24 
hours post plating B) 48 hours post plating (n=3). 
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The viable cell count, assessed by Trypan blue exclusion, at 24 hours was almost halved 
compared to only a 6% increase in the basal apoptosis rate in cells transfected with 
pcDNA3.1-PP4c, so effects on reduced viable cell number may suggest an effect on PP4c 
on the proliferation rate. Therefore, the effect of PP4c up-regulation on the proliferation of 
K562 cells was further assessed by Ki-67 labelling of proliferating cells (Iatropoulos and 
Williams, 1996). Despite a high proliferation rate observed in parental (mock transfected) 
and pcDNA3.1 expressing cells, PP4c over-expression in K562 cells showed a significant 
decrease of almost 10% (from 82.08% with pcDNA3.1 to 75.74% with pcDNA3.1-PP4c) 
in the number of Ki67-positive cells (Figure 4.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 PP4c over-expression in K562 decreases the cell proliferation. The proliferation of PP4c 
transfected cells and control cells were determined by Ki-67 staining and Muse Cell analyser. PP4c over-
expression decreases the proliferation rate of pcDNA3.1-PP4c transfected cells as compared to 
pcDNA3.1 (*p<0.05; one-way ANOVA test followed by Bonferroni test; n=3). 
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To determine whether this reduction in the viable cell count, induction of apoptosis and 
reduced cellular proliferation of K562 cells that were transfected with pcDNA3.1-PP4c 
were due to cell cycle arrest, cell cycle analysis was performed at 24 hours post-plating. 
Cell cycle analysis revealed that in G0/G1 phase the percentage of the proliferating cells 
with PP4c over-expression was significantly higher as compared to the control cells 
associated with a concomitant decrease in the percentage of cells in S phase (Figure 4.5). 
These findings support the previous results of Ki67 proliferation assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collectively, these results suggest that PP4c over-expression in K562 cells decreases cell 
viability and proliferation rate, as well as increasing basal apoptosis. So the next section 
focused on the effects of PP4c down-regulation in these cells. 
Figure 4.5 PP4c over-expression alters the cell cycle profile of K562 cells. Cell cycle analysis was 
performed by Muse™ Cell Cycle kit which revealed a significant elevation in the number of the K562-
pcDNA3.1-PP4c transfected cells in G0/G1 phase compared to mock transfected cells and cells 
transfected with pcDNA3.1 (**p<0.01), this was accompanied with a significant reduction in the number 
of the transfected cells in S phase (**p<0.01) as compared to mock and pcDNA3.1 transfected cells 
(Two-way ANOVA test followed by Bonferroni test; n=3). 
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4.3.1.2. PP4c down-regulation (knock-down)  
The effects of PP4c on K562 cells were further investigated by using specific siRNAs to 
down-regulate endogenous PP4c expression in these cells. Cells were transfected with 
negative or scrambled siRNA, siRNA1, siRNA2, siRNA8 and siRNA9.  
Western blotting technique was used to confirm that the siRNAs effectively down-
regulated PP4c expression at the protein level and the results showed that all targeted PP4c 
siRNAs reduced the expression of endogenous PP4c, with a 33.19%, 57.69%, 65.54% and 
65.78% decrease in PP4c expression levels observed in cells transfected with PP4c 
siRNA1, PP4c siRNA2 & PP4c siRNA8, and PP4c siRNA9 respectively, as compared to 
the cells transfected with -siRNA (Figure 4.6). Following confirmation of the silencing of 
PP4c and because of the significant lower expression of PP4c, only cells transfected with 
PP4c siRNA 8 and PP4c siRNA 9 were assessed for viability, cell cycle and apoptosis. 
PP4c down-regulation results showed a significant increase in the viable cell number of the 
cells transfected with PP4c siRNA 8 (p<0.05) at 48 hours post-plating as assessed by 
Trypan blue vital dye exclusion assay (Figure 4.7). The knockdown of PP4 by siRNA 8 
and 9 had no effect on the basal apoptosis rate in K562 cells which was measured using 
Muse™ Annexin V and dead cell assay and Muse analyser at 48 hours post-plating the 
cells, as compared to control cells (Figure 4.8).  
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Figure 4.6 Effects of PP4c specific siRNA transfection on endogenous level of PP4c in K562 cells. 
Western blotting and subsequent quantification shows a significant reduction in the expression of PP4c 
in transfected cells as compared to control (*p<0.05 for PP4c siRNA8 and PP4c siRNA9; two-way 
ANOVA test followed by Bonferroni test). A) Representative immunoblot of PP4c protein expression in 
PP4c siRNA1, PP4c siRNA2 & PP4c siRNA8, PP4c siRNA9, -siRNA and K562 parental cells. Cells 
lysates of 1x106 cells/lane were separated by SDS-PAGE on 12% resolving gels followed by transfer to 
PVDF and detection of PP4c. Blots were stripped and re-probed for -actin. B) A bar graph represents 
three independent experiments expressed as mean ± SEM. Relative expression is the ratio of PP4c level 
versus β-actin as determined using Licor image analysis software (n=3, see appendix A, page 191). 
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Figure 4.7 PP4c down-regulation in K562 leukaemic cell line increases viable cell count. K562 cells 
were transfected with scrambled siRNA and PP4c siRNA 8 and PP4c siRNA 9. Viable cell count carried 
out by Trypan blue vital dye exclusion shows a significant elevation in viable cell count of K562 cells 
with PP4c siRNA 8 at 48 hours post-plating the cells as compared to the negative control (*p<0.05; two-
way ANOVA test followed by Bonferroni test; n=3). 
Figure 4.8 PP4c down-regulation in K562 cells has no effect on the level of basal apoptosis. At 48 
hours post-plating, the apoptosis percentage was measured using the Muse annexin V & dead cell assay 
carried out by Muse cell analyser. Transfected cells with PP4c siRNA8 and PP4c siRNA 9 show no 
difference in total apoptotic percentage as compared to -siRNA (n=3).  
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Given that PP4c silencing increased viable cell number but with no reduction in basal 
apoptosis, the effects on cell proliferation was also measured. The Ki67 proliferation 
assessment showed no difference in the percentage of Ki-67 positive cells between the 
cells transfected with PP4c siRNA 8 or PP4c siRNA 9 and -siRNA transfected cells 
(Figure 4.9). This figure shows that the basal proliferation rate (mock and -siRNA) is 
already very high, making any further increases difficult to detect over these short time 
points and therefore the long-term ability of the cells to form colonies was investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Effects of PP4c down-regulation on K562 cell proliferation. The proliferation of PP4c 
transfected cells and control cells were determined by Ki-67 staining and Muse Cell analyser. PP4c 
down regulation has no effect on the proliferation rate of K562 cells (n=3). 
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It was found that K562 cells transfected with the selected siRNAs (PP4c siRNA 8 and 
PP4c siRNA 9) have no significant difference in colony forming ability in comparison to 
the negative control -siRNA and mock cells (Figure 4.10). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 PP4c knockdown affects colony forming ability in K562 cells. Long term survival is 
compromised following transfection of the cells with siRNA 8 and PP4c siRNA 9 as compared to the 
cells transfected with scrambled siRNA. The figure shows no significant difference in colony forming 
ability of siRNA 8 and PP4c siRNA transfected cells in comparison to the negative control -siRNA and 
mock cells (n=3).  
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A cell cycle analysis was performed to study the effect of PP4c down-regulation on the 
growth and proliferation of K562 cells. Cells transfected with PP4c siRNA 8 and siRNA 9 
showed no significant differences in the percentage of cells in all cell cycle phases in 
comparison to the cells transfected with negative control (Figure 4.11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, PP4c down-regulation in K562 cells increased the number of viable cells, 
however with no effect on their proliferation rate, colony formation or apoptosis. These 
effects of modulating PP4c endogenous level on cell survival in the CML cell line model 
(K562) arises the importance of investigation of these effects in different leukaemic cell 
models, such as AML (HL-60). 
Figure 4.11 The effects of PP4c down-regulation on the cell cycle profile of K562 cells. Cell cycle 
analysis was performed by Muse™ Cell Cycle kit and the results showed no significant difference in the 
number of the PP4c siRNA 8 and PP4c siRNA 9 transfected cells in all phases compared to mock 
transfected cells and cells transfected with -siRNA (n=3). 
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4.3.2. HL-60 cell line 
4.3.2.1. PP4c over-expression  
The effects of modulating the endogenous level of PP4c were also investigated in the HL-
60 cell line. HL-60 cells were also transfected with pcDNA3.1 empty vector and 
pcDNA3.1-PP4c for 24 hours before being re-plated and again the effects of PP4c over-
expression on cell viability, Ki-67 proliferation and cell-division cycle were examined after 
a further 24 and 48 hours post-replating.  
Due to the transfection method used, there were problems in isolating sufficient cell 
numbers for viability, proliferation or cell cycle analysis and for Western blotting analysis, 
and due to technical problems with this technique, out of four experiments, only one 
immunoblot observed the expression of PP4c in HL-60 cells, suggesting only modest over 
expression of PP4c in those cells that could be recovered for analysis post-transfection 
(Figure 4.12). Over-expression of PP4c in HL-60 cells showed no significant but lower 
viability in pcDNA3.1-PP4c transfected cells as compared to pcDNA3.1 transfected cells 
at 24 hour post-plating, with a significant decrease in viable cell number from 4.04×105 
cells/mL with pcDNA3.1 empty vector to 1.63×105 cells/mL with pcDNA3.1-PP4c 
(p<0.05), as assessed by Trypan blue vital dye exclusion assay, observed at 48 hours post-
plating (Figure 4.13).  
On the other hand, PP4c up-regulation in HL-60 cells has no effect on the proliferation rate 
of cells transfected with pcDNA3.1-PP4c compared to cells transfected with the empty 
vector; pcDNA3.1 as assessed by Ki-67 proliferation assay at 24 hours (Figure 4.14). The 
lack of significance with the Ki67 proliferation assay supports the cell count at 24 hours, 
collectively this may be related to poor transfection efficiency and recovery of the cells, 
given that even under mock transfection conditions only 54% of cells were Ki-67 positive 
compared to 90% with K562 cells under the same experimental conditions (Figure 4.4). 
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Cell-division cycle assay was performed 24 hours post-plating and showed no difference in 
the cell cycle profile of the cells transfected with pcDNA3.1-PP4c as compared to mock 
cells or pcDNA3.1 transfected cells (Figure 4.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Effects of pcDNA3.1-PP4c transfection on endogenous PP4c levels in HL-60 cells. The 
expression of PP4c gene was hardly assessed by Western blotting technique and it shows a slightly 
elevation in transfected cells as compared to control.  Immunoblot of PP4c protein expression in HL-60-
pcDNA3.1/PP4c-transfected cells, HL-60-pcDNA3.1-transfected cells and HL-60 parental cells. 
 
Figure 4.13 PP4c over-expression in HL-60 cell line decreases the viable cell count. HL-60 cells 
were transfected with empty vector pcDNA3.1 and pcDNA3.1-PP4c. The number of viable cells was 
determined by Trypan blue vital dye stain 24 and 48 hours post-plating. At 48 hours post-plating, cells 
transfected with pcDNA3.1-PP4c were significantly less viable than cells transfected with pcDNA3.1 
only (*p<0.05; two-way ANOVA test followed by Bonferroni test; n=3).  
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Figure 4.15 PP4c overexpression has no effect on the cell cycle profile of HL-60 cells. Cell cycle 
analysis was performed by Muse™ Cell Cycle kit which showed no difference in the number of the 
pcDNA3.1-PP4c transfected cells in all phases compared to mock transfected cells and cells transfected 
with pcDNA3.1 (n=3). 
Figure 4.14 Effects of PP4c expression on HL-60 cell proliferation. The proliferation of PP4c 
transfected cells and control cells were determined by Ki-67 staining and Muse Cell analyser. PP4c over-
expression has no effect on the proliferation rate of pcDNA3.1-PP4c transfected cells as compared to 
pcDNA3.1 (n=3). 
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4.3.2.2. PP4c down-regulation  
The effects of PP4c on HL-60 cells were also investigated by using siRNAs to down-
regulate endogenous PP4c expression in these cells. Similarly to K562 cells, HL-60 cells 
were transfected with negative or scrambled siRNA, siRNA1, siRNA2, siRNA8 and 
siRNA9 but using the HiPerFect transfection method instead (Chapter 3, section 3). 
Western blotting technique was used to confirm that the siRNAs effectively down-
regulated PP4 expression at the protein level and the results showed that all targeted PP4c 
siRNAs reduced the expression of endogenous PP4c by 23.11%, 14.55%, 41.30% and 
34.88% in the cells transfected with PP4c siRNA1, PP4c siRNA2 & PP4c siRNA8, and 
PP4c siRNA9 respectively, as compared to the cells transfected with -siRNA (Figure 4.16). 
Following silencing of PP4c, only cells transfected with PP4c siRNA 8 and PP4c siRNA 9 
were assessed for viability, cell cycle and apoptosis. 
PP4c down-regulation in HL-60 cells showed no significant increase in the viable cell 
number at 24 and 48 hours, whereas a significant increase was observed at 72 hours post-
plating in PP4c siRNA 8 transfected cells (p<0.001) and PP4c siRNA 9 transfected cells 
(p<0.0001), as assessed by Trypan blue vital dye exclusion assay (Figure 4.17). Similarly 
to K562 cells, the knockdown of PP4 by siRNA 8 and 9 had no effect on the basal 
apoptosis rate in HL-60 cells which was measured using Muse™ annexin V and dead cell 
assay and Muse analyser at 48 hours post-plating the cells, as compared to control cells 
(Figure 4.18). Moreover, long-term survival was also carried out at 48 hours post-plating. 
The results showed no difference in the ability of cells transfected with PP4c siRNA 8 or 
PP4c siRNA 9 to survive and to form colonies as compared to the cells transfected with 
negative control (-siRNA) (Figure 4.19).  
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Figure 4.16 Effects of PP4c specific siRNA on endogenous level of PP4c in HL-60 cells. Western 
blotting and subsequent quantification shows a significant reduction in the expression of PP4c in 
transfected cells as compared to control (**p<0.01 for PP4c siRNA8 and *p<0.05 for PP4c siRNA9; 
two-way ANOVA test followed by Bonferroni test). A) Representative immunoblot of PP4c protein 
expression in PP4c siRNA1, PP4c siRNA2, PP4c siRNA8 & PP4c siRNA9, -siRNA and HL-60 parental 
cells. Cells lysates of 1x106 cells/lane were separated by SDS-PAGE on 12% resolving gels followed by 
transfer to PVDF and detection of PP4c. Blots were stripped and re-probed for. B) A bar graph 
represents mean ± SEM from 3 independent experiments. Relative expression is the ratio of PP4c level 
versus β-actin as determined using Licor image analysis software (n=3, see appendix A, page 191). 
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Figure 4.17 PP4c down-regulation in HL-60 cell line increases viable cell count. HL-60 cells were 
transfected with scrambled siRNA and PP4c siRNA 8 and 9. Viable cell count carried out by vital dye 
exclusion shows an elevation in viable cell count of HL-60 cells with PP4c siRNA 8, and 9 at 72 hours 
post-plating the cells as compared to the negative control (***p<0.001 for PP4c siRNA 8 and 
****p<0.0001 for PP4c siRNA 9; Two-way ANOVA test followed by Bonferroni test; n=3). 
Figure 4.18 PP4c knockdown has no effect on the level of spontaneous apoptosis of HL-60 cells. 
Cells were transfected with -siRNA, PP4c siRNA 8 and 9. At 48 hours post-plating, the apoptosis 
percentage was measured using the Muse annexin V & dead cell assay carried out by Muse cell analyser. 
Transfected cells with PP4c siRNA8 and 9 show no difference in total apoptotic percentage as compared 
to -siRNA (n=3).  
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The previous findings that showed an increase in viable cell number only at 72 hours post 
plating, the lack of any change in basal apoptosis and the lack of effect on long term 
survival suggest any effect on cell growth may be limited, in comparison to K562 cells.   
Additionally, cell proliferation was also measured by Ki-67 staining and Muse cell 
analyser at 24 hours post-plating, to determine if an increase in the proliferation marker at 
earlier time points could account for higher cell number seen at 48-72 hours. The 
assessment showed that there was no difference in the percentage of Ki-67 positive cells 
between the cells transfected with PP4c siRNA 8 or PP4c siRNA 9 and negative control 
transfected cells (Figure 4.20). 
Figure 4.19 PP4c knockdown has no effect on colony forming ability in HL-60 cells. Long term 
survival was assessed following transfection of the cells with siRNA 8 and 9 and compared to the cells 
transfected with scrambled siRNA. The figure shows no differences in colonies formation in cultures 
transfected with the PP4c siRNA 8 and PP4c siRNA 9 as compared to control (n=3).  
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Similarly to PP4c silencing in K562 cells, the high proliferation rate of HL-60 mock 
transfected cells assessed by Ki67 proliferation assay makes the assessment for effect of 
PP4c silencing difficult, so a cell cycle assay was also performed at 24 hours post re-
plating. PP4c down regulation in HL-60 cells affects the cell-division cycle and the results 
showed a significant decrease in cells proportion of S phase in cells transfected with PP4c 
siRNA 8 (p<0.05), and a significant increase in cells proportion of G2/M phase in cells 
transfected with PP4c siRNA 8 (p<0.05) and PP4c siRNA 9 (p<0.01) as compared to the 
corresponding cells transfected with negative control siRNA (Figure 4.21). 
Figure 4.20 PP4c down-regulation has no effect on HL-60 cell proliferation. The proliferation of 
PP4c transfected cells and control cells were determined by Ki-67 staining and Muse Cell analyser. PP4c 
down regulation has no effect on the proliferation rate of K562 cells (n=3). 
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Figure 4.21 PP4c down-regulation affects the cell cycle profile of HL-60 cells. PP4c silencing 
decreases the proliferating cells count in S phase and increases the proliferating cells count in G2/M 
phase. This figure revealed a significant reduction in the number of the PP4c siRNA8 transfected cells in 
S phase and a significant elevation in the number of the PP4c siRNA8 and PP4c siRNA9 transfected 
cells in G2/M phase as compared to control (-siRNA) (*p<0.05; **p<0.01; two-way ANOVA test 
followed by Bonferroni test; n=3). 
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4.4. Discussion   
Many studies have suggested that  PP4c has a crucial role in controlling cell growth, 
survival and proliferation in different types of cancers such as breast cancer, lung cancer 
and lymphoma (Wang et al., 2008; Mourtada-Maarabouni and Williams, 2008; 2009; 
Brechmann et al., 2012).  
The aim of this chapter was to investigate the effects of modulating the endogenous level 
of PP4c in two different types of model system cell lines; K562 for CML and HL-60 for 
AML. As mentioned previously, the kinases that are activated in K562 cells differ from 
those  activated in HL-60 cells, and on the other hand, the difference in their response to 
transfection methods (see chapter 3), particularly the poor recovery of HL-60 cells, 
suggests that their sensitivity to changes in PP4c will be different. Collectively however, 
the results implicate that PP4c has an effect on the growth and survival of specific 
leukaemic cells. Over-expression of PP4c in K562 cells resulted in suppression of cell 
viability and proliferation rate, and subsequently resulted in an increase in  apoptosis at 
different time points (24 and 48 hours post plating). The experiments have also 
demonstrated that over-expression of PP4c in K562 cells increases the percentage of cells 
in G0/G1 phase and decreases the percentage of cells in S phase suggesting that PP4c over-
expression commits the cells to the G0/G1 transition leading to G1 phase arrest and 
accumulation instead of progressing to S phase, possibly contributing to increased cell 
death. On the other hand, over-expression of PP4c in HL-60 cells resulted in suppression 
of cell viability. The lack of significance in some assays with HL-60 cells may be related 
to the low transfection efficiency and the high toxicity of the nucleofection method that 
used to over-express PP4c that led to poor recovery of the HL-60 cells post transfection.  
The findings of the effect of the modulation of the endogenous level of PP4c in K562 and 
HL-60 cells are in agreement with previous studies on CEM-C7 and Jurkat cells 
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(Mourtada-Maarabouni and Williams, 2009) and on MCF7 and MDA-MB-231 cells 
(Mohammed et al., 2016). PP4c over-expression increases cell death and decreases cell 
viability and proliferation in both leukaemic T-cells and untransformed human peripheral 
T-cells (Mourtada-Maarabouni and Williams, 2009) and in breast cancer cells (Mohammed 
et al., 2016). Previous results have also shown that PP4c is an important modulator of 
apoptosis and cell proliferation in the human embryonic kidney cell line HEK 293T 
(Mourtada-Maarabouni and Williams, 2008).  
This study also showed that down-regulation of PP4c by around 65% in K562 cells, using 
specific PP4 siRNAs, significantly increased the number of viable cells at 48 hours post-
plating, while down-regulation of PP4c by 34-42% in HL-60 cells significantly increased 
the viability of the cells after 72 hours post-plating. Whilst expression levels of PP4c were 
normalised to the levels of beta actin, as an endogenous loading control, small variations in 
expression levels of such ‘housekeeping’ proteins, sample loading and/or signal saturation 
may skew data normalised in this way. Further quantitation with total protein strategies 
such as the anionic dyes Coomassie blue or Ponceau S, or in-gel stain free labelling, can 
reduce uncertainty from minor experimental variation in sample loading or signal 
saturation of single endogenous controls. Though such a strategy would have been 
applicable in the current study, blots were imaged using the Licor C-digit scanner rather 
than conventional radiography. Such technology is reported to minimise signal saturation 
owing to advanced imaging optics of the scanner (Licor, undated) and the blot images for 
PP4c and actin in siRNA transfected cells indicate lack of saturation in these bands.  
The differences in the expression and the response of these two cell lines to PP4c knock-
down may be related to differences in kinases expressed in these cells and the downstream 
signalling pathways that they are associated with, as well as differences in levels of the 
phosphatase regulatory subunits expressed, which may impact the sensitivity of the cells. 
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These results are also in agreement with studies on HEK293 cells and both leukaemic T-
cells and untransformed human peripheral blood T-cells which showed that PP4c 
silencing increases cell viability, decreases apoptosis and alters the cell cycle profile by 
increasing the number of the cells in G1 phase in HEK293, CEM-C7 and Jurkat cells 
(Mourtada-Maarabouni and Williams, 2008; 2009). It was also reported that silencing 
PP4c increase the cell proliferation rate and migration in oestrogen receptor-positive and 
triple negative breast cancer (TNBC) cell line types (Mohammed et al, 2016). Silencing 
PP4c by gene specific siRNAs in K562 cells increased their ability to form colonies more 
than mock cells and scrambled siRNA transfected cells. In contrast to over expression 
results, PP4c down-regulation has no effect on basal apoptosis and on the proliferation rate 
in both K562 cells and HL-60 cells; this might be related to the high proliferation rate of 
the basal cells, making any further decrease difficult to detect over these short time points. 
PP4c silencing in HL-60 cells alters the cell-division cycle by increasing the cell number in 
G2/M phase which confirm the results of increased cell viability in these cells post PP4c 
knock-down.  
Whilst limited studies have investigated the role of PP4c in leukaemic cell line models, the 
impairment in the regulation of the activity of PP2A has been reported. Since PP4c is a 
PP2A-related Ser/Thr protein phosphatase and shares about 65-66% identity in the amino 
acid sequences with the PP2A α and PP2A β catalytic subunits, though their regulatory 
subunits are very distinct (Chen et al., 2008), PP2Ac and PP4c have been shown to 
dephosphorylate the same residue on a substrate (in vitro, both phosphatases 
dephosphorylate nucleosomal γ-H2AX in a dose-dependent manner (Chowdhury et al., 
2008)), and so similar modes of action between these two phosphatases can be suggested. 
This overlap in substrate specificity may allow dephosphorylation to occur at a different 
subcellular location or under different cellular conditions (Lee et al., 2010). Moreover, 
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PP2Ac has been suggested to be involved in DNA repair after exogenous DNA damage, 
while PP4c plays a greater role in the repair during DNA replication (Lee et al., 2010). 
Also due to their homology, certain cellular functions of PP2A may in fact be those of PP4 
(Shui et al., 2007; Zhou et al., 2002). The above studies suggested that PP4c might have a 
similar role in leukaemic cells to that of PP2Ac. Many studies have implicated the role of 
PP2Ac in leukaemia; a study showed that B55α, a subunit of PP2A regulatory subunit 
which is identified as a specific regulator of the levels of Akt phosphorylation at Thr308, 
was inhibited and loss of complete haematological remission in acute AML patients. Thus 
it could serve as a biomarker in AML or could be a novel target for AML chemotherapy 
(Ruvolo et al., 2011). Whereas in CML, it has been reported that PP2A over-expression 
suppresses the activity of Bcr-Abl kinase, promotes apoptosis and enhances imatinib 
activity (Neviani et al., 2005; 2007). The findings of PP2A over-expression in K562 cells 
are similar to the findings of the current study. 
Many studies on PP4c have suggested that it might function as an oncogene. It has been 
reported that PP4c is over-expressed in breast and lung cancers and any inhibition of PP4c 
expression may increase the sensitivity of breast and lung cancer cells to cisplatin 
treatment (Wang et al., 2008). An immunohistochemical study on stage II pancreatic ductal 
adenocarcinoma (PDAC) samples showed that over-expression of PP4c is associated with 
poor prognosis and suggest that PP4c could act as a marker for the diagnosis of invasive 
PDAC and a new approach for the treatment of this disease via targeting its signalling 
pathways (Weng et al., 2012). Recently, a study revealed that PP4c also plays an 
oncogenic role in glioma's development and progression (Li et al., 2016b).  
It is interesting to note that when scaffold and regulatory subunits of PP2A are deregulated 
in cancer cells, the cell tries to maintain a constant level of functional catalytic subunit 
activity (Seshacharyulu et al., 2013). Therefore, the over-expression of PP4c in these types 
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of cancer could be the results of the deregulation in the expression or activity of PP4 
regulatory subunits. For example, PP4R1 depletion in cutaneous T cell lymphoma (CTCL) 
causes constitutive IKK/NF-κB signalling (Brechmann et al., 2012). This study showed 
that PP4R1 forms part of a PP4 holoenzyme and bridges the inhibitor of NF-κB kinase 
(IKK) complex and the phosphatase PP4c, thereby directing PP4c activity to 
dephosphorylate and inactivate the IKK complex. Deficiency of PP4R1 leads to an inactive 
PP4c and causes sustained and increased IKK activity, T cell hyperactivation, and aberrant 
NF-κB signalling in NF-κB-addicted T cell lymphomas (Seshacharyulu et al., 2013). 
Whilst another study on colorectal carcinoma suggested that PP4c up-regulated MMP-2 
and MMP-9 via PI3K/Akt pathway, associated with lymphatic nodes and consequently 
promotes distant metastasis (Li et al., 2015b).  
The findings of this study showed many distinct differences in the response of K562 and 
HL-60 cells to PP4c endogenous modulation. The different kinases linked with CML and 
AML may be altered by PP4 levels/activity by interacting with some of the downstream 
targets, alongside possible differences in regulatory subunit interactions. Previous studies 
on K562 cell line involving the cell survival assessment at 4 to 24 hours post treatment 
with an inducing stimulus have demonstrated that Bcr-Abl kinase expression restores the 
cells resistant to the induction of apoptosis (McGahon et al., 1997). Furthermore, Martins 
et al. (1997) suggested that this expression of Bcr-Abl kinase in K562 cells delays cell 
death rather than preventing it (Martins et al., 1997). 
With PP4c over expression in K562 cells a decrease in viable cell number at 24 hours and 
decreased proliferation rate, suggested an increase in cell death, supported by changes in 
the cell-division cycle in G0/G1 and S phases, while PP4c over expression in HL-60 only 
affected viable cell numbers after 48 hours. Moreover, the results revealed that the K562 
mock transfected cells show higher Ki67 staining than the HL-60 mock transfected cells 
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under similar experimental conditions, supporting the lower tolerance of HL-60 cells to the 
nucleofection method. Transfection efficiencies of PP4c over-expression in HL-60 cells 
was very low (less than 40%), unlike the transfection efficiency of PP4c over-expression in 
K562 cells which was more than 80% (see chapter 3 section 3.4.1), supporting poor cell 
recovering, possibly accounting for the limited effect of PP4c over-expression in HL-60. 
Moreover, the effects of PP4c over-expression in HL-60 were difficult to conclude because 
of the cell loss during transfection, affecting data from the apoptosis assay in HL-60 cells 
due to low cell numbers. 
Differences were also observed with PP4c siRNA; in comparison to K562, the extent of 
down-regulation in HL-60 cell is not as great. PP4c down regulation in K562 cells 
increased the viable cell number at 24 and 48 hours, while PP4c down regulation in HL-60 
cells only increased the viable cell number at 72 hours, this could be related to differences 
in the extent of PP4c down-regulation but may also suggest a differential sensitivity of the 
two models to changes in PP4c levels, which may also in part reflect the data from PP4c 
over-expression. Unlike K562 cells where there was a clear trend on long-term survival 
post PP4c silencing, this was not apparent in the colony forming assay with HL-60. PP4c 
down-regulation in these two cell lines also altered the cell-division cycle profile 
differently. These differences and the sensitivity of these cells towards PP4c endogenous 
modulation might be related to the different mutations and dysregulation of tyrosine kinase 
activity, the translocation chromosomes that they possess, oncoprotein expression, and the 
signalling pathways involved. So, further studies are needed to understand the signalling 
pathways impacted on by PP4c in K562 and HL-60 cells.  
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From the findings of this chapter, it can be concluded that the effects of PP4c over-
expression and down-regulation in both K562 and HL-60 cells are very distinct and the 
observation that PP4c down-regulation under basal conditions has no effect on both 
apoptosis rate and Ki67 proliferation assay in K562 and HL-60 cells needs to be further 
explored. Moreover, previous study indicated that PP4c silencing may increase the 
sensitivity of cells in other cancer models such as breast and lung cancer cells to cisplatin 
(Wang et al., 2008). For these reasons, the next chapter will focus on the effects of PP4c 
silencing on the K562 and HL-60 cells response to some anti-cancer drugs in term of the 
apoptosis rate and proliferation rate of these leukaemic cells. 
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5. Effect of PP4c silencing in K562 and HL-60 cells on the response to 
anti-cancer drugs 
5.1. Introduction 
The importance of PP4c in cancer progression by regulating many signalling pathways 
such as NF-κB, JNK and m-TOR pathways has been demonstrated previously (Zhou et al., 
2004; Mourtada-Maarabouni and Williams, 2008). Any excessive or insufficient activity of 
PP4c could be lethal to the cells and this could be associated with cisplatin sensitivity 
(Zhou et al., 2004; Mourtada-Maarabouni and Williams, 2008; 2009). Another study has 
reported that the low expression of PP4c results in increased sensitivity of breast and lung 
cancer cells to cisplatin treatment (Wang et al., 2008). In vitro, the effects of UV-C 
radiation treatment post PP4c endogenous modulation in HEK 239T, CEM-C7, and Jurkat 
cell lines have been studied (Mourtada-Maarabouni and Williams, 2008; 2009). The results 
showed that PP4c over-expression enhanced the cellular proliferation inhibition of the UV-
exposed cells, while PP4c silencing in these cells enhanced their ability to form colonies 
and consequently resist the cell death that induced under these conditions (Mourtada-
Maarabouni and Williams, 2008; 2009). In addition, these studies demonstrated that other 
cytotoxic stimuli including cisplatin showed similar effects of radiation therapy on HEK 
239T, CEM-C7, and Jurkat cell lines suggesting that PP4c plays an important role in 
apoptosis (Mourtada-Maarabouni and Williams, 2008; 2009). 
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The findings of the current study in the previous chapter suggested that PP4c knock-down 
under basal conditions has no effect on the apoptosis and proliferation rates in both K562 
and HL-60 cells, therefore, the aim of this chapter is: 
 To evaluate the effects of the PP4c silencing in K562 and HL-60 cells on their 
response to the selected anti-cancer drugs; cisplatin, doxorubicin, imatinib and 
rapamycin, by measuring their cells viability percentage and total apoptosis rate. In 
other words, to examine if PP4c down-regulation protects against anticancer drugs-
induced apoptosis and consequently affects some important pathways such as 
caspase-dependent pathways and MAPK pathways in which PP4c plays an 
important role. 
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5.2. Methodology 
In this chapter, the effect of PP4c down-regulation on the cytotoxic response of the cells to 
four different drugs was investigated. Seventy-two (72) hours post PP4c silencing in K562 
cells by nucleofection V reagent (Chapter 2 section 6.1) and HL-60 cells by HiPerFect 
transfection reagent (Chapter 2 section 6.2), the cells were re-plated with the anti-cancer 
agents; cisplatin, doxorubicin, imatinib (only K562 cells) and rapamycin.   
According to the findings of the current study in chapter three, K562 cells were re-plated 
with 10 µM cisplatin, 0.2 µM doxorubicin, 0.2 µM imatinib, or 20 nM rapamycin at 2×105 
cells/mL in 24-well plates, while HL-60 cells were re-plated with 2 µM cisplatin, 0.1 µM 
doxorubicin, or 20 nM rapamycin also at 2×105 cells/mL in 24-well plates and incubated 
for 24 and 48 hours before assessment of cell viability and apoptosis as described in 
chapter 2 sections 7.1 and 8. 
Trypan blue exclusion method was used to count the number of viable cells 24 and 48 
hours post treatment as described in chapter 2 in section 7.1 and the results represented in 
this chapter as the number of viable cells/mL (×105) and viability expressed as a 
percentage of the total cell number (% viability). 
Apoptosis was also assessed by Muse™ Annexin V and Dead Cell Assay kit using Muse™ 
Cell Analyser according to manufacturer's instruction as explained in chapter 2 section 8. 
The results were expressed as total apoptotic percentage (% Total apoptotic). 
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5.3. Results 
5.3.1. Effects of PP4c down-regulation in K562 cells on their response to some of 
the anti-cancer drugs 
In chapter 4, the results of PP4c down-regulation in K562 cells showed an elevation in cell 
viability but with no effect on basal apoptosis. Therefore, in this chapter, the effect of some 
of chemotherapeutic drugs on the viability of K562 cells following silencing of PP4c was 
investigated. At 72 hours post nucleofection, the cells were counted, treated with drugs and 
plated at 2×105 cells/mL in 24-well plates to evaluate the viable cell number, viability and 
total apoptosis.  
Mock, -siRNA, PP4c siRNA8 and PP4c siRNA9 transfected K562 cells were treated with 
0.2 µM doxorubicin and the results showed that doxorubicin treatment decreased the 
number of viable cells under all transfection conditions after 24 hours (Figure 5.1A), which 
was further decreased after 48 hours (Figure 5.1B). Thus, figures 5.1C and D (data 
expressed as percentage viability) showed no significant difference in cell viability of 
PP4c-transfected cells at 24 and 48 hours post-treatment with doxorubicin when compared 
to negative siRNA (-siRNA) suggesting no effect of PP4c silencing on the K562 cells’ 
sensitivity to doxorubicin.  
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Figure 5.1 PP4c silencing has no effect on K562 cells viability in response to doxorubicin 
treatment. Transfected K562 cells were treated with 0.2 µM doxorubicin. Viable cell count carried out 
by Trypan blue dye exclusion at 24 and 48 hours showed a decrease in viable cell count (A, B) and the 
viability (C, D) of mock, -siRNA, PP4c siRNA 8 and PP4c siRNA 9. PP4c down regulation in K562 
cells showed no resistance to doxorubicin treatment (n=3). 
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Total apoptotic percentage was also analysed at 24 hours post doxorubicin treatment 
(Figure 5.2a), and the results showed around a 6-fold increase in the apoptosis rate of all 
transfected K562 cells. Representative scatter plots from the Muse analyser showed a 
characteristic shift from viable pre-treatment, to early apoptotic stage post-treatment, and 
no differences in the apoptosis profiles of PP4c-siRNA transfected K562 cells as compared 
to mock or -siRNA (Figure 5.2b). These results, similar to Figure 5.1, suggested that PP4c 
silencing has no effect on the sensitivity of K562 cells towards doxorubicin treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2a PP4c silencing has no effect on K562 cells apoptosis in response to doxorubicin 
treatment. At 24 hours post 0.2 µM doxorubicin treatment, the apoptosis percentage was measured 
using the Muse annexin V & dead cell assay carried out by Muse cell analyser. Transfected cells with 
PP4c siRNA8 and PP4c siRNA 9 show no difference in total apoptotic percentage as compared to -
siRNA (n=3).    
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      Mock           Mock & Doxorubicin  
 
 
 
 
 
    -siRNA          -siRNA & Doxorubicin 
  
 
 
 
 
    siRNA8        siRNA8 & Doxorubicin 
 
 
 
 
 
    siRNA9         siRNA9 & Doxorubicin  
 
 
 
 
 
 
 
 
Figure 5.2b PP4c silencing has no effect on K562 cells apoptosis in response to doxorubicin 
treatment. Representative pictures from Muse analyser showed no significant difference in the early and 
late apoptotic percentages of the K562-PP4c siRNAs transfected cells as compared to mock and negative 
control cells at 24 hours. 
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Transfected K562 cells were also treated with 10 µM cisplatin and the viable cell number 
and cell viability percentage were assessed at 48 hours post-treatment according to the 
optimisation results (Chapter 3) which showed that the treatment of parental K562 cells 
with cisplatin becomes significantly effective at 48 hours. 
The results of treating K562 cells with 10 µM cisplatin showed a comparable reduction in 
the number of viable cells in mock, -siRNA, PP4c siRNA8 and PP4c siRNA9 transfected 
K562 cells at 48 hours (Figure 5.3A) and consequently, there was no significant difference 
in cell viability (expressed as a percentage) of PP4c-transfected cells at 48 hours post-
treatment as compared to mock or -siRNA transfected cells (Figure 5.3B). These findings 
suggested that PP4c silencing in K562 cells has no effect on the sensitivity to cisplatin 
treatment. 
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Figure 5.3 PP4c silencing has no effect on K562 cells viability in response to cisplatin treatment. 
Transfected K562 cells were treated with 10 µM cisplatin. Viable cell count carried out by Trypan blue 
dye exclusion at 48 hours showed a decrease in viable cell count (A) and the viability (B) of mock, -
siRNA, PP4c siRNA 8 and PP4c siRNA 9. PP4c down regulation in K562 cells showed no resistance to 
cisplatin (n=3).  
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K562 cells were treated with 0.2 µM imatinib post PP4c down-regulation and the results 
showed a noticeable reduction in the viable cell number of K562-PP4c siRNA8 and K562-
PP4c siRNA9 at 24 and 48 hours (Figures 5.4A and B).  
A significant inhibition in percentage cell viability of PP4c siRNA9 (34.6%, p<0.05) 
transfected cells can be seen as compared to the -siRNA cells at 24 hours (Figure 5.4C), 
whilst at 48 hours a significant decrease in the viability level of both PP4c siRNA8 
(27.5%, p<0.05) and PP4c siRNA9 (31.8%, p<0.05) transfected cells as compared to the 
negative control -siRNA cells was observed (Figure 5.4D).  
These results suggested that PP4c silencing enhances the action of imatinib in K562 cells, 
leading to a further reduction in cell viability.  
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Figure 5.4 PP4c silencing decreases the viability of K562 cells in response to imatinib treatment. 
Transfected K562 cells were treated with 0.2 µM imatinib. Viable cell count carried out by Trypan blue 
dye exclusion at 24 and 48 hours showed a reduction in the number of viable cells of mock, -siRNA, 
PP4c siRNA 8 and PP4c siRNA 9 (Figures A, B). Figures (C) and (D) show significant reduction in the 
viability percentage of the PP4c siRNA8 and PP4c siRNA9 cells compared to negative control cells (-
siRNA) 24 and 48 hours respectively (*p<0.05; one-way ANOVA test followed by Bonferroni test; n=3) 
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Moreover, total apoptosis percentage was assessed 24 and 48 hours post imatinib 
treatment, and the results showed a significant elevation in the apoptosis rate at 48 hours of 
treating K562-PP4c siRNA8 cells (23.0%, p<0.05) and K562-PP4c siRNA9 cells (24.4 %, 
p<0.05) with 0.2 µM imatinib as compared to negative control (-siRNA) (Figure 5.5a). 
Representative scatter plots from the Muse analyser showed the apoptosis profiles of 
transfected K562 cells (mock, -siRNA, PP4c siRNA8 and PP4c siRNA9) pre and post 
treatment (Figure 5.5b), with an increased shift in the percentage of cells scored as 
apoptotic. Together, these results suggest that PP4c silencing may promote the action of 
imatinib and increase the apoptosis percentage significantly in K562 cells.  
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Figure 5.5a PP4c silencing increases the total apoptotic percentage of K562 cells in response to 
imatinib treatment. At 24 and 48 hours post 0.2 µM imatinib treatment, the apoptosis percentage was 
measured using the Muse annexin V & dead cell assay carried out by Muse cell analyser. PP4c silencing 
has no effect on total apoptotic percentage of PP4c siRNA8 and PP4c siRNA9 transfected cells when 
treated with 0.2 µM Imatinib at 24 hours as compared to -siRNA (A). PP4c silencing significantly 
increased the total apoptotic percentage of PP4c siRNA 8 and PP4c siRNA 9 at 48 hours post-treatment 
as compared to -siRNA (*p<0.05; two-way ANOVA test followed by Bonferroni test; n=3). 
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     Mock     Mock & Imatinib  
 
 
 
 
 
     -siRNA               -siRNA & Imatinib 
  
 
 
 
 
    siRNA8               siRNA8 & Imatinib 
 
 
 
 
 
    siRNA9      siRNA9 & Imatinib  
 
 
 
 
 
 
 
 
Figure 5.5b PP4c silencing increases the total apoptotic percentage of K562 cells in response to 
imatinib treatment. PP4c down regulation increase the total apoptotic percentage of K562 cells 48 
hours post-treatment with Imatinib. Representative pictures from Muse analyser show elevation in the 
early and late apoptotic percentages of the PP4c siRNAs K562 transfected cells compared to mock and 
negative control cells (n=3). 
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Similar results were observed when K562 cells treated with 20 nM rapamycin post PP4c 
silencing. Rapamycin treatment post PP4c silencing reduced the viable cell number of 
mock, -siRNA, PP4c siRNA8, and PP4c siRNA9 transfected cells at 48 hours (Figure 
5.6A). A significant reduction (about 25%; p<0.05) in the viability level of both PP4c 
siRNA8 and PP4c siRNA9 transfected cells as compared to the -siRNA cells at 48 hours 
(Figure 5.6B) was thus observed, suggesting that PP4c silencing enhanced the action of 
rapamycin in K562 cells leading to a reduction in viable cell numbers.  
 
To summarise the effects of PP4c down-regulation in K562 cells on the action of the anti-
cancer agents, the results showed that PP4c silencing has no effect on the sensitivity of the 
cells towards doxorubicin or cisplatin treatment; however, it enhanced the action of 
imatinib and rapamycin action.    
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Figure 5.6 PP4c silencing decreases the viability of K562 cells in response to rapamycin treatment. 
Transfected K562 cells were treated with 20 nM rapamycin. Viable cell count carried out by Trypan blue 
dye exclusion at 48 hours showed a reduction in the number of viable cells of mock, -siRNA, PP4c 
siRNA 8 and PP4c siRNA 9 (Figure A). Figure (B) shows a significant reduction in the viability 
percentage of the PP4c siRNA8 and PP4c siRNA9 cells compared to negative control cells (-siRNA) 48 
hours (*p<0.05; one-way ANOVA test followed by Bonferroni test; n=3) 
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5.3.2. Effects of PP4c down-regulation in HL-60 cells on their response to some 
of the anti-cancer drugs 
The effect of the same chemotherapeutic drugs (except imatinib) on cell viability of HL-60 
cells following silencing of PP4c was also investigated. HL-60 cells were counted 72 hours 
post nucleofection, treated with drugs and plated at 2×105 cells/mL in 24-well plates to 
evaluate cell viability and total apoptosis.  
PP4c down-regulation in HL-60 cells showed no effect on basal apoptosis, therefore, 
mock, -siRNA, PP4c siRNA8 and PP4c siRNA9 transfected HL-60 cells were treated with 
0.1 µM doxorubicin and the results showed that doxorubicin decreased the number of 
viable cells of mock, -siRNA, PP4c siRNA8 and PP4c siRNA9 transfected cells at 24 
hours (Figure 5.7A), which was further reduced at 48 hours (Figure 5.7B). Figures 5.7C 
and D show no significant difference in cell viability of PP4c-transfected cells at 24 and 48 
hours post-treatment when compared to -siRNA suggesting no effect of PP4c silencing on 
the HL-60 cells’ sensitivity to doxorubicin.  
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Figure 5.7 PP4c silencing has no effect on HL-60 cells viability in response to doxorubicin 
treatment. Transfected HL-60 cells were treated with 0.1 µM doxorubicin. Viable cell count carried out 
by Trypan blue dye exclusion at 24 and 48 hours showed a decrease in viable cell count (A, B) and the 
viability (C, D) of mock, -siRNA, PP4c siRNA 8 and PP4c siRNA 9. PP4c down regulation in HL-60 
cells showed no resistance to doxorubicin treatment (n=3). 
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Total apoptotic percentage was also analysed at 24 hours post doxorubicin treatment 
(Figure 5.8), and the results showed a comparable elevation in the apoptosis rate of all 
transfected HL-60 cells (mock, -siRNA, PP4c siRNA8 and PP4c siRNA9 transfected 
cells). These results, similar to Figure 5.7, suggest that PP4c silencing has no effect on the 
sensitivity of the HL-60 cells towards doxorubicin treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 PP4c silencing has no effect on HL-60 cells apoptosis in response to doxorubicin 
treatment. At 24 hours post 0.1 µM doxorubicin treatment, the apoptosis percentage was measured 
using Muse annexin V & dead cell assay carried out by Muse cell analyser. Transfected cells with PP4c 
siRNA8 and PP4c siRNA 9 show no difference in total apoptotic percentage as compared to -siRNA 
post doxorubicin treatment (n=3).    
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Mock, -siRNA, PP4c siRNA8 and PP4c siRNA9 transfected HL-60 cells were treated with 
2 µM cisplatin and the results showed that the number of viable cells of all transfected 
cells decreased at 24 hours post cisplatin treatment (Figure 5.9A). Similarly to 48 hours 
post doxorubicin treatment findings, a further reduction in the number of viable HL-60 
cells of all transfected cells post cisplatin treatment (Figure 5.9B) was observed, regardless 
of PP4c silencing and consequently, there was no significant difference in cell viability of 
PP4c-transfected cells at 24 and 48 hours post-treatment as compared to mock or -siRNA 
transfected cells (Figures 5.9 C and D). These findings suggested that PP4c silencing in 
HL-60 cells has no effect on the sensitivity to cisplatin treatment. 
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Figure 5.9 PP4c silencing has no effect on HL-60 cells viability in response to cisplatin treatment. 
Transfected HL-60 cells were treated with 2 µM cisplatin. Viable cell count carried out by Trypan blue 
dye exclusion at 24 and 48 hours showed a decrease in viable cell count (A, B) and the viability (C, D) 
of mock, -siRNA, PP4c siRNA 8 and PP4c siRNA 9. PP4c down regulation in HL-60 cells showed no 
resistance to cisplatin treatment (n=3). 
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Likewise, HL-60 cells were treated with 20 nM rapamycin, the mTOR inhibitor, post PP4c 
silencing and the results showed that rapamycin has the lowest effect on these cells 
comparing to doxorubicin or cisplatin. The results revealed that rapamycin treatment 
decreased the number of viable cells of mock, -siRNA, PP4c siRNA8 and PP4c siRNA9 
transfected cells at 24 and 48 hours (Figure 5.10). Similarly to doxorubicin and cisplatin 
results, rapamycin treatment post PP4c silencing showed no significant difference in viable 
cell number and cell viability of PP4c-transfected cells at 24 and 48 hours post-treatment 
when compared to mock or -siRNA.  
 
148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collectively, PP4c silencing in HL-60 cell has no effect on the cell viability and apoptosis 
when they treated with doxorubicin, cisplatin or rapamycin. 
 
Figure 5.10 PP4c silencing has no effect on HL-60 cells viability in response to rapamycin 
treatment. Transfected HL-60 cells were treated with 20 nM rapamycin. Viable cell count carried out by 
Trypan blue dye exclusion at 24 and 48 hours showed a decrease in viable cell count (A, B) and the 
viability (C, D) of mock, -siRNA, PP4c siRNA 8 and PP4c siRNA 9. PP4c down regulation in HL-60 
cells showed no resistance to rapamycin treatment (n=3). 
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5.4. Discussion  
The results in this chapter describe the effects of PP4c down-regulation on the response of 
K562 and HL-60 cells to cisplatin, doxorubicin, imatinib and rapamycin. For K562 cells, 
the results showed that down-regulation of PP4c with siRNA8 and PP4c siRNA9 
significantly decreased cell viability and increased apoptosis at 24 and 48 hours post 
imatinib treatment. Moreover, rapamycin treatment significantly decreased cell viability of 
K562-PP4c siRNA8 and K562-PP4c siRNA9 cells as compared to -siRNA. Silencing PP4c 
had no effect on the sensitivity of the K562 cells towards doxorubicin and cisplatin 
treatment. On the other hand, the results of HL-60 cells treatment with cisplatin, 
doxorubicin and rapamycin post PP4c silencing showed no effect on the response of HL-
60 cells to these anti-cancer agents. 
The above results suggested that PP4c silencing may enhance the action of both imatinib 
and rapamycin in K562 cells and may have a relation the protein tyrosine kinase gene Bcr-
Abl expressed by K562 cells only.  
Cisplatin is a platinum-based genotoxic agent that has successfully used in treating 
different types of solid tumours including breast and lung cancer (Rabik and Dolan, 2007). 
In contrast to this study, several cancer cell lines develop cellular resistance to cisplatin 
and this resistance may be in part due to PP4’s integral role in regulating cell cycle 
checkpoints or DNA damage repair by γ-H2AX de-phosphorylation generated during DNA 
replication (Rabik and Dolan, 2007; Wang et al., 2008). The over-expression of PP4c-
PP4R2-PP4R3α complex that was reported in breast and lung tumours dephosphorylates γ-
H2AX and promotes DNA replication, regardless of replication block and consequently 
cells escaped cisplatin-induced apoptosis (Chowdhury et al., 2008; Wang et al., 2008). 
Therefore, PP4c silencing sensitised breast and lung cancer cells to cisplatin treatment 
(Wang et al., 2008). In addition to other cytotoxic stimuli, cisplatin resistance post PP4c 
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modulation has been reported in leukaemic and T-lymphoid cell lines, HEK 239T, CEM-
C7, and Jurkat (Mourtada-Maarabouni and Williams, 2008; 2009). PP4c silencing 
enhanced the viability of HEK 239T, CEM-C7 and Jurkat cells and protected them from 
losing their ability of colony-forming that induced by cisplatin treatment (Mourtada-
Maarabouni and Williams, 2008; 2009).  
On the other hand, some studies correlated imatinib-induced apoptosis to γ-H2AX 
phosphorylation to understand the mechanism of apoptosis induced by imatinib in CML 
and why some patients develop imatinib resistance (Zhang et al., 2012). In their study, 
Zhang and colleagues demonstrated that H2AX C-terminal phosphorylation is involved in 
K562 cell apoptosis and that treatment with imatinib for 24 or 48 hours induced H2AX C-
terminal phosphorylation at Ser139 and Tyr142 (Zhang et al., 2012). It has been reported 
that PP4c regulates cell cycle checkpoints and DNA damage repair by dephosphorylation 
of γ-H2AX (Chowdhury et al., 2008; Wang et al., 2008). Moreover, PP4 has been shown 
to be a positive regulator of haematopoietic progenitor kinase 1 (HPK1) and the HPK1-
JNK signaling pathway (Zhou et al., 2004), and its down-regulation activates PEA-15 
(Mourtada-Maarabouni and Williams, 2009). Other studies revealed that higher 
concentrations of imatinib (more than 1 µM) had no further effect on Bcr-Abl kinase 
activity and the viability of K562 cells (Majsterek et al., 2006). Both K562 and HL-60 cells 
are p53-deficent; however, some studies have revealed that imatinib treatment activates 
p53 in Bcr-Abl-expressing cells as a result of Bcr-Abl kinase inhibition (Wendel et al., 
2006). Taken together, this can explain the enhancement of imatinib action that 
significantly decreased cell viability and proliferation and increased apoptosis post PP4c 
silencing seen in the present study. 
Furthermore, targeting the mTOR pathway has been established as potential strategy in the 
treatment of patients with imatinib-resistant chronic myeloid leukaemia (Sillaber et al., 
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2008). It has been reported that PI3K/Akt/mTOR signalling pathways were activated in 
Bcr-Abl fusion protein positive K562 cells and that PI3K/Akt/mTOR deregulation might 
contribute to the development of CML (Ly et al., 2003; Cheng et al., 2008b). Rapamycin 
enhances the action of imatinib and increases cell death in CML cell lines when they are 
combined in vitro and may control imatinib resistance (Ly et al., 2003; Sillaber et al., 
2008). As PP4c has reported to regulate many pathways including mTOR (Cohen et al, 
2005), this suggests that PP4c may directly or indirectly deregulate the Bcr-Abl kinase 
activity or its downstream target signaling pathways. 
Again, HL-60 cell showed a different response from K562 cells to the same chemotherapy 
drugs, suggesting that the different signalling pathways activated and the kinases that are 
expressed by these two cell lines have a vital link to their viability and proliferation. In the 
present study, HL-60 cells showed a 50% reduction in cell viability during the first 24 
hours when treated with cisplatin, while K562 cells showed a reduction in cell viability at 
48 hours post cisplatin treatment. Moreover, a large reduction (up to 95%) in HL-60 viable 
cell number and cell viability was observed following treatment with both doxorubicin and 
cisplatin at 48 hours, while K562 cells showed a 70% reduction in cell viability when 
treated with doxorubicin and cisplatin for the same period of time. Although the response 
of mock and -siRNA transfected HL-60 cells was similar to that of mock and -siRNA 
transfected K562 cells post rapamycin treatment, PP4c silencing showed a significant 
decrease in K562 cell compared to no difference in HL-60 cells treated with rapamycin 
under these conditions.  
More studies are needed to explain and understand the differences of these cell line models 
in term of their response to the anti-cancer agents and the effect of PP4c and its regulatory 
subunits on the signalling pathways that associate with leukaemia and the kinases that 
over-expressed. 
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6. General discussion  
In the last decades, much attention has focused on  the role that protein kinases play in 
cancer targeted therapies including leukaemia, more than the role of protein phosphatases 
(Bamborough, 2012), with targeted therapies in leukaemia treatment concentrating on 
strategies that inhibit the activity of these kinases (McConnell and Wadzinski, 2009). One 
such successful targeted therapy is imatinib, a small-molecule drug designed to interfere 
with the continuous Bcr-Abl tyrosine kinase activation in chronic myeloid leukaemia and 
consequently inhibit this activation (Druker et al., 1996; 2001; Talpaz et al., 2006).  
The effects of serine/threonine protein phosphatases on cell signalling and other cellular 
processes are complex. These enzymes act on a number of target proteins, many of which 
have yet to be identified. Numerous studies have highlighted the importance of protein 
phosphatases in leukaemia and their potential as targets for novel therapies (McConnell 
and Wadzinski, 2009). In particular, the serine/threonine phosphatase PP2A has emerged 
as an important tumour suppressor in myeloid leukaemia and strategies aimed at 
reactivating this phosphatase in addition to the inhibition of the tyrosine kinase activity 
have shown great promise for a new generation of leukaemia therapies (McConnell and 
Wadzinski, 2009; Neviani et al., 2005; 2007).  
Another of these protein phosphatases is PP4, which is comparatively less studied than 
other PPP family members such as PP1 and PP2A, therefore, the effects of PP4c 
modulation in leukaemia was studied in the current research. Studies have shown that PP4 
regulates an increasing number of cellular functions in different cellular locations and have 
resulted in the identification of several PP4 regulatory subunits and binding proteins (Shui 
et al., 2007; Xie et al., 2013; Brechmann et al., 2012). Similar to other serine/threonine 
phosphatases, PP4 is likely to be targeted to its specific sites of action by these regulatory 
subunits. It is also likely that the interchange between the different regulatory subunits and 
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binding proteins plays an important role in regulating the activity of PP4 complexes 
(Brechmann et al., 2012; Xie et al., 2013).  
PP4 is implicated in NF-κB (Gingras et al., 2005), it also recognised to regulate other 
cellular pathways including the DNA damage response, the activation of c-Jun N-terminal 
kinase MAPK 8 (Mihindukulasuriya et al., 2004; Mourtada-Maarabouni et al., 2003), 
interacts with the target of rapamycin (TOR) pathway (Bertram et al., 2000) and with 
insulin receptor following TNFα stimulation (Mihindukulasuriya et al., 2004). The role of 
PP4 in T-cell signalling has been reported by Zhou and colleagues as they suggested that 
PP4 positively regulates the activity of haematopoietic progenitor kinase 1 (HPK1) in a T-
cell receptor (TCR)-dependent manner (Zhou et al., 2004). In addition, PP4 has been 
reported to associate with HDAC3, an important gene expression regulator, and to inhibit 
its activity (Zhang et al., 2005), with depletion of PP4c resulting in a prolonged checkpoint 
arrest in human cells, suggesting that PP4c plays a critical role in dephosphorylating 
H2AX after DNA damage (Nakada et al., 2008). Many studies suggested that  PP4c has a 
crucial role in controlling cell growth, survival and proliferation in different types of 
cancers such as breast cancer, lung cancer, lymphoma and leukaemic T cells (Wang et al., 
2008; Mourtada-Maarabouni and Williams, 2008; 2009; Brechmann et al., 2012). 
Moreover, the role of PP4c regulatory subunits is also studied, especially PP4R1 and 
PP4R2. It has been reported that PP4R1 knockdown inhibits cell proliferation and colony 
formation in breast cancer cells (Qi et al., 2015), hepatocellular carcinoma cells (Wu et al., 
2015) and lung cancer cells (Zhu et al., 2016). While PP4R2 suppression results in de-
phosphorylation impairment of phosphorylated DNA damage response proteins such as 
γH2AX and p53 and thus contribute to the pathogenesis of AML (Herzig et al., 2017). 
On the other hand, many studies have implicated PP2A in a wide range of cellular 
signalling pathways, many of which are involved in cellular proliferation, apoptosis and 
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differentiation (McConnell and Wadzinski, 2009). The inactivation of PP2A by leukaemia 
associated tyrosine kinases was found to be a common theme in myeloid leukaemia 
(Roberts et al., 2010). Importantly, re-activation of PP2A results in dephosphorylation, and 
deactivation, of the kinase and subsequent inhibition of leukaemogenesis. Therefore, re-
activation of PP2A is considered as an attractive strategy for leukaemia therapy (Neviani et 
al., 2005; 2007; Kalla et al., 2007). Based on the hypothesis that PP2A act as a tumour 
suppressor besides the previous studies on PP4c modulation in other cell models including 
lymphoma and breast cancer that support this hypothesis (Mourtada-Maarabouni and 
Williams, 2008; 2009; Mohammed et al., 2016) and the similarity between PP2Ac and 
PP4c structures, besides the importance of PP4c in many pathways, therefore, this study 
aimed to investigate the role of endogenous PP4c modulation on the cell fate of CML and 
AML cell models.   
The current study found that PP4c over-expression in K562 resulted in suppression of cell 
viability and induction of apoptosis. The experiments have also demonstrated that over-
expression of PP4c in K562 cells can suppress their proliferation and promote cell cycle 
arrest in G0/G1. On the other hand, an increase in PP4c protein level in HL-60 cells was 
associated with a decrease in cell viability only. These findings are in agreement with 
studies on CEM-C7, Jurkat cells (Mourtada-Maarabouni and Williams, 2009) and on 
MCF7 and MDA-MB-231 cells (Mohammed et al., 2016). These studies revealed that any 
increase in PP4c protein levels negatively regulates the survival of leukaemic T-cells, 
untransformed human peripheral blood T cells, oestrogen receptor-positive and TNBC 
cells and is consistently associated with a decrease in cell viability and long term survival 
as well as apoptosis induction in the absence of extracellular cytotoxic stimuli (Mourtada-
Maarabouni and Williams, 2009; Mohammed et al., 2016). Previous results have also 
shown that PP4c is an important modulator of apoptosis and cell proliferation in HEK 
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293T cell line (Mourtada-Maarabouni and Williams, 2008). PP4c significantly decreased 
the mutation rate of human embryonic kidney 293T cells and induced cell cycle arrest in 
phase G1 (Mourtada-Maarabouni and Williams, 2008). The current study revealed 
differences in the response of K562 and HL-60 cells to PP4c endogenous modulation. 
When PP4c was over-expressed in K562 cells the results showed a reduction in viable cell 
number and in their proliferation rate, accompanied with an increase in apoptosis and 
changes in the cell-division cycle profile, while PP4c over-expression in HL-60 cells only 
decrease the viable cell numbers. However, these differences could be related to the 
sensitivity of HL-60 cells towards the nucleofection solution V. The lower tolerance of 
HL-60 cells to the nucleofection reagent was supported by observations with the Ki67 
proliferation assay showing that K562 mock transfected cells had a much higher 
proliferation rate than the HL-60 mock transfected cells under similar experimental 
conditions.  
In contrast to PP4c up-regulation, the present study also reveals that PP4c down-regulation 
increased the viable cell number with K562 cells but had no effect on basal apoptosis and 
on the proliferation rate. PP4c silencing in HL-60 cells increased cell viability and affected 
their cell cycle profile by decreasing the cell population in S phase and increasing the cell 
population in G2/M phase. Furthermore, PP4c down-regulation also had no effect on basal 
apoptosis and on the proliferation rate percentage in HL-60 cells. These results are partially 
in agreement with studies on MCF7 and MDA-MB-231 cells (Mohammed et al., 2016) and 
HEK293 cells and both leukaemic T-cells and untransformed human peripheral blood T-
cells (Mourtada-Maarabouni and Williams, 2008; 2009). PP4c silencing in breast cancer 
cells caused an increase in cell viability and migration, decreased the proportion of cells in 
subG0 and increased the proportions of cells in S and G2/M phases, effects associated with 
a decrease in the apoptosis rate (Mohammed et al., 2016), while PP4c silencing in 
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HEK293, CEM-C7 and Jurkat cells increased their viability and decreases apoptosis 
(Mourtada-Maarabouni and Williams, 2008; 2009). Moreover, some of the pathways that 
are regulated by PP4 are also reported to be deregulated in myeloid leukaemia. It has been 
reported that NF-κB activation through the IKK pathway may play an important role in the 
pathogenesis of myeloid leukaemia induced by Bcr-Abl (Hsieh and Van Etten, 2014). 
PP4R1 deficiency leads to an inactive PP4c and causes sustained and increased IKK 
activity, T cell hyperactivation, and aberrant NF-κB signalling in T cell lymphomas 
(Seshacharyulu et al., 2013), while PP4c or PP4R2 depletion in human osteosarcoma cells 
delayed γH2AX dephosphorylation during recovery from irradiation (Nakada et al., 2008). 
Recently, the role of PP4R2 has been also reported in AML (Herzig et al., 2017). PP4R2 
suppression leads to the impairment of DNA damage response proteins such as γH2AX 
and p53 and consequently leads to AML development (Herzig et al., 2017). 
The effects of PP4c down-regulation in HL-60 cells were different from those seen in 
K562 cells. Firstly, transfection of HL-60 cells with PP4c siRNAs did not yield a high 
transfection efficiency using nucleofection method, unlike with K562 cells, so that, 
HiPerFect, a different method was used. PP4c down-regulation in K562 cells showed an 
elevation in viable cell number at 48 hours post-plating associated with a clear trend on 
long-term survival, while PP4c down-regulation in HL-60 cells increased the viable cell 
number at 72 hours post-plating and affected the cell cycle profile by decrease the cell 
population in S phase and increase the cell population in G2/M phase.   
In the current study, the PP4c endogenous modulation in acute myeloid leukaemia models, 
HL-60 and NB4 (initial experiments, results are not shown), revealed a very low 
expression using nucleofection solution V and no expression using both Lipofectamine 
2000 and Lipofectamine 3000 reagents. On the other hand and despite the high percent of 
transfection efficiency, the Western blot results of PP4c silencing in HL-60 cells 
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comparing to the results of K562 cells demonstrated a relatively weak gene knock-down 
and this could be due to the poor release of the siRNA from the complex, despite high 
efficiency of delivery to the cell, as assessed by Cy3-labelled siRNA delivery. It has been 
reported that transfection method has many limitations including toxicity, lack of cell-type 
specificity and targeting nonspecificty, therefore, a new powerful method called 
CRISPR/Cas9 could be more useful to manipulating the PP4c gene in these types of cells. 
CRISPR/Cas9 is a genetic engineering technique in which can either splice out part of a 
gene to disrupt its function, or insert a new sequence into the genome to code for a new 
function (Wang et al., 2016). CRISPR/Cas9 has two key components: CRISPR (Clustered 
Regularly Interspaced Short Palindromic Repeats), a short strand of RNA which is a 
chemical messenger; and Cas9, a special CRISPR-associated nuclease that can cut a 
double DNA strand at a very precise point, nick it, or block its gene expression. The 
CRISPR helps guide the Cas9 enzyme to bind with a specific sequence on the genome 
where it will make a specific cut (Wang et al., 2016). The CRISPR/Cas9 method could be 
considered as another technique to investigate the role of PP4c in other cell line models for 
other types of leukaemia such as acute lymphocytic leukaemia (ALL) and chronic 
lymphocytic leukaemia (CLL).      
As PP4c down-regulation in both K562 and HL-60 cells had no effect on apoptosis rate, 
four different anti-cancer drugs have been used post PP4c silencing to examine if these 
drugs cause apoptosis or the cells develop resistance. Treating K562 cells with cisplatin 
and doxorubicin post PP4c silencing showed no effect on the cell viability as well as the 
apoptosis rate of the mock or negative control transfected cells. Treating HL-60 cells with 
doxorubicin and cisplatin post PP4c silencing also showed no different effect on the cell 
viability and the apoptosis rate of control cells. This study revealed that K562 and HL-60 
cells could not escape cisplatin- or doxorubicin-induced apoptosis and develop resistance, 
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these findings are in disagreement with previous studies which suggested that PP4c down-
regulation increases the resistance of breast and lung cells (Wang et al., 2008) and the T-
leukaemic cell lines CEM-C7 and Jurkat (Mourtada-Maarabouni and Williams, 2009) to 
cisplatin treatment. Additionally, PP4c silencing partially protects T-leukaemic cells 
against Fas-induced apoptosis leading to cisplatin-induced apoptosis and consequently 
developed resistance (Mourtada-Maarabouni and Williams, 2009). This difference in cell 
response might be related to the oncoproteins that expressed by each type of cells. For 
example, it has been reported that cisplatin activates extracellular signal-regulated kinase 
(ERK) in cancer cells via p53 phosphorylation (Dasari and Tchounwou; 2014) while K562 
and HL-60 are p53-deficient, so that these cells could not escape cisplatin-induced 
apoptosis and consequently develop resistance.   
The results of the current study showed that K562 cells treatment with imatinib post PP4c 
silencing significantly decreased their viability and increased the apoptosis rate. In 
addition, rapamycin treatment post PP4c silencing decreased K562 cell viability. In 
opposition to the findings of K562 cells, treating HL-60 cells with rapamycin showed no 
different effect on the cell viability of control cells. The crucial role of PP4c in regulating 
cell cycle checkpoints and DNA damage repair by γ-H2AX de-phosphorylation has been 
reported in breast and lung cancer cells suggesting that PP4c down-regulation in these cells 
promotes DNA replication regardless of replication block and consequently sensitized 
them to cisplatin treatment (Rabik and Dolan, 2007; Chowdhury et al., 2008; Wang et al., 
2008). In addition to that, imatinib-induced apoptosis has been correlated to γ-H2AX 
phosphorylation (Zhang et al., 2012). Although K562 cells are p53-mutant, p53 might be 
activated by imatinib treatment as a result of Bcr-Abl kinase inhibition (Wendel et al., 
2006). In CML, the mammalian target of rapamycin (mTOR) pathway is one of the 
multiple signalling pathways activated by Bcr-Abl (Ly et al., 2003). mTOR is a 
159 
 
serine/threonine kinase that forms two different complexes; mTORC1 and mTORC2. 
mTORC1 positively regulates the biosynthesis of proteins necessary for cell growth, and 
proliferation, and also known to inhibit the autophagy process, while mTORC2 is a critical 
regulator of Akt (Gentzler et al., 2012). mTOR is usually described as a member of the 
canonical PI3K/Akt/mTOR pathway. It was reported that together with imatinib, inhibition 
of mTORC1 has been shown to induce apoptosis to treat patients with imatinib-resistant 
chronic myeloid leukaemia (Ly et al., 2003; Sillaber et al., 2008), while mTORC1 and 
mTORC2 inhibitions could induce apoptosis in cells expressing the T315I-mutated Bcr-
Abl gene (Carayol et al., 2010). It was also reported that the oncogenic kinase Bcr-Abl 
activates signalling pathways, such as PI3K/Akt, STAT5 and Ras/MEK/ERK1/2 (Jacquel 
et al., 2003). Given PP4 has been described to be a positive regulator for haematopoietic 
progenitor kinase 1 (HPK1) and the HPK1-JNK signaling pathway (Zhou et al., 2004), and 
silencing PP4 amplified PEA-15 activation (Mourtada-Maarabouni and Williams, 2009), 
therefore, the K562 cells are more sensitive to the chemotherapeutic drugs imatinib and 
rapamycin post PP4c silencing, suggesting a relation between PP4c and the tyrosine kinase 
gene Bcr-Abl and/or its pathway and collectively, the current study suggested that PP4c 
may be involved in the regulation of signalling pathways of growth factor-independent 
proliferation and survival of myeloid leukaemic cells. 
Using proteomic analysis, it has been shown that PP4 expression changes have important 
effects on the phosphorylation status of various proteins that are involved in regulating 
apoptosis and cell proliferation such as the critical apoptosis regulators Bad, PEA-15, 
cofilin, STAT3, and ERK2 (Mourtada-Maarabouni and Williams, 2008). This study 
reported that the phosphorylation of Bad and PEA-15 proteins increased when PP4c levels 
are suppressed, and it is reduced when PP4c levels are increased (Mourtada-Maarabouni 
and Williams, 2008). The dephosphorylation of PEA-15 by PP4c may counteract the 
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effects of AMPK by switching the activity of PEA15 from a tumour promoter to a tumour 
suppressor (Mourtada-Maarabouni and Williams, 2008). In the same concept, this balance 
in the activities of AMPK and PP4c are likely to be crucial in the development and 
progression of breast cancer (Mohammed et al., 2016). Thus, further studies are required to 
investigate whether the effects of PP4c on K562 and HL-60 cells are mediated through the 
alteration of the phosphorylation status of these proteins. In addition, more investigations 
are needed to give more explanations to the results of this research and to understand why 
the K562 cells response to PP4c endogenous modulation and to the anti-cancer agent, 
rapamycin, was different from the response of the HL-60 cells.  
  
6.1. Limitations and Recommendations  
Chronic myeloid leukaemia (CML) has unusual protein tyrosine-kinase activity (Ren, 
2005), and this study provided strong evidence that protein phosphatases, represented by 
PP4, play a role in the survival of K562 and HL-60 cells; an area where further study is 
now required to continue to explore the signalling pathways targeted by PP4c and their 
significance to cell survival. These include the mTOR (mammalian target of rapamycin), 
protein kinase B (Akt), the extracellular signal-regulated kinase 1 (ERK1) and ERK2 
pathways, as well as the critical apoptosis regulators BAD and PEA-15 (Phosphoprotein 
Enriched in Astrocytes). Similar to previous multiplexed phosphorylation screens in HEK 
293T cells (Mourtada-Maarabouni and Williams, 2008), the characteristics of the 
signalling pathways targeted by PP4c in myeloid leukaemic cell lines can be studied by 
Kinetworks phosphoprotein analysis (an antibody based protein microarray incorporating 
over 600 phospho-specific antibodies), or other phosphoproteomic approaches, to examine 
the phosphorylation status of key cellular proteins/signalling pathways in lysates of cells 
where PP4c expression levels is modulated.  
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Whilst this study reports effects based on alteration in expression of the PP4 catalytic 
subunit, it is known that PP4c interacts with many proteins; regulatory subunits, including 
one shared with PP2A (α4/IGBP1), as well as other scaffolding and inhibitory proteins. 
Therefore, further studies should not only focus on phosphoproteomic analysis to detect 
changes in the phosphorylation status in signalling pathways downstream of PP4c, but 
should also address the complexity of the associations between PP4c and its interacting 
proteins. This will better define the critical importance of PP4c in determining cell fate in 
CML and AML models through a better understanding of not only it’s downstream 
signaling effects, but also factors controlling endogenous PP4c activity. Such interacting 
proteins are also important in controlling subcellular targeting of the PP4 holoenzyme as 
well as its catalytic activity (Chowdhury et al., 2008; Lee et al., 2010; Davis and Chen, 
2012) and in particular, the roles of the PP4 regulatory subunits, PP4R1 and PP4R2, have 
been studied in various cancer models (Brechmann et al., 2012; Seshacharyulu et al., 2013; 
Qi et al., 2015; Wu et al., 2015; Zhu et al., 2016; Herzig et al., 2017). For example, it has 
been reported that PP4R1 deficiency leads to an inactive PP4c and causes sustained and 
increased IKK activity, T cell hyperactivation, and aberrant NF-κB signalling in NF-κB-
addicted T cell lymphomas (Seshacharyulu et al., 2013), while PP4R2 depletion in U2OS 
human osteosarcoma cells delayed γH2AX dephosphorylation during recovery from 
irradiation (Nakada et al., 2008), with PP4R2 having previously been shown to be of 
importance for PP4c targeting to centrosomes. Similarly, the overexpression of both 
PP4R3/Smek and PP4c increased nuclear accumulation of the complex (Mendoza et al., 
2005; Hastie et al., 2000).     
Therefore, experiments on PP4 regulatory subunits, PP4R1, PP4R2, PP4R3, PP4R4, and 
4/IGBP1 should be expanded to determine their role in mediating the PP4c effects on cell 
proliferation and cell death in myeloid leukaemic cell lines, as reported in the current 
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study. Initial studies should determine the expression levels of PP4c (as well as other PPP 
family members) and its regulatory subunits at the mRNA level using TissueScan™ 
Lymphoma and Normal Tissue cDNA Arrays or real-time PCR approaches; with 
endogenous expression levels of select proteins of interest (based on the findings from 
initial array/RT-PCR screens) confirmed by Western blotting. Additionally, this strategy 
can also be employed using samples in which the endogenous levels of PP4c have been 
modulated (as in the current study) to determine if changes in PP4c expression lead to 
alterations in the basal expression of its interacting proteins, as well as other PPP members. 
This, alongside phosphoproteomic analysis in PP4c modulated cells will further contribute 
to defining a critical role of PP4c in CML and AML models. A better understanding of the 
functional roles of relevant PP4c interacting proteins in K562 and HL-60 cells (as well as 
other relevant cell line models) could be further explored in studies analysing effects on 
cell viability, apoptosis and drug response following their endogenous modulation by the 
regular transfection methods that have been used in this study, or using CRISPR/Cas9 
approaches (particularly given the limitations of the transfections methods used with HL-
60 cells in the current study). Further analysis of how changes in the expression level of 
PP4c interacting proteins control PP4c activity should also be undertaken. In view of the 
fact that PP4c-containing complexes are found throughout the cell, ranging from cytosolic 
to nuclear or centrosomal localisations with different regulatory protein compositions, 
substrate specificities, and activities (Chen et al., 2008; Cohen et al., 2005), 
immunocytochemistry could be used to study PP4c subcellular localisation following 
changes in the expression of interacting proteins. This should also be considered alongside 
phosphoproteomic analysis to identify changes in PP4c activity in these models.  
Furthermore, since CRISPR/Cas9 methodology could be applied to studies furthering 
mechanistic insight into the role of PP4c and its interacting proteins, following the 
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demonstration of significant functional effects in the current study, this technology could 
also be applied to better define the importance of specific PP4c interactions. Since, whilst 
PPP family members display high sequence homology in the core catalytic domain, 
differences in the N- and C- terminal regions are thought to control, in part, the interactions 
with regulatory proteins (reviewed by Honkanen and Golden, 2002). Therefore 
CRISPR/Cas9 (or other site-directed mutagenesis techniques) could be employed to 
generate truncation mutants of PP4c, alongside immuno-precipitation approaches to 
identify specific regulatory protein interactions (or the lack of), together with 
immunocytochemistry (to investigate subcellular localisation) and functional assays of cell 
viability, apoptosis and drug sensitivity, to further the understanding of how PP4c 
complexes control cell fate in the current models.   
Additional studies to expand the drug sensitivity data post changes in PP4c levels, as 
demonstrated in the current study with imatinib and rapamycin in K562 cells, could also be 
explored. Whilst the current study utilised a range of standard and targeted (e.g. imatinib) 
drugs individually, as a rationale to investigate potential downstream signaling pathways 
impacted on by alterations in PP4c, such as possible effects of PP4c on the mTOR pathway 
relating to enhanced sensitivity to rapamycin, combination drug treatments could also be 
explored. A basis for combination chemotherapy is to use drugs that work by different 
mechanisms, thereby reduces drug resistance, reducing tumour growth and metastatic 
potential, arresting mitotically active cells, reducing cancer stem cell populations, and 
inducing apoptosis. Further studies could therefore use combined doses of the drugs 
employed, possibly requiring lower individual doses selected on the basis of the 
preliminary MTS assay screens in the current study. Investigations into the relationship 
between PP4c expression levels and drug sensitivity could also be expanded to explore 
mechanisms underpinning the functional effects (changes in cell viability and apoptosis 
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rate) already demonstrated. Imatinib-induced apoptosis has been correlated to γ-H2AX 
phosphorylation (Zhang et al., 2012) and p53 may be activated by imatinib treatment as a 
result of Bcr-Abl kinase inhibition (Wendel et al., 2006). In addition to that, PP4c has a 
crucial role in regulating cell cycle checkpoints and DNA damage repair by γ-H2AX de-
phosphorylation (Chowdhury et al., 2008); an observation that can also be related to PP4c 
subcellular localisation controlled by interactions with regulatory partners and so drug 
sensitivity can also be explored in further studies investigating functional roles of PP4c 
interacting proteins. Additionally, the mTOR pathway has been reported in CML models 
as one of the multiple signalling pathways activated by Bcr-Abl (Ly et al., 2003). Thus, 
combined effects of imatinib and rapamycin, which showed positive effects individually 
with enhanced reduction in cell viability in K562 cells post-PP4c silencing, should also be 
explored after lowering their doses. This approach would also be supported by previous 
studies using a combination of imatinib and rapamycin to treat patients with imatinib-
resistant CML, with results showing that rapamycin enhanced imatinib's action and 
induced apoptosis (Ly et al., 2003; Sillaber et al., 2008), further highlighting an important 
relationship between Bcr-Abl and the mTOR pathway, together with the observation in the 
current study that PP4c silencing enhanced the action of both drugs individually.    
Finally, to further investigate the role of PP4c in leukaemia, PP4c endogenous modulation 
(and its interacting proteins) in cell line models of other types of leukaemia such as acute 
lymphocytic leukaemia (ALL) and chronic lymphocytic leukaemia (CLL) using 
appropriate transfection methods for each cell line would support the results of this 
research and continue to better define the importance of PP4c in this context.  
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6.2. Conclusion 
Protein phosphatase 4 catalytic subunit plays an important and critical role in the 
regulation of different cellular processes. Modulating the level of PP4c expression in two 
leukaemic cell line models has demonstrated to have an effect on their proliferation, 
survival, as well as cell cycle progression. PP4c over-expression in K562 cells decreased 
their viable cell number and survival sharply. An obvious reduction in cell proliferation of 
those transfected with PP4c and an elevation in the number of cells in G0/G1 in the cell 
cycle associated with high amount of cell death are strong evidences that PP4c may play a 
crucial role in chronic myeloid leukaemia cell fate. On the other hand, silencing PP4c gene 
in K562 cell line increased cell viability and cell proliferation and, additionally, enhanced 
their response to imatinib and rapamycin.  
In addition, PP4c over-expression in HL-60 cells showed a decrease in viable cell number 
while PP4c silencing in these cells elevated the viable cell number and the number of the 
cells in G2/M in cell cycle. Unlike K562 cells, HL-60 cells displayed no enhanced 
response post PP4c down-regulation towards the same anti-cancer drugs.  
The differences and the sensitivity of K562 and HL-60 cells towards the PP4c endogenous 
modulation might be related to the different mutations and dysregulation of tyrosine kinase 
activity, the expression levels and roles of PP4c interacting proteins and the downstream 
signalling pathways. These areas warrant further study, since the current research 
highlights the importance of studying the modulation of the endogenous level of PP4c in 
leukaemic cell lines as a starting point to widening the knowledge and understanding of the 
pathways are that involved in leukaemia pathogenesis; the mechanisms by which 
phosphatases regulate cell fate may allow the development of novel anti-cancer therapeutic 
strategies in the future. 
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Appendix A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure B. Replicate Western blots for PP4c down-regulation in HL-60 cells. Three immunoblots of 
PP4c protein expression in PP4c siRNA1, PP4c siRNA2 & PP4c siRNA8, PP4c siRNA9, -siRNA and 
HL-60 parental cells. Cells lysates of 1x106 cells/lane were separated by SDS-PAGE on 12% resolving 
gels followed by transfer to PVDF and detection of PP4c. Blots were stripped and re-probed for -actin.  
 
Figure A. Replicate Western blots for PP4c down-regulation in K562 cells. Three immunoblots of 
PP4c protein expression in PP4c siRNA1, PP4c siRNA2 & PP4c siRNA8, PP4c siRNA9, -siRNA and 
K562 parental cells. Cells lysates of 1x106 cells/lane were separated by SDS-PAGE on 12% resolving 
gels followed by transfer to PVDF and detection of PP4c. Blots were stripped and re-probed for -actin.  
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